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Several serious diseases remain without non-toxic curative treatments. To fill this 
void, one of the promising groups of medicines is that of oligonucleotides, 
encompassing aptamers, transcription factor decoys, and antisense therapeutics 
such as short interfering RNA and splice-correcting oligonucleotides. These short 
strands of DNA or RNA can bind to specific cellular nucleic acids or proteins and 
thereby inhibit or correct the function of disease-causing molecules. Extensive 
enzymatic degradation and poor cellular uptake are the most important obstacles 
for systemic oligonucleotide therapy. Numerous chemical modifications have been 
introduced to improve enzymatic stability, but they must be carefully optimized to 
avoid toxicity and to maintain target affinity. One solution is to design topological 
modifications, such as looped or circular oligonucleotides, which conserve the 
natural phosphodiester backbone but cannot be attacked by exonucleases. 
Cellular uptake has proven to be even more challenging. Oligonucleotides are 
internalized into cells by endocytosis, after which they often remain trapped in 
endosomes. Therefore, it would be advantageous to develop delivery vectors capable 
of bypassing endocytic routes of uptake or enhancing endosomal escape. Cell-
penetrating peptides, for example, exploit several mechanisms of uptake, some of 
which lead to rapid entry without endosomal localization. In addition, encouraging 
results have been achieved using liposomes, gold nanoparticles, and other 
nanocarriers, which also shield the oligonucleotide from degrading enzymes. 
The aim of this work was to improve the in vitro delivery of oligonucleotides by 
employing chemical modifications and nanoparticle carriers. The synthesis of the 
compounds, their characterization by various analytical methods, and the evaluation 
of biological effects are described. First, we covalently conjugated several cell-
penetrating peptides to unmodified and phosphorothioate oligonucleotides via 
disulfide linkages by convergent conjugation of separately synthesized and purified 
compounds. Confocal microscopy of conjugate-treated cells revealed endosomal 
entrapment, explaining the observed lack of antisense activity in cells.  
In another study we used similar disulfide linkages to circularize phosphodiester 
oligonucleotides, resulting in significantly improved enzymatic stability in serum 
and cellular extracts and enhanced selectivity to complementary targets.  
Altogether 44 compounds, including the above mentioned constructs, a peptide–
ribozyme conjugate, and several additional peptide–oligonucleotide conjugates 
prepared by stepwise solid-phase synthesis without intermediate purifications, were 
analyzed by negative ion electrospray ionization mass spectrometry or liquid 
chromatography–mass spectrometry with a maximum mass error of 0.05%.  
Finally, we synthesized cationic gold nanoparticles modified with a Tat-related 
cell-penetrating peptide, and characterized them with various methods. The gold 
particles did not affect cell viability and effectively delivered short interfering RNA 
into cells as non-covalent complex. In addition, the gold nanoparticles seemed to 
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Diseases are frequently caused by malfunctioning proteins and, therefore, 
conventional drug development strives to find small molecules which affect at the 
protein level. As small-molecule drugs are often non-specific and thereby somewhat 
toxic, research has been directed towards the earlier phases of protein synthesis, 
according to the ‘central dogma of molecular biology’ known since 1958 (Crick 
1970): DNA makes RNA makes protein. In theory, pharmacotherapy can be 
rendered more specific by inhibiting the translation of disease-causing proteins at 
the RNA level. An especially high selectivity of RNA targeting can be achieved by 
employing short strands of complementary nucleic acids. These strands, known as 
oligonucleotides (ONs), are now widely used as tools in molecular biology and 
investigated as potential gene-based therapeutics for e.g. cancer, genetic diseases 
and viral infections. Moreover, it has recently been found that besides coding for 
harmful proteins, RNA can have a disease-causing function per se (O’Rourke and 
Swanson 2009; Bennett and Swayze 2010), highlighting the demand for RNA-
targeting medicines. 
Therapeutic ONs display a wide variety of pharmacodynamic mechanisms, the 
most advanced one being the antisense approach (Figure 1). Bennett and Swayze 
(2010) define antisense ONs as “ONs of 8 to 50 nucleotides in length which affect 
the function of a specific target RNA upon binding by Watson-Crick base pairing”. 
The two primary modes of antisense effect are (1) degradation of the target RNA and 
(2) modulation of its function by non-degrading mechanisms. The cleavage of the 
target can be achieved via various routes: activation of the cellular enzyme 
ribonuclease H (RNase H) by ‘classical’ antisense ONs (Zamecnik and Stephenson 
1978), the intrinsic catalytic activity of ribozymes (RNA enzymes) (Cech et al. 1981) 
and deoxyribozymes (DNAzymes) (Breaker and Joyce 1994), harnessing the natural 
gene silencing pathway of RNA interference (RNAi) by short interfering RNAs 
(siRNAs) (Fire et al. 1998), or inhibition of polyadenylation by U1 adaptors 
(Goraczniak et al. 2009).  
Steric block antisense ONs, in contrast, do not activate any terminating events 
and exert their effect by stoichiometric binding to target RNA. They can be used as 
splice-correcting ONs which correct aberrant splicing of pre-mRNA (Sierakowska et 
al. 1996), as antagomirs, i.e. anti-miRNA ONs, which antagonize the gene regulating 
effects of microRNA (miRNA) (Krützfeldt et al. 2005), to block the translation of 
disease-causing proteins such as mutant huntingtin by binding to expanded triplet 
repeats in mRNA (Hu et al. 2009), or as competitive inhibitors of the cancer-related 
reverse transcriptase enzyme called telomerase (Norton et al. 1996). There are also 
non-antisense ONs, which do not target RNA but bind to specific proteins in the 
case of aptamers (Tuerk and Gold 1990) and transcription factor decoys (Bielinska 
et  al.  1990),  or  to  DNA  in  the  case  of  triple  helix-forming  ONs,  i.e. antigene ONs 




Currently, RNA interference and splicing correction are the ON strategies 
undergoing the most extensive research, including clinical studies. The traditional 
RNase H-recruiting antisense approach is also still very much alive and widely 
represented in ongoing clinical studies. Two local ON treatments have so far 
reached the market as ocular injections for ophthalmic diseases: the RNase H-
activating antisense ON fomivirsen (de Smet et al. 1999) and the RNA aptamer 
pegaptanib (Ng et al. 2006). Very recently, the FDA approved the first systemic ON 
drug mipomersen (Crooke and Geary 2012), a subcutaneously administered RNase 
H-competent antisense ON against homozygous familial hypercholesterolemia. 
However, the EMA refused to grant marketing authorization to mipomersen due to 
its serious adverse effects (EMA 2012), and even in the US it can only be prescribed 
and sold by specially trained personnel (Genzyme 2013). The progress of ONs as 
systemic therapeutics remains, therefore, in its beginning phase. Apart from toxicity 
issues, this progress has been delayed by the poor pharmacokinetic properties of 
ONs. Firstly, ONs are rapidly degraded in serum by nuclease enzymes if they are 
administered as unmodified natural nucleic acids. The enzymatic stability has been 
enhanced by introducing numerous chemical modifications, which need to be 
carefully optimized in order to maintain or increase the efficacy and specificity of 
ONs. Even more importantly, the main limitation of ONs is their inefficient cellular 
delivery, preventing them from reaching the site of action. Nanocarriers are 
promising ON vehicles which combine shielding against degradation with enhanced 
cellular uptake and/or endosomal escape. 
This thesis is focused on improving the enzymatic stability and cellular uptake of 
antisense ONs and siRNAs, comprising synthetic methods to produce the ONs and 
their carriers, analytical methods to characterize them, and biological methods to 
test their effect. In the literature review, strategies for the chemical modification of 
ONs and for the use of cell-penetrating peptide (CPP)-based carriers for ON delivery 
are discussed, followed by methods for the mass spectrometric characterization of 
modified ONs. The experimental part describes the modification of phosphodiester 
ONs by circularization, covalent conjugation of phosphorothioate ONs to CPPs, the 
characterization of the products by various analytical methods, and testing the 
biological properties of the modified ONs such as enzymatic stability, hybridization 
selectivity, cellular uptake, and antisense activity in vitro. The synthesis and 
characterization of positively charged CPP-modified gold nanoparticles and their 
complexes with siRNA is also reported, followed by the evaluation of their effect on 











Figure 1 Mechanisms of action of antisense oligonucleotides (ONs). Blue, target RNA 
(principal site of action for the target); red, ON class; green, proteins/enzymes. 
Effects: (1) Correction of aberrant splicing. (2) Cleavage of target (pre-)mRNA 
by RNase H. (3) Inhibition of polyadenylation. (4) Steric inhibition of translation. 
(5) Cleavage of target mRNA via RNA interference. (6) Cleavage of target 
mRNA by catalytic nucleic acids. (7) Competitive inhibition of telomerase action. 
(8) Inhibition of microRNA-mediated gene regulation. (9) Selective steric 
blocking of the translation of mutant proteins. 
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2 REVIEW OF THE LITERATURE 
2.1 Chemical modifications of oligonucleotides 
2.1.1 Changing the chemistry of natural oligonucleotides 
ONs with the natural phosphodiester backbone (PO-ONs) (Figure 2) have a half-
life of only about 5 minutes in human serum (Akhtar et al. 1991). The enzymatic 
stability can be enhanced by altering the carbohydrate ring or the phosphate 
internucleotide linkage, by replacing the entire backbone with an isostere, or by 
changing the topology of the oligonucleotide by e.g. cyclization (reviewed in Milligan 
et al. 1993; Kool 1996b; Kurreck 2003; Shukla et al. 2010). The heterocyclic bases 
can also be modified, but that is beyond the scope of this review. Table  1 shows 
examples on how the most promising ON chemistries affect biological properties. As 
classification according to generations is rather arbitrary, the following chapters will 
discuss modifications according to their site in the ON structure. 





Special characteristics and 
applications 
First generation    
Phosphodiester (PO)2   Natural DNA or RNA structure 
Phosphorothioate (PS)2,4 +++ – Protein binding, toxicity; is  
     combined with 2’-O-alkyl 
Second generation    
2’-O-Methyl (2’-OMe)3,4 + + Oral antisense formulation,  
     splicing correction 
2’-O-(2-Methoxyethyl) (2’-MOE)4 +++ + Antisense 
2’-Deoxy-2’-fluoro (2’-F)3,4  +++ Fixed C3’-endo conformation 
Third generation    
2’-Deoxy-2’-fluoro- D-arabino- 
     nucleic acid (FANA)2,4 
+ + Ribose is replaced by its       
     2’-epimer, D-arabinose 
N3’P5’ thio-phosphoramidate  
     (NPS) 
++ ++ Competitive inhibitors of  
     telomerase, RNA decoys 
Locked nucleic acid (LNA)3,4 ++ +++ Fixed C3’-endo conformation 
Unlocked nucleic acid (UNA) + – Acyclic; specificity modifier  
Cyclohexene nucleic acid (CeNA)2,4 + + Six-membered ring analog 
Peptide nucleic acid (PNA) +++ +++ Non-ionic peptide backbone 
Phosphorodiamidate morpholino  
     oligomer (PMO) 
+++ + Six-membered ring; non-ionic;  
     splicing correction 
4’-Thio-RNA3,4 + + Annular oxygen replaced by  
     sulfur; aptamers, siRNA 
1 Compared to natural DNA/RNA. 2 RNase H-competent. 3 Aptamer-compatible. 4 siRNA-compatible. 
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2.1.2 Modifications to the phosphate linkage 
The most common alterations of the phosphate linkage, representing the first and 
third generations of ON modifications, are shown in Figure 2. All of these 
modifications significantly improve the enzymatic stability of ONs (Letsinger et al. 
1986; Akhtar et al. 1991; Gryaznov et al. 1996). 
 
Modification     X     Y      
Phosphodiester (PO)1    O     O 
Phosphorothioate (PS)2        O     S 
Methylphosphonate (MP)2   O     CH3 
Phosphoramidate (PA)2     O     NR2 
N3'P5' phosphoramidate (NP)3            NH  O 
N3'P5' thio-phosphoramidate (NPS)3  NH  S 
Figure 2 Chemical modifications to the phosphate linkage of oligonucleotides. (B = any 
of the nucleobases A, G, C, or T. 1 Natural 2’-deoxyribonucleotide. 2 First 
generation modifications. 3 Third generation modifications. Modified from 
Milligan et al. 1993, Gryaznov 2010.) 
Phosphorothioates. The most successful analogs up to date are the phosphoro-
thioates (PS-ONs), in which the non-bridging oxygen in the phosphodiester linkage 
is replaced by sulfur (reviewed in Agrawal 1999). Fomivirsen, a PS-ON used in 
cytomegalovirus (CMV) retinitis as intravitreal injections (de Smet et al. 1999), was 
the first antisense drug approved by the FDA in 1998, though it soon became 
redundant due to efficient anti-HIV treatments which rendered active AIDS 
uncommon. A uniformly modified PS-ON has a half-life of about 9 hours in human 
serum (Campbell et al. 1990). Although PS-ONs exhibit a somewhat lowered affinity 
to target RNA (Morvan et al. 1993), they are the only phosphate bond modified ONs 
that activate RNase H (Agrawal 1999). However, in addition to sequence-specific 
antisense activity, they display multiple mechanisms of action, including sequence-
specific non-antisense and non-sequence-specific effects (Matsukura et al. 1987; 
Agrawal et al. 1988). Moreover, PS-ONs cause toxicity in the form of immune 
stimulation (Schechter and Martin 1998). The non-antisense and immune 
stimulating effects may arise from the extremely polyanionic nature that makes PS-
ONs especially prone to bind proteins (Agrawal 1997). Mipomersen, the first 
systemic ON drug approved by the FDA in 2013 to treat hypercholesterolemia, 
contains uniform PS linkages combined with other modifications (Genzyme 2013). 
Mipomersen suffers from adverse effects such as flu symptoms and liver toxicity 
which severely limit its use. 
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Methylphosphonates and phosphoramidates. Another early analog, the methyl-
phosphonate (MP) (Jayaraman et al. 1981), failed to enhance cellular uptake despite 
of its non-ionic structure (Bennett and Swayze 2010). More importantly, MP-ONs 
form significantly weaker hybrids with target RNA than PO-ONs do (Morvan et al. 
1993). Replacing the non-bridging oxygen with an amino group in phosphor-
amidates (PA) (Letsinger et al. 1986) resulted in even weaker hybridization to RNA 
than with MP-ONs (Froehler et al. 1988). In the more promising third generation 
variants, N3’P5’ phosphoramidates (NP) (Gryaznov and Chen 1994) and N3’P5’ 
thio-phosphoramidates (NPS) (Pongracz and Gryaznov 1999), the nitrogen replaces 
the bridging 3’-oxygen. These compounds exhibit a remarkable affinity to target 
RNA, forming RNA-resembling A-form double helices due to the favored N-type 
(i.e. C3’-endo)  conformation  of  the  sugar  (Gryaznov  et  al.  1995).  This  shift  in  the  
equilibrium from the S-type (i.e. C2’-endo) sugar puckering, typical for 2’-deoxy PO-
ONs (Figure 3), towards the N-type, favored by ribonucleotides, arises from the 
substitution of O3’ with the less electronegative nitrogen, allowing the anomeric 
nucleobase effect to prevail over the sugar 3’-gauche effect (Thibaudeau et al. 1994). 
NPs and NPSs are being investigated in various antisense, antigene and RNA mimic 
applications (reviewed in Gryaznov 2010) and as telomerase inhibitors (Herbert et 
al. 2002). 
 
Figure 3 Sugar conformations in nucleic acids. In RNA, the favored ribose conformation 
is C3’-endo; in DNA, 2’-deoxyribose predominantly adopts the C2’-endo form. 
(Modified from Noronha and Damha 1998, Manoharan 1999.) 
2.1.3 Carbohydrate 2’-modifications 
Modifications to the 2’-position of the carbohydrate ring of ONs, depicted in Figure 
4, are usually called second generation modifications (reviewed in Manoharan 
1999). They exhibit altered pharmacokinetic properties in vivo and a significantly 
increased binding affinity to target RNA because of the more electronegative 
substituent at the 2’-position, which turns the sugar puckering equilibrium towards 
the N-type (C3’-endo) conformation. An extremely high binding affinity is thus 
achieved with the 2’-deoxy-2’-fluoro (2’-F) modification, which locks the sugar ring 
almost completely in the N conformation but does not protect against nucleases 
(Kawasaki et al. 1993, cited in Manoharan 1999). 
2’-O-alkyl modifications. The most extensively studied 2’-modifications are 2’-
O-alkyl derivatives such as 2’-O-methyl (2’-OMe) ONs, which exhibit increased 
affinity to target RNA (Inoue et al. 1987) and a somewhat improved resistance to 
nucleases (Sproat et al. 1989). Increasing the alkyl chain length decreases the 
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binding affinity and enhances the enzymatic stability in vitro (Cummins et al. 1995). 
In vivo, however, 2’-propoxy ONs showed substantial degradation after injection to 
mice  (Crooke et al. 1996). Therefore, a complete or partial PS backbone is usually 
combined  to  2’-O-alkyl modifications. 2’-OMe ONs have been studied extensively 
for splice correction applications (Sierakowska et al. 1996; Williams et al. 2009) and 
also as anti-miRNA ONs (Krützfeldt et al. 2005), U1 adaptors (Goraczniak et al. 
2009), and telomerase inhibitors (Beisner et al. 2010). An even more promising 2’-
O-alkyl modification, the 2’-O-(2-methoxyethyl) (2’-MOE), confers both good 
binding affinity (Freier and Altmann 1997) and a nuclease resistance comparable to 
that of PS-ONs (reviewed in Manoharan 1999). 
 
Modification X     Y          
RNA1 H     OH 
2’-O-Methyl (2’-OMe)2        H     O–CH3 
2’-O-Propyl (2’-propoxy)2 H     O–(CH2)2–CH3 
2’-O-(2-Methoxyethyl) (2’-MOE)2 H     O–(CH2)2–O–CH3  
2’-Deoxy-2’-fluoro (2’-F)2 H     F 
D-Arabinonucleic acid (ANA)3 OH  H 
2’-Deoxy-2’-fluoro-ANA (FANA)3 F      H 
Figure 4 Chemical modifications to the 2’-position of the sugar ring of oligonucleotides.  
(B = any of the nucleobases A, G, C, or T/U. 1 Natural ribonucleotides. 2 Second 
generation modifications. 3 Third generation modifications. Modified from 
Manoharan 1999.) 
Chimeric ‘gapmer’ oligonucleotides. Due  to  the  inability  of  2’-modified  ONs  to  
activate RNase H, second generation antisense ONs are usually designed as  
‘gapmers’, chimeric ONs with a central 2’-deoxy-PS gap for RNase H recruitment 
and 2’-O-alkyl-PS wings at both ends (Manoharan 1999). These gapmers, also 
known as end-modified mixed-backbone ONs, exhibit fewer polyanionic-related 
side effects and a highly improved nuclease stability in vivo, allowing oral 
administration in some cases (Agrawal 1999). Mipomersen, a chimeric 2’-MOE/PS 
antisense ON against apolipoprotein B (Crooke and Geary 2012), has been approved 
by the FDA for the treatment of hypercholesterolemia. 
Arabinonucleic acid derivatives. To overcome the limitation that 2’-O-
modified ONs cannot activate RNase H, researchers have also designed compounds 
such as the D-arabinonucleic acid (ANA) derivatives, 2’-stereoisomers of RNA, 
which have been found to activate RNase H (Damha et al. 1998, cited  in Manoharan 
1999). The target affinity of 2’-OH-ANA is quite low but is enhanced in 2’-deoxy-2’-
fluoro-D-ANA (FANA). The nuclease stability of both compounds is between that of 
PO-ONs and PS-ONs. 
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2.1.4 Conformational restriction and backbone replacement 
In many of the advanced third generation modifications, the ribose conformation 
has been restricted or the ON backbone completely replaced (Figure 5).  
Locked nucleic acids. The  sugar  puckering  is  fixed  at  the  N-type  (C3’-endo) 
conformation in locked nucleic acids (LNAs), bicyclic ribonucleotide analogs 
bearing a 2’-O,4’-C-methylene bridge in the ribose ring (Obika et al. 1997; Koshkin 
et al. 1998; reviewed in Veedu and Wengel 2010). LNAs exhibit a substantially 
increased target affinity (Obika et al. 1998) and high nuclease stability but do not 
activate RNase H as uniformly modified ONs (Kurreck et al. 2002). Promising 
results have been achieved with LNA-modified AS-ONs and DNAzymes (Jakobsen 
et al. 2007), siRNA (Mook et al. 2007), aptamers (Lebars et al. 2007), anti-miRNA 
ONs (Elmen et al. 2008), and U1 adaptors (Goraczniak et al. 2009). 
Ethylene-bridged, unlocked, and 4’-thio nucleic acids. A further variation of 
the bicyclic ribose structure, 2’-O,4’-C-ethylene-bridged nucleic acid (ENA) (Morita 
et  al.  2002a;  reviewed  in  Koizumi  2004),  retains  the  high  binding  affinity  of  LNA  
and shows a remarkable stability towards nucleases. ENAs have shown potential as 
antisense (Morita et al. 2002b), antigene (Koizumi et al. 2003), and splice 
correcting ONs (Yagi et al. 2004). In contrast to these rigid structures, unlocked 
nucleic acid (UNA; 2,3-seco-RNA) (Nielsen et al. 1995; reviewed in Pasternak and 
Wengel 2011) is an acyclic ribose derivative with increased flexibility and decreased 
target affinity. Depending on the site of modification, UNA monomers can either 
decrease or increase the specificity of target binding, making them versatile tools for 
ON optimization. Another alteration of the sugar moiety is the 4’-thio-RNA (Bellon 
et al. 1993), where the annular oxygen has been replaced by sulfur. 4’-Thio-RNA has 
shown enhanced nuclease resistance and hybridization affinity compared to natural 
RNA, and has been successfully used to modify aptamers (Hoshika et al. 2004) and 
siRNAs (Dande et al. 2006). 
Phosphorodiamidate morpholinos. Several modifications have replaced the 
entire ribose ring with another heterocycle, as is the case in phosphorodiamidate 
morpholino oligomers (PMOs) (Stirchak et al. 1989; reviewed in Amantana and 
Iversen 2005). PMOs are extremely resistant to nucleases (Hudziak et al. 1996), 
and, in spite of their inability to activate RNase H, have proven efficient enough to 
progress to clinical trials in antisense (Kipshidze et al. 2007) as well as splice 
correction applications (Cirak et al. 2011). Due to their non-ionic backbone, PMOs 
should also be able to avoid the non-specific effects typical for PS-ONs. 
Hexitol, cyclohexene, and peptide nucleic acids. Other examples of a six-
membered ring in the ON structure (reviewed in Herdewijn 2010) are the hexitol 
nucleic acids (HNAs) (Verheggen et al. 1993), which have shown antisense activity 
as HNA–PS–HNA gapmers (Kang et al. 2004), and the cyclohexene nucleic acids 
(CeNAs) (Wang et al. 2000), flexible analogs that are able to activate RNase H, 
albeit weakly (Verbeure et al. 2001). The sugar-phosphate backbone is completely 
replaced with a polyamide chain in peptide nucleic acids (PNAs) (Nielsen et al. 1991; 
reviewed in Nielsen 2010). PNAs form very stable duplexes with complementary 
nucleic acids and bind double-stranded DNA via strand displacement. They have 
shown effective splice-correcting (Yin et al. 2008) and antibacterial (Tan et al. 
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2005) activity in vivo as well as antiviral (Tripathi et al. 2007) and targeted gene 
repair (Lonkar et al. 2009) activity in vitro. 
Modifications tolerated in aptamers and siRNAs. Some groups of ONs only 
allow certain modifications due to restrictions caused by the mechanism of action or 
the method of drug discovery. Since aptamer ONs are enzymatically enriched from a 
random library via a procedure called systematic evolution of ligands by exponential 
enrichment (SELEX) (Tuerk and Gold 1990), only modifications recognized by the 
enzymes can be used (Ng et al. 2006). 2’-F substitutions to pyrimidines and 2’-OMe 
substitutions to purines meet this requirement, and they are used for example in 
pegaptanib, the only approved RNA aptamer against wet age-related macular 
degeneration  (AMD)  (Ng  et  al.  2006;  Eyetech  2008).  LNA  modifications  can  be  
introduced to aptamers post-enrichment (Veedu and Wengel 2010). On the other 
hand, siRNAs need to be incorporated into the RNAi machinery, and the antisense 
(i.e. ‘guide’) strand then guides the degrading enzyme to the target sequence 
(Bumcrot et al. 2006; Behlke 2008). Modifications such as 2’-MOE, FANA and LNA 
are thus better tolerated in the sense (i.e. ‘passenger’) strand (Hornung et al. 2005; 
Prakash et al. 2005). In contrast, PS, 2’-OMe, 2’-F, CeNA, and 4’-thio-RNA residues 
can be placed in either strand, resulting in slightly reduced, unaffected or even 
improved RNAi activity (Prakash et al. 2005; Dande et al. 2006; Muhonen et al. 
2007; Nauwelaerts et al. 2007). Some modifications have, in addition, been able to 
reduce the non-specific immune stimulation (Hornung et al. 2005; Judge et al. 
2006) and off-target effects (Jackson et al. 2006) often caused by siRNA. 
 
Figure 5 Third generation chemical modifications of oligonucleotides. (B = any of the 
nucleobases A, G, C, or T/U. Modified from Morita et al. 2002, Kurreck 2003, 
Hoshika et al. 2004, Herdewijn 2010, Pasternak and Wengel 2011.) 
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2.1.5 Topological modifications 
The main source of degradation in serum have been found to be the 3’-exonucleases, 
and ONs containing modified residues at the 3’-end have been shown to exhibit 
relatively good stability in serum (Shaw et al. 1991; Temsamani et al. 1992; Gilar et 
al. 1998). In RNAi, it is standard procedure to protect the siRNA strands with 3’-
dTdT overhangs (Elbashir et al. 2001). Topological modifications (Figure 6) such 
as hairpin loops and especially circularization (reviewed in Kool 1996a) render the 
ON resistant to exonucleases due to the absence of free termini (Chu and Orgel 
1992). In cells, however, endonucleolytic activity has also been detected (Fisher et 
al.  1993;  Crooke  et  al.  2000),  and  only  modestly  improved  stability  was  found  for  
end-blocked PO-ONs in mice (Sands et al. 1995). Nevertheless, topologically 
modified ONs exhibit several favorable characteristics and are being investigated in 
various applications. 
 
Figure 6 Topological modifications of oligonucleotides. (Partially modified from Kool 
1996a. Modifications introduced in: 1 Azhayeva et al. 1995, 2 Giovannangeli et 
al. 1991, 3 Chaudhuri and Kool 1995, 4 Kool 1991, 5 Chu and Orgel 1991, and 6 
Billen and Li 2004.) 
Looped, branched, and circular ONs. Triple helix-forming antigene ONs pre-
organized by a circular (Kool 1991), hairpin loop (Giovannangeli et al. 1991), or 
cross-linked (Chaudhuri and Kool 1995) structure have shown enhanced binding 
affinity and sequence selectivity. Looped ONs capable of forming stable hybrid 
complexes, i.e. adjacent double and triple helices (Azhayeva et al. 1995), and double 
helix-forming circular ONs (Azhayeva et al. 1997) have also been synthesized and 
tested in vitro. Branched ONs can inhibit splicing by mimicking lariat intron 
branchpoint sequences (Carriero and Damha 2003). Circular deoxyribo ONs may 
also be used as vectors to express ribozymes (Daubendiek and Kool 1997) and 
miRNA mimics  (Seidl  and Ryan 2011)  due to  their  ability  to  undergo rolling circle  
transcription by RNA polymerases (Daubendiek et al. 1995). Remarkably, Billen and 
Li  (2004)  were  able  to  link  together  two  ON  circles  to  form  ‘linked-ring’  circular  
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ONs in an effort to design more complex deoxyribozyme molecules. Recently, Tang 
et al. (2010) designed antisense ONs circularized via photolabile linkers, which can 
affect their targets only upon irradiation and subsequent linearization. These ‘caged’ 
light-activated ONs have been studied with different ON backbones, including 
unmodified phosphodiester (Tang et al. 2010), 2’-OMe/PS (Wu et al. 2012), and 
PMO (Wang et al. 2012).  
Circular dumbbell oligonucleotides. Self-complementary dumbbell-shaped 
circular ONs have been of particular interest to researchers because of their 
stabilized double-helical structure, especially in the decoy approach, which employs 
double-stranded ONs mimicking transcription factor recognition sequences to 
influence gene expression (reviewed in Gambari 2004). The double-stranded DNA-
mimicking structure should also stabilize the ON against nuclease degradation 
compared to unpaired circular ONs, as it is known that double-stranded nucleic 
acids are more nuclease-resistant than single-stranded ones (Chu and Orgel 1992). 
Circular dumbbell decoy ONs have shown inhibition of hepatocyte nuclear factor 1 
(HNF1) ex vivo (Clusel  et  al.  1993)  and  of  nuclear  factor-kappaB  (NF-B) in vivo 
(Kim et al. 2009; Kim et al. 2010). Another decoy-type application for circular 
dumbbell ONs is to use them as irreversible inhibitors of the cancer-related enzyme 
DNA topoisomerase I (Li et al. 2007). A prodrug-like circular dumbbell chimeric 
RNA/DNA antisense ON has also been introduced where the RNA strand is cleaved 
by RNase H, releasing the active antisense DNA strand to inhibit viral replication 
(Abe et al. 1998).  
2.2 Cell-penetrating peptides as vectors of oligonucleotide 
delivery 
2.2.1 Pharmacokinetics and delivery of oligonucleotides 
Cellular uptake and intracellular pharmacokinetics. Free ONs have been shown 
to enter cells via endocytosis, after which they become partially entrapped in 
endosomal compartments (Beltinger et al. 1995). Release from endosomes thus 
represents one rate-limiting step in ON delivery, as suggested also by the enhancing 
effect in vitro of cationic polymers, fusogenic peptides and pH-sensitive agents (vide 
infra). In contrast, ONs microinjected into the cytoplasm rapidly enter the nucleus 
(Leonetti  et  al.  1991;  Fisher  et  al.  1993).  This  seems  promising  especially  for  
antigene and decoy ONs, splice-correcting steric block ONs, telomerase inhibitors, 
and U1 adaptors, which are expected to act in the nucleus. The intracellular site of 
action for other ONs depends on target mRNA localization. For RNase H-activating 
antisense ONs, the site of action can reside either in the nucleus or in the cytoplasm, 
while siRNA, ribozymes, and translation-inhibiting steric block ONs mainly bind to 
cytoplasmic mRNA. Furthermore, siRNA has been shown to spontaneously 
accumulate in the appropriate site (Berezhna et al. 2006). 
In vivo pharmacokinetics. Most of the research concerning the in vivo 
pharmacokinetics of ONs has been done using PS-ONs (Agrawal et al. 1991; Geary et 
al. 1997). PS-ONs are highly bound to plasma proteins and are excreted mainly in 
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the urine (Agrawal 1999; Juliano et al. 2009). Since PO-ONs exhibit much less 
plasma protein binding, they are excreted faster than PS-ONs (reviewed in Bennett 
and Swayze 2010). Displacement of protein-bound ONs due to saturation or 
competition leads to increased urinary elimination (Agrawal et al. 1991). The 
charge-neutral PMO analogs, in contrast, exhibit minimal protein binding but are 
still excreted much slower due to their efficient tissue accumulation (reviewed in 
Amantana and Iversen 2005). As larger entities such as nanocarrier-bound ONs are 
unable to undergo glomerular filtration, uptake by the mononuclear phagocyte 
system  (MPS)  forms  an  important  route  of  elimination  (Juliano  et  al.  2009).    
Kidney and liver are the main sites of ON uptake, which makes them ideal target 
sites for systemic ON treatment but increases the risk of renal or hepatic toxicity, as 
is seen in the case of mipomersen (vide ultra). Other target tissues may be difficult 
to reach, and many applications have employed local administration, e.g. 
intraocular injections (de Smet et al. 1999) or nasal spray (DeVincenzo et al. 2008), 
thus enhancing the bioavailability at the site of action and reducing adverse effects 
(reviewed in Whitehead et al. 2009). 
Delivery vehicles. ON treatment is usually carried out with a delivery agent in 
order to (1) protect the ON from enzymatic degradation and (2) to enhance its 
cellular uptake. The most widely used vehicles are positively charged compounds, 
which spontaneously form non-covalent electrostatic complexes with the negatively 
charged ON. Excess cationic charge is usually created in the complex mixture, 
facilitating the interaction with negatively charged moieties on the cell surface such 
as glycosaminoglycans (GAGs). However, the cationic charge also renders the 
vehicle prone to protein binding, which causes non-specific toxicity and inactivation 
of the complex by serum proteins.  
The delivery agents most commonly used for ONs in vitro are cationic lipids 
(reviewed in Li and Szoka 2007). Their ON complexes, i.e. lipoplexes, are 
internalized by endocytosis (Zelphati and Szoka 1996). Cationic lipids facilitate 
endosomal release when combined with neutral helper lipids or fusogenic peptides 
(Jääskeläinen et al. 2000). Most cationic lipids are, however, toxic at high 
concentrations and ineffective in the presence of serum (Felgner et al. 1987; Bennett 
et al. 1992; Spagnou et al. 2004). Cationic polymers have also been widely studied as 
delivery agents for ONs as complexes, i.e. polyplexes. Poly(ethylene imine) (PEI) 
effectively delivers PO-ONs (Dheur et al. 1999) and siRNA (Urban-Klein et al. 
2005), and has been suggested to exert endosomal escape via a ‘proton sponge’ 
effect (Boussif et al. 1995). For PS-ONs complexed with PEI, however, activity in 
vitro has not been achieved despite the enhanced cellular uptake (Dheur et al. 1999; 
Jääskeläinen et al. 2000). In addition, PEI exhibits significant cytotoxicity (Fischer 
et al. 2003; Neu et al. 2005). More recently designed nanocarriers aim at efficient in 
vivo delivery causing minimal toxicity. Gold nanoparticles (GNPs), for example, 
have been used in vitro as covalently linked antisense ON carriers (Rosi et al. 2006) 
and as complexes, i.e. nanoplexes, with siRNA (Lee et al. 2008; Bonoiu et al. 2009). 
Numerous other nanoparticles based on e.g. biodegradable polymers, dendrimers, 
cyclodextrins, mesoporous silica, and cell-penetrating peptides (CPPs) have also 
been investigated. However, only few of them have been studied in vivo so far.  
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Three notable nanocarrier functions have been widely pursued to improve the in 
vivo delivery of ONs: (1) enhanced endosomal escape, (2) avoidance of phagocytes, 
and (3) active targeting. To facilitate endosomal release, researchers have developed 
pH-sensitive liposomes, which are destabilized at the acidic pH of the endosome 
(reviewed in Fattal et al. 2004). To reduce protein binding and MPS clearance, 
Papahadjopoulos et al. (1991) designed sterically stabilized liposomes coated with 
poly(ethylene glycol) (PEG). These PEGylated ‘stealth’ liposomes, termed stable 
nucleic acid lipid particles (SNALPs) by Jeffs et al. (2005), have proven efficient in 
siRNA delivery against e.g. Ebola virus in vivo (Geisbert et al. 2006). Cholesterol 
conjugation, which affords partial targeting to the liver, has long been known to 
enhance the cellular uptake of antisense ONs in vitro (Krieg et al. 1993) and was 
also successfully employed to deliver cholesterol-lowering siRNA to mice in vivo 
(Soutschek et al. 2004). Various ligands have aided to target siRNA specifically to 
tumors, which overexpress receptors such as transferrin (TF) (Heidel et al. 2007) 
and folate (Yoshizawa et al. 2008). 
Clinical trials. As discussed in previous chapters, marketing authorizations have 
been granted to only three ONs, two of which are administered locally as intraocular 
injections. Various systemic ON formulations are, however, being investigated in 
clinical studies (reviewed in Bennett and Swayze 2010; Burnett and Rossi 2012). 
Examples of ONs undergoing clinical trials for systemic use are shown in Table 2. 
The target diseases range from myasthenia gravis to cancers and Duchenne 
muscular dystrophy (DMD). While modern applications such as siRNA, splicing 
correction, and telomerase inhibition are present, it is noteworthy that RNase H-
activating antisense ONs are still among the most numerous and successful ones. 
The chemistry of choice seems to be the second generation 2’-O-alkyl, which is also  
studied as an orally administered compound. This major advance has been enabled 
by the remarkably high nuclease resistance afforded by the uniform combination of 
2’-OMe with PS linkages.  
As the chemical modification of siRNA structure is not as straightforward as for 
other antisense ONs (vide ultra), siRNAs are usually studied as unmodified or 
slightly modified compounds, which are highly susceptible to degradation and 
exhibit unfavorable delivery properties. Thus it is not surprising that most siRNAs 
currently in clinical trials are administered locally (e.g. eye drops, ocular injections, 
or inhalations) or ex vivo (reviewed in Burnett and Rossi 2012). While these routes 
allow the use of naked siRNA, systemic administration without a delivery vehicle 
would require very high doses, increasing the cost of therapy and the prevalence of 
non-specific effects. Therefore, most research on systemic siRNAs in vivo is 
concentrated on the use of nanoparticle carriers to achieve maximal protection from 
enzymes and accumulation in the site of action. As Burnett and Rossi point out in 
their review (2012), the indications of systemic siRNAs clearly reflect the pharmaco-
kinetic consequences of each delivery method: naked siRNAs end up in the kidneys, 
warranting their use for renal diseases, while nanocarrier-bound ONs generally stay 
in the liver, making them useful against hepatic cancer. For targeted delivery agents, 
the destination depends on the ligand used. Tumor targeting, for instance, was 
achieved by TF in the multifunctional PEGylated cyclodextrin-based nanoparticles 
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used in the first clinical trial of systemically administered siRNA, which also 
provided the first evidence of systemic RNAi in humans (Davis et al. 2010). 
Table 2. Examples of systemic oligonucleotide drugs in clinical trials. (Modified from 
Bennett and Swayze 2010, Burnett and Rossi 2012.) 











































siRNA Naked Thompson et 
al. 2012 
ALN–VSP02 Hepatic cancer siRNA SNALP Vaishnaw et 
al. 2011 
CALAA–01 Cancer siRNA PEG-coated TF- 
nanoparticles 








1 Approved by FDA. 2 Oral formulation.  3 Duchenne muscular dystrophy. 4 Clinical studies suspended. 
2.2.2 Cell-penetrating peptides in oligonucleotide delivery 
Cell-penetrating peptides (CPPs), also referred to as protein transduction domains 
(PTDs) or membrane permeable peptides (MPPs), have been shown to enhance the 
cellular uptake of varying cargoes, especially therapeutic macromolecules such as 
peptides, proteins, DNA, ONs, and siRNA (reviewed in Lindgren et al. 2000; 
Fonseca et al. 2009; Coursindel et al. 2012). Several types of CPPs have been 
discovered displaying a wide range of structures, most of them being relatively 
small, less than 30 amino acids, and exhibiting either a net positive charge or 
amphipathicity (Patel et al. 2007). While the polycationic nature of various CPPs 
has been estimated a key factor in their success, many of the most promising CPPs, 
especially those deemed capable of non-endocytic uptake (vide infra), are 
amphipathic and display at least some hydrophobicity. Table 3 shows amino acid 




Table 3. Sequences of cell-penetrating peptides. 
Name Amino acid sequence  Reference  
Protein-derived   
Penetratin (Antp4358) RQIKIWFQNRRMKWKK Derossi et al. 1994 
EB1 LIRLWSHLIHIWFQNRRLKWKKK Lundberg et al. 2007 
Tat4860 GRKKRRQRRRPPQ Vivès et al. 1997 
Chimeric   
MPM(K-FGF)–NLS(NF-B) AAVALLPAVLLALLAPVQRKRQKLMPC Lin et al. 1995 
MPG GALFLGWLGAAGSTMGAWSQPKKKRKV Morris et al. 1997 
MPGNLS GALFLGWLGAAGSTMGAWSQPKSKRKV Simeoni et al. 2003 
MPG (P) GALFLAFLAAALSLMGLWSQPKKKRKV Deshayes et al. 2004c 
MPG-8 AAFLGWLGAWGTMGWSPKKKRK Crombez et al. 2009 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL Pooga et al. 1998 
TP10 AGYLLGKINLKALAALAKKIL Soomets et al. 2000 
Synthetic   
MAP KLALKLALKALKAALKLA Oehlke et al. 1998 
Oligoarginine (R8, R9) RRRRRRRR, RRRRRRRRR Mitchell et al. 2000 
Pep-1 (Chariot™) KETWWETWWTEWSQPKKKRKV Morris et al. 2001 
Pep-2 KETWFETWFTEWSQPKKKRKV Efimov et al. 2001 
Pep-3 KWFETWFTEWPKKRK Morris et al. 2007 
 
Covalent and non-covalent strategies. CPPs  can  be  chemically  coupled  to  ONs,  
forming covalent peptide–ON conjugates (POCs), or used as electrostatic 
complexes. Numerous synthetic methods have been introduced to conjugate CPPs to 
ONs and siRNAs (reviewed in Tung and Stein 2000; Meade and Dowdy 2007; 
Lebleu et al. 2008). The most frequently used bond types are disulfide, maleimide, 
thioether and amide. The bioreducible disulfide bridge has been reported to confer 
higher efficacy in vitro than  a  stable  linker  (Abes  et  al.  2007).  The  POCs  with  the  
most promising results are formed with neutral steric block ONs, frequently used for 
splicing correction, such as PNAs and PMOs (Lebleu et al. 2008). As non-ionic 
molecules they do not form electrostatic complexes with cationic compounds, and 
delivery vehicles can only be used as covalent conjugates, as complexes based on 
some other type of interaction (e.g. hydrophobic), or encapsulated inside the 
vehicle. 
Negatively charged ONs, in contrast, have been complexed to cationic CPPs in 
various cases with good results (vide infra). Meade and Dowdy (2008) argue that 
non-covalent CPP/ON complexes might provide more efficient siRNA delivery, as 
the cationic charge in covalent conjugates could be neutralized by the anionic siRNA 
strands. Furthermore, they postulate that the enhanced siRNA delivery by 
unpurified CPPs observed in some studies (Chiu et al.  2004; Davidson et al.  2004; 
Muratovska and Eccles 2004) was not caused by the covalent CPP–siRNA 
conjugates but, in fact, by excess free peptide in solution acting as non-covalent 
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delivery vehicle. This hypothesis was supported by the failure of purified conjugates 
to assist in achieving significant gene silencing at usual siRNA concentrations 
(Moschos et al. 2007; Turner et al. 2007). 
2.2.3 Classes and efficacies of cell-penetrating peptides 
In the literature, CPPs have been classified by two different criteria: either according 
to the origin of the sequence or the structural characteristics of the peptide. The 
latter includes three categories: i) primary amphipathic CPPs with alternating 
hydrophilic and hydrophobic amino acids along the sequence, ii) secondary 
amphipathic CPPs, where the amphipathicity is revealed upon formation of 
secondary structures, and iii) non-amphipathic cationic CPPs (Madani et al. 2011). 
Here we will discuss the most important CPPs divided to three classes by their 
origin: i) CPPs derived from the membrane-translocating sequences of cellular 
proteins, ii) chimeric CPPs composed of two parts, one of which is usually a nuclear 
localization sequence (NLS) of natural origin, and iii) synthetic CPPs specifically 
designed for this purpose (Lindgren and Langel 2011). Table  4 summarizes the 
impact of CPPs on ON delivery found in the literature, discussed in more detail in 
the following text. This table emphasizes the sequence-specific response in reporter-
expressing or disease-relevant cell lines as a measure of enhanced delivery. This 
measure is more reliable than observed cellular uptake, because many uptake assays 
cannot distinguish membrane-bound from truly internalized ONs. 
Protein-derived CPPs. Homeoproteins are transcription factors that bind to 
DNA via a specific 60-amino acid sequence called homeodomain (reviewed in 
Gehring 1987). In the early 1990s, it was found that the homeodomain of 
Antennapedia, a Drosophila homeoprotein, could enter nerve cells and accumulate 
in the nuclei (Joliot et al. 1991). Later a 16-amino acid secondary amphipathic 
peptide in the third helix of Antennapedia was specified as the sequence needed for 
cellular uptake (Derossi et al. 1994) and was termed as penetratin (Derossi et al. 
1998). Penetratin covalently linked to a 2’-OMe PS-ON exhibited enhanced cellular 
uptake and sequence-specific splicing correction in vitro (Astriab-Fisher et al. 2002) 
in HeLa–pLuc/705 cells, where the luciferase reporter gene is coupled to a 
thalassemic -globin intron preventing luciferase expression unless splice-corrected 
(Kang et al. 1998). However, penetratin did not deliver the ON even nearly as 
efficiently as cationic lipids (Astriab-Fisher et al. 2002). Better results were obtained 
with penetratin linked to the 5’-end of the sense strand of siRNA, showing an equal 
or better delivery than cationic lipids in various cell lines (Davidson et al. 2004; 
Muratovska and Eccles 2004). 
Tat  (trans-activator of transcription) is a protein involved in the replication of 
HIV-1 that activates gene expression from the HIV-1 long terminal repeat (LTR) 
(Sodroski et al. 1985). Tat was shown to readily enter cells via endocytosis and 
localize to the nucleus (Mann and Frankel 1991). It was discovered that cellular 
uptake depends on the basic domain extending from residues 48 to 60 (Vivés et al. 
1997). The basic domain contains the NLS sequence GRKKR (Ruben et al. 1989), 
but the NLS alone is not sufficient to induce uptake without the rest of the basic 
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domain (Vivés et al. 1997). Similar to penetratin (vide ultra), covalently conjugated 
Tat48–60 only moderately enhanced the cellular uptake of a 2’-OMe PS-ON (Astriab-
Fisher et al. 2002). In contrast, Tat47–57 conjugated to the 3’-end of the antisense 
strand of siRNA produced cellular uptake comparable to that mediated by cationic 
lipids and sequence-specific gene silencing in HeLa cells (Chiu et al. 2004). 
Chimeric CPPs. Several CPPs have been designed combining NLSs to signal 
sequences, i.e. membrane translocating sequences (MTSs), which guide translated 
proteins to different cellular organelles (Lindgren et al. 2000). The cationic NLS of 
the p50 subunit of NF-B was combined with a membrane permeable motif (MPM) 
comprising the hydrophobic region of the signal peptide of Kaposi fibroblast growth 
factor (K-FGF), known to interact with lipid bilayers (Lin et al. 1995). A conjugate 
composed of MPM and the homopolypeptide poly(L-lysine) complexed with PS-ONs 
was internalized in various cell lines, but no biological activity testing was 
performed on these complexes (Dokka et al. 1997). After the conjugation of the 
MPM to 2’-OMe/LNA mixmer steric block ONs, neither uptake nor inhibitory 
activity were observed in luciferase-expressing HeLa cells (Arzumanov et al. 2003). 
Another CPP constructed this way is MPG (Morris et al. 1997), in which the 
hydrophobic domain is derived from the fusion sequence of HIV gp41 and the 
hydrophilic  domain from the NLS of  Simian virus  40 (SV40) large T antigen.  As  a  
non-covalent complex with PS-ONs, MPG promoted rapid nuclear uptake in human 
fibroblasts. Complexes with siRNA resulted in sequence-specific gene silencing 
comparable to Oligofectamine in various cell lines, which was further enhanced by a 
mutated NLS part impairing the nuclear localization in the MPGNLS analog 
(Simeoni et al. 2003). MPG also exhibited nuclear import and sequence-specific 
gene silencing in a study that, extraordinarily, showed transcriptional inhibition by 
siRNA in human cells (Morris et al. 2004a). Deshayes et al. (2004c) slightly 
modified the sequence of MPG and designed MPG (P), which has a higher helical 
content. MPG exhibited ability for hydrophobic interactions with any phospho-
lipid, while MPG seemed to favor anionic lipids. However, MPG delivered siRNA 
30-fold less efficiently than Lipofectamine 2000 in vitro (Veldhoen et al. 2006). 
Langel et al. (1996) designed the primary amphipathic peptide galparan, which 
is a combination of the neuropeptide galanin and the wasp venom toxin amphiphilic 
peptide toxin mastoparan, the latter of which is known to increase membrane 
permeability. The [Lys13]galparan analog, transportan, demonstrated efficient 
uptake in Bowes’ melanoma cells (Pooga et al. 1998). The transportan analog 
transportan 10 (TP10), with a truncated galanin part to reduce potential side-effects, 
also showed promising cellular uptake (Soomets et al. 2000). Covalent conjugation 
to TP10 failed to enhance the delivery of 2’-OMe/LNA mixmer steric block ONs 
(Arzumanov et al. 2003), whereas transportan–siRNA conjugates were efficiently 
delivered and exhibited RNAi (Muratovska and Eccles 2004). Coupling of 
transportan and TP10 to a PNA and subsequent hybridization of the conjugate with 
a partially complementary decoy ON was shown to confer NF-B binding activity in 
rat insulinoma cells (Fisher et al. 2004). A similar strategy incorporating an 
additional NLS to the TP10–PNA conjugate conferred good uptake and inhibition of 
the oncogene c-Myc in cancer cells (El-Andaloussi et al. 2005). 
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Table 4. Oligonucleotide delivery by cell-penetrating peptides in the literature.1 
Cell-penetrating 
peptide Efficacy
2 Response Cell line / in vivo Complex/  covalent 
Oligo-
nucleotide 
Penetratin (+) SC HeLa–pLuc/705 Covalent 2’-OMe/PS 
 + KD Primary cells Covalent siRNA 
 ++ KD COS-7,CHO,EOMA Covalent siRNA 
Penetratin–R6 ++ SC HeLa–pLuc/705 Covalent PNA 
EB1 (+)/+ KD HeLa, HepG2 Complex siRNA 
Tat4860 (+) SC HeLa–pLuc/705 Covalent 2’-OMe/PS 
 (+) SC HeLapLuc/705 Covalent PNA 
 (+) KD HeLa  Covalent siRNA 
MPM(K-FGF) 3 –
 AI HeLa  Covalent 2’-OMe/LNA 
MPG +/(+) KD HeLa, COS-7 Complex siRNA 
 ++ KD 4 293FT Complex siRNA 
MPGNLS ++/+ KD HeLa, COS-7 Complex siRNA 
MPG (P) (+)/+ KD HTOL,ECV GL3 Complex siRNA 
CholMPG8 + KD In vivo in mice    Complex siRNA 
Transportan ++ KD COS-7,CHO,EOMA Covalent siRNA 
TransportanPNA + TFI Rinm5F Complex decoy ON 
TP10 – AI HeLa Covalent 2’-OMe/LNA 
TP10–PNA + TFI Rinm5F Complex decoy ON 
StearylTP10 + SC HeLapLuc/705 Complex 2’-OMe/PS 
PepFect6 ++ KD In vivo in mice Complex siRNA 
Endo-Porter + KD HeLa,Huh,Hek293T Complex siRNA 
MAP ++ AI Primary cells Covalent PNA 
 ++ SC HeLa–pLuc/705 Covalent PNA 
Pep-1 (Chariot™) + KD Primary cells Complex siRNA 
Pep-2 ++ AI HS-68, 293, HeLa, 
MCF-7  
Complex PNA analog 
 ++ AI HUVEC,Jurkat Complex PNA analog 
Pep-3 ++ AI HUVEC,Jurkat Complex PNA analog 
(RxR)4 5 + SC HeLa–pLuc/705 Covalent PNA 
 + SC HeLa–pLuc/705 Covalent PMO 
 + VRI In vivo in mice  Covalent PMO 
Stearyl(RxR)4 + SC HeLapLuc/705 Complex 2’-OMe/PS 
StearylR9  SC HeLapLuc/705 Complex 2’-OMe/PS 
1 The corresponding references are given in the text. 2 Compared to cationic lipids / evaluated 
otherwise: – no effect, (+) less effective / modest effect, + as effective / significant effect, ++ more 
effective / extensive effect. 3 MPM part only. 4 Transcriptional silencing. 5 x = 6-aminohexanoic acid.  
Response types: AI, antisense inhibition. KD, gene knockdown via RNA interference. SC, splicing 
correction. TFI, transcription factor inhibition. VRI, viral replication inhibition. 
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Synthetic CPPs. To overcome the need for unique protein-derived sequences, a 
model amphipathic peptide (MAP) was designed, the cellular uptake of which 
depended solely on its amphipathicity (Oehlke et al. 1998). Despite of its extensive 
cellular uptake in various cell lines without cargo, MAP exhibited poor delivery of 
PS-ONs conjugated via disulfide linkage or as non-covalent complexes (Oehlke et al. 
2002). However, MAP stably linked to antisense PNA showed clearly enhanced 
cellular uptake and pharmacological effect in rat cardiomyocytes (Oehlke et al. 
2004). MAP-conjugated PNA also exhibited enhanced splicing correction in HeLa–
pLuc/705 cells, both disulfide and stable linkers working equally efficiently (Wolf et 
al. 2006). This might reflect cargo-dependence of the CPP carrier, as PNA is a DNA 
mimic with a peptide backbone. The CPP Pep-1 (Morris et al.  2001), which adopts 
an -helical conformation in contact with phospholipids (Deshayes et al. 2004b), 
seems to be more versatile: it has been found effective in protein (Morris et al. 
2001),  PNA  (Morris  et  al.  2004b),  and  siRNA  delivery  (Arita  et  al.  2005).  In  
contrast, the helical MPG analog MPG displayed a significantly weaker siRNA 
delivery than did the nonstructured/-sheet-forming parent compound (vide infra). 
The Pep-1 analogs Pep-2 (Morris et al.  2004b) and Pep-3 (Morris et al.  2007) also 
exhibited efficient PNA delivery in vitro and in vivo, respectively. 
Polyarginines have been shown to be internalized by Jurkat cells more efficiently 
than other polycationic homopolypeptides (Mitchell et al. 2000). In a study by Abes 
et al. (2007), penetratin was coupled to an oligoarginine (R6) stretch to improve the 
cellular delivery of PNA, and the compounds did indeed exhibit increased splicing 
correction activity in HeLa–pLuc/705 cells. Polyarginine derivatives have been 
investigated especially for the delivery of neutral steric block ONs, and significantly 
enhanced splicing correction in HeLa–pLuc/705 cells was obtained by using 
covalent conjugates of (RxR)4, where x = 6-aminohexanoic acid, with PNA (Resina 
et  al.  2007)  and  PMOs  (Abes  et  al.  2008).  Furthermore,  (RxR)4–PMO conjugates 
have shown high antiviral activity in vivo (Burrer et al. 2007; Deas et al. 2007). 
2.2.4 Mechanisms of cellular uptake 
Originally, for penetratin, Tat and transportan, the mechanism of internalization 
was believed to be non-endocytic since uptake was observed at 4	C as well as at 37	C 
(Derossi  et  al.  1994;  Vivès  et  al.  1997;  Pooga  et  al.  1998).  However,  it  was  later  
discovered that the nuclear import of another CPP, VP22 derived from herpes 
simplex virus protein, was an artifact arising from cell fixation (Lundberg and 
Johansson 2001). The same was demonstrated for Tat, R9, and Tat–PNA conjugates 
(Richard et al. 2003). A study with penetratin–ON conjugates also suggested an 
energy-dependent pathway, as the uptake was found to be clearly temperature-
dependent (Astriab-Fisher et al. 2002). Thus, as Madani et al. (2011) state in their 
review, the effect of surface-bound cationic CPPs must be eliminated by treating the 
cells with trypsin or by quenching surface-bound fluorophores, and methods such as 
live cell imaging, reporter assays, or target mRNA quantitation are to be preferred. 
Console et al. (2003) recognized negatively charged glycosaminoglycans (GAGs) 
on the cell surface as essential mediators of the cellular uptake of penetratin and 
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Tat, and confirmed that the major route of uptake was endocytosis. Duchardt et al. 
(2007) found that penetratin, Tat, and R9 employ three different endocytic pathways 
and, at higher concentrations, enter cells via a rapid endocytosis-independent, 
heparan sulfate-dependent mechanism. Moreover, a previous study had indicated 
that the uptake mechanism of Tat may depend on its cargo: smaller cargoes such as 
peptides displayed rapid translocation, while globular proteins were taken up by 
endocytosis (Tünnemann et al. 2006). The exact mechanism of this concentration- 
and cargo-dependent rapid uptake, assuming it was the same in both studies, 
remains to be investigated. Recently, the role of GAGs in CPP uptake was questioned 
by  Subrizi  et  al.  (2012),  who  unexpectedly  found  a  higher  Tat  uptake  in  a  GAG-
deficient mutant cell line compared to wild-type CHO cells. Interestingly, they found 
the same amount of uptake for several structural analogs of Tat, suggesting that 
cationic charge rather than the exact amino acid sequence may be the main property 
governing the translocation of Tat-related CPPs. 
According to  a  review by Madani  et  al.  (2011),  primary amphipathic  CPPs (e.g. 
transportan, TP10, and MPG) are more likely to exhibit direct membrane 
penetration than cationic CPPs. A conformational study was performed on MPG to 
find the mechanism of the observed non-endocytic cellular internalization 
(Deshayes et al. 2004a). The results suggested the mechanism to be transient 
transmembrane pore formation (Figure 7;  Deshayes  et  al.  2008)  resulting  from  
transition from non-structured to -sheet conformation. A similar transition, but to 
an -helix structure, was seen for Pep-1 (Deshayes et al. 2004b). In contrast, the 
MPG analog MPG adopts a helical structure regardless of the presence or absence 
of lipids (Deshayes et al. 2004c), and has shown clear signs of endocytic uptake and 
endosomal entrapment as complex with siRNA (Veldhoen et al. 2006). Transportan, 
which is also mostly helical in various conditions, and penetratin, which shifts from 
helical to -sheet conformation in contact with lipids (Magzoub et al. 2003), both 
exhibited endocytic uptake as covalent conjugates with splice-correcting PNA in 
HeLa–pLuc/705 cells in a comparative study by Lundin et al. (2008). Therefore, 
one might speculate that transition from non-structured to either helical or  
structure favors direct transmembrane penetration. However, this mechanism 
remains unconfirmed and controversial, and more mechanistic studies are needed 
to fully elucidate its possibility and significance.  
 
2.2.5 Combining cell-penetrating peptides to other modifications 
Many known CPPs display promising but not ideal properties. For example, they 
may be trapped inside endosomes following their uptake by endocytosis, or high 
concentrations of CPP may be required for direct transmembrane penetration. 
These characteristics might be improved by modifications such as conjugation to 






Figure 7 Proposed cell entry mechanism for the cell-penetrating peptides MPG and Pep-
1. (1) Complex formation with the cargo. (2) Interaction with cell-surface glycos-
aminoglycans (GAGs). (3) Membrane insertion. (4) Transient transmembrane 
pore formation via rac1 activation. (5) Cytoplasmic release of the cargo. 
[Reprinted from Deshayes et al. 2008, p. 544, with permission from Elsevier.] 
Promoting endosomal escape. One of the major limitations of CPP-mediated 
delivery, endosomal entrapment, may be avoided if the escape from endosomes is 
facilitated. This can be achieved by e.g. increasing  the  hydrophobicity  of  the  CPP  
(Vivès et al. 2008). Systemic injection of siRNA as a complex with cholesterol-
functionalized MPG-8, a tryptophan-rich MPG analog, resulted in highly efficient 
tumor growth inhibition in vivo (Crombez et al. 2009). Non-covalent packaging of 
2’-OMe PS-ONs with stearylated TP10 (Mäe et al. 2009) and stearylated (RxR)4 
(Lehto et al. 2010) significantly enhanced the splice correction activity in HeLa–
pLuc/705 cells. In contrast, unexpectedly, stearylation of R9 failed to provide any 
enhancement (Lehto et al. 2010). Endosomal escape can also be promoted with the 
use  of  fusogenic  (i.e. endosomolytic) peptides, which undergo conformational 
changes upon endosome acidification (Endoh and Ohtsuki 2009). Akita et al. (2010) 
used stearylated R8 to package siRNA inside lipids to form a multifunctional 
envelope-type nanodevice (MEND), which was surface-modified with stearyl-R8. 
When a pH-sensitive fusogenic peptide, GALA, was introduced among the lipids, the 
construct showed clear signs of enhanced endosomal escape and improved gene 
silencing effect in dendritic cells ex vivo, thus combining CPP-mediated uptake and 
pH-triggered endosomal release. 
Histidine-rich peptides have been used as endosomolytic CPPs in various 
studies, as the weak base is protonated at acidic pH. A histidine-rich penetratin 
analog, EB1, enhanced gene silencing in HeLa and HepG2 cells compared to other 
CPPs (Lundberg et  al.  2007).  The authors  propose a  mechanism where EB1 forms 
an -helix upon protonation in the acidic environment of endosomes, resulting in 
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membrane disruption and cargo release (Figure 8). In agreement with this 
mechanism, the commercial amphipathic histidine-rich peptide Endo-Porter 
displayed pH-dependent -helix formation and endosomal release of siRNA, leading 
to RNAi effects in various cell lines (Bartz et al. 2011). Combining both the 
hydrophobic and pH-titratable endosomolytic properties, PepFect6, a stearylated 
TP10 analog bearing covalently linked proton-accepting trifluoromethylquinoline 
moieties, showed facilitated endosomal escape, remarkable siRNA delivery 
efficiency in various cell lines, and strong RNAi responses in vivo (El Andaloussi et 
al. 2011). While these peptides display favorable properties, it is noteworthy that 
endosomal release is still not 100%, and the majority of siRNA does enter 
lysosomes. 
Even more high-tech approaches to enhance the endosomal escape used near-
infrared (NIR) laser to release siRNA from Tat–lipid-coated gold nanoshells (Braun 
et al. 2009) and gold nanorods (Lee et al. 2009), achieving laser-activated gene 
silencing. Such triggered release strategies offer an attractive means of focusing the 
pharmacological effect at a restricted area, e.g. solid tumor, and thus avoiding 
adverse effects at other sites. 
 
 
Figure 8 Proposed endosomal escape mechanism for the endosomolytic peptide EB1. 
[Reprinted from Lundberg et al. 2007, p. 2670, with permission from FASEB.] 
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Combining cell-penetrating peptides with nanoparticle vectors. Nanoparticle 
delivery vectors can also be modified with CPPs in order to enhance the cellular 
uptake of the vector. Tat peptide, especially, has been combined with numerous 
nanocarriers (reviewed in Torchilin 2008). Tat-liposomes have been found effective 
in intratumoral gene delivery in vivo (Torchilin et al. 2003), and siRNA delivery has 
been achieved with R8-liposomes in vitro (Zhang et al. 2006) and with Tat peptide-
modified methoxy poly(ethylene glycol)–poly(-caprolactone) (MPEG–PCL) 
nanomicelles in vivo (Kanazawa et al. 2012). Gold nanospheres have been studied 
extensively in siRNA delivery (reviewed in Lytton-Jean et al. 2011), employing for 
example PEI-coated GNPs (Lee et al. 2011b) or sandwich-type multilayer 
siRNA/GNP complexes (Lee et al. 2011a). However, few studies have examined 
CPP-modified GNPs for siRNA delivery, and GNPs have been conjugated to CPPs 
mainly for nuclear targeting experiments. 20-nm GNPs coated with BSA-conjugated 
SV40 large T antigen NLS showed cytoplasmic localization in HeLa, 3T3/NIH, and 
HepG2 cells (Tkachenko et al. 2004). The same NLS conjugated to gold nanorods, 
in contrast, was able to enter both the cytoplasm and the nucleus of HaCaT and 
HSC-3 cells (Oyelere et al. 2007). Tat enabled nuclear entry in immortalized 
primary human fibroblasts  when conjugated to  small  but  not  to  35-nm GNPs;  the 
latter entered the cytoplasm but showed no obvious advantage over PEG-coated 
GNPs (Berry et al. 2007). Sun et al. (2008) functionalized 35-nm GNPs with the 
octaarginine derivative CALNNR8 and achieved efficient nuclear delivery in HeLa 
cells. 
Combining cell-penetrating peptides with targeting moieties. According to 
Vivès  et  al.  (2008),  the  main  drawback  of  CPPs  is  their  complete  lack  of  cell  
specificity. They propose that CPPs be combined with cell-targeting peptides in 
order to achieve both tissue-specific targeting, allowing the CPP to accumulate in 
the correct tissue, and subsequent cellular internalization. Kale and Torchilin 
(2007) combined passive tumor targeting with CPPs in their ‘smart’ pH-sensitive 
PEGylated nanoparticles, where Tat peptide was masked under pH-sensitive PEG-
lipids until the particles reached the more acidic intratumoral space. These particles 
were further augmented with tumor-specific monoclonal antibody to enhance 
doxorubicin delivery (Koren et al. 2012). Cell penetration and cell targeting were 
also combined in multifunctional siRNA-conjugated PEG–quantum dots, which 
displayed both RGD peptide, for brain tumor cell-specific delivery, and Tat peptide 
(Jung et al. 2010). 
2.3 Analysis of modified oligonucleotides by mass 
spectrometry 
2.3.1 Mass spectrometry of oligonucleotides 
The major applications of mass spectrometry (MS) regarding ONs include the 
confirmation of the structure of synthesis products and the analysis of metabolites. 
The traditional methods, including liquid scintillation counting (LSC) and polyacryl-
amide gel electrophoresis (PAGE), used to study the pharmacokinetics of ONs, 
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require radioactive labels (Agrawal et al. 1991; Zhang et al. 1996). Somewhat more 
rapid and automatable techniques include high-pressure liquid chromatography 
(HPLC) (Bourque and Cohen 1993; Wallace et al. 1996) and capillary gel electro-
phoresis (CGE) (Leeds et al. 1996; Geary et al. 1997). Compared to these methods, 
MS has the advantage that the analysis is particularly specific and informative, in 
addition to being easy, rapid and reasonably sensitive. In MS, the mass-to-charge 
(m/z) ratio of the analyte is determined, precluding any ambiguities arising from the 
intrinsic nature of other methods, which detect e.g. radioactivity of the label or UV 
absorption. The main disadvantage is the requirement of appropriate pre-treatment 
of biological samples, especially in the case of electrospray ionization (ESI), to avoid 
damage to the instrument and excessive noise due to the matrix. 
Ionization techniques. The MS analysis of ONs became possible when the soft 
ionization techniques, matrix-assisted laser desorption/ionization (MALDI) and 
ESI, were introduced in the 1990s (reviewed in Siuzdak 1994). In MALDI, the 
matrix-embedded sample is bombarded with a pulsed laser, and the spectra exhibit 
little or no fragmentation of the ON and singly charged ions as the major species. As 
MALDI produces uncomplicated spectra, it is frequently used for complex mixtures 
such as following enzymatic digestion (Gao et al. 2009) and for POCs synthesized by 
stepwise solid-phase synthesis (Grijalvo et al. 2010). In ESI, the analyte molecules 
are already ionized in solution, and they are brought to the gas phase by spraying 
the solution through a high-voltage capillary and facilitating the solvent evaporation 
with  dry  gas  and/or  heat,  ultimately  leading  to  the  expulsion  of  the  ions  from  the  
droplet (Siuzdak 1994). ESI is particularly suitable for the analysis of ONs, which 
are large, polar, thermally labile, and polyanionic in neutral to basic solutions 
because of the phosphate groups. As ESI is more straightforward and versatile for 
ON analysis than MALDI, this review mainly focuses on ESI applications. 
Interpretation of electrospray ionization (ESI) spectra. The negative ion ESI 
spectra of ONs display a series of multiply deprotonated ions of the form [MnH]n, 
the charge states typically ranging from 2 to 12 lost protons (Covey et al. 1988; 
Deroussent et al. 1995). An ESI-MS spectrum of a fluorescein-labeled PS-ON is 
shown in Figure 9 as an illustrative example. The production of multiply charged 
ions enables the analysis of high-molecular-weight compounds with low mass range 
instruments; for example, an ion trap may have an upper m/z limit of only 2 kDa, 
which would preclude the analysis of usual size (15 to 25 bases) ONs if only singly 
charged ions were generated. The relative abundances of the charge states depend 
on the length of the ON but can be influenced by the choice of eluent; especially 
adding organic bases to the solution reduces the charge states (Muddiman et al. 
1996; Griffey et al.  1997b). In addition, organic bases such as triethylamine (TEA), 
piperidine and imidazole reduce cation adduction by replacing the nonvolatile 
sodium  or  potassium  ions  with  volatile  adduct  ions  (Greig  and  Griffey  1995;  
Muddiman et al. 1996). Cation adduction can severely decrease the signal-to-noise 
ratio of ESI-MS spectra of ONs. Therefore, the preanalytical desalting of the sample 
is  crucial,  especially  for  PS-ONs  which  have  a  higher  affinity  for  cations  than  
unmodified ONs. Several strategies for the on-line desalting of ONs directly before 
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injecting to the ESI source have been proposed, e.g. microdialysis (Liu et al. 1996). 
The molecular weight (M) of the ON can be calculated with the formula 
(1)  =  × ( + 1), 
where  z  =  the  charge  of  the  peak  and  p  =  the  m/z ratio of the peak. Using two 
consecutive peaks in the spectrum, the charge of the second peak (z2) can be 






where p1 = the m/z ratio of the first peak and p2 = the m/z ratio of the second peak. 
The molecular weight can be reconstructed either manually or by deconvolution 
software. Mass accuracies of ±0.01% can be routinely achieved using ESI-MS 
(Siuzdak 1994). 
 
Figure 9 Negative ion ESI mass spectrum of a 5’-fluorescein-labeled phosphorothioate 
oligonucleotide (5’-TGG CGT CTT CCA TTT-3’; MW = 5624). Eluent: 25 mM 
triethylamine in 80% acetonitrile. [U. Tengvall, previously unpublished.] 
Tandem MS. Apart from measuring the intact molecular ions, the ON sequence can 
be confirmed by tandem MS (MSn; n = the generation of the fragment ions). In MSn, 
the molecular ion is fragmented due to collision-induced dissociation (CID), where a 
selected mother or precursor ion collides with a gas such as argon and dissociates 
into  daughter  or  product  ions  (Siuzdak  1994).  The  MSn of  ONs  produces  a  
characteristic pattern of daughter ions, suitable for sequence confirmation 
(McLuckey  and  Habibi-Goudarzi  1993;  Barry  et  al.  1995;  Boschenok  and  Sheil  
1996). The fragmentation pathways of modified ONs such as PS (Lotz et al.  1998), 
MP (Bartlett et al. 1996), and LNA ONs (Huang et al. 2010) have also been studied. 
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2.3.2 Liquid chromatography–mass spectrometry of oligonucleotides 
The compatibility of ESI with aqueous solutions and relatively high flow rates has 
enabled the routine use of MS as a detector for HPLC (reviewed in Siuzdak 1994). 
Liquid chromatography–mass spectrometry (LC/MS) confers better sensitivity by 
reducing chemical background noise and facilitates the analysis of modified ONs 
(Bothner et al. 1995) or complex mixtures such as ON metabolites in biological 
samples (Gaus et al. 1997). The method of choice for ESI-LC/MS is ion-pair 
reversed-phase HPLC, employing an amphiphilic ion-pair reagent and a gradient of 
acetonitrile, methanol or 2-propanol. For ONs, the most commonly used ion-pair 
reagents are alkylamines such as TEA (Huber and Krajete 1999) or tripropylamine 
(TPA) (Gaus et al. 1997) with a suitable acid component, e.g. acetate (Graham et al. 
2001) or bicarbonate (Huber and Krajete 1999). As an alternative ion-pair acid 
component, Apffel et al. (1997) introduced 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) 
adjusted to pH 7 with TEA, which proved to enhance both the chromatographic 
resolution and ESI sensitivity, one of which is usually compromised in LC/MS. 
HFIP was used successfully in the analysis of in vivo metabolites of PS-ONs (Griffey 
et al. 1997a). Beverly et al. (2005) used the HFIP-TEA ion-pairing buffer for the 
ESI-LC/MS of siRNA, and the intact duplex siRNA was preserved and separated 
from the single-stranded sense and antisense components. In contrast, in another 
study employing ESI-UPLC/MS with hexylamine acetate as ion-pairing reagent for 
the separation of siRNA from truncated duplexes, the siRNA duplexes did not fully 
survive the ionization process (McCarthy et al. 2009). 
2.3.3 Mass spectrometry of peptide–oligonucleotide conjugates 
In addition to the dominant method ESI, POCs can be characterized by negative ion 
MALDI-MS  (Bruick  et  al.  1996;  Zubin  et  al.  1999;  Gogoi  et  al.  2007).  In  the  early  
work, fast atom bombardment (FAB), the predecessor of MALDI, was used for the 
characterization of a small nucleopeptide (Robles et al. 1994). While FAB is limited 
to relatively small molecules, ESI enables the analysis of ONs more than 100 
nucleotides  long  as  well  as  of  POCs  (Potier  et  al.  1994;  Robles  et  al.  1997).  
Soukchareun et al. (1995) used direct injection and LC/MS with ion spray to 
characterize PO-ONs coupled to HIV-1 gp41 fusion peptides. A more systematic 
study on the MS of POCs revealed that the behavior of the conjugates during MS is 
governed mainly by the ON part (Jensen et al. 1996). Comparing the two ionization 
methods, MALDI was found to be more sensitive and tolerant to sample impurities, 
while ESI exhibited better mass accuracy and resolution. ESI-MS and ESI-LC/MS 
were also used in our group to routinely characterize POCs (Antopolsky and 
Azhayev 1999; Antopolsky et al. 1999; Antopolsky and Azhayev 2000; Antopolsky et 
al. 2002). Recently, a method was developed for distinguishing peptide–ON cross-
links from free peptides or ONs according to fractional mass differences by accurate 
mass LC/MSn (Pourshahian and Limbach 2008). 
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3 AIMS OF THE STUDY 
The  general  aim  of  the  study  was  to  improve  the  in vitro delivery of antisense 
oligonucleotides and siRNA with chemical modifications and nanocarriers. More 
specifically, the aims were: 
1) to optimize various analytical methods for the characterization of 
oligonucleotides, including electrospray ionization mass spectrometry, 
liquid chromatography–mass spectrometry, pre-treatment for biological 
samples, and chromatographic separation of metabolites; 
2) to enhance the enzymatic stability and target selectivity of 
oligonucleotide probes by circularization; 
3) to enhance the cellular uptake and sequence-specific activity of antisense 
oligonucleotides by covalently conjugating them to cell-penetrating 
peptides; 
4) to enhance the delivery and gene silencing effect of siRNA by complexing 
it with cationic cell-penetrating peptide-modified gold nanoparticles. 
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4 SUMMARY OF THE METHODS 
The majority of the methods related to this thesis are of chemical nature. Table 4 
summarizes the methods, used in publications I–IV, related to this thesis. Briefly, 
the main methods were : i) the synthesis and purification of oligonucleotides (ONs), 
short interfering RNAs (siRNAs), and peptide-modified gold nanoparticles (GNPs); 
ii) the characterization of linear and circular ONs and peptide–ON conjugates by 
electrospray ionization mass spectrometry (ESI–MS) and liquid chromatography–
mass spectrometry (LC/MS), and iii) of the GNPs by UV/VIS spectroscopy and 
transmission electron microscopy (TEM); iv) the enzymatic stability study; and v) 
effects of the GNPs on siRNA delivery and cell viability in SEAP-ARPE-19 cells. 
Table 5. Experimental and mathematical methods used in this thesis. 
Method Target Publ. 
Synthesis   
Solid-phase DNA synthesis Phosphodiester and phosphorothioate ONs I–III 
Disulfide cross-linking Peptide–ON conjugates I–II 
 Circular ONs III 
Solid-phase RNA synthesis Phosphodiester ribo ONs (siRNA) IV 
Reduction of gold salts Peptide-modified GNPs IV 
Post-synthesis purification   
IE- and RP-HPLC, desalting Phosphodiester and phosphorothioate ONs I–III 
by gel filtration or RP-SPE Phosphodiester ribo ONs (siRNA) IV 
Dialysis Peptide-modified GNPs IV 
Characterization   
UV/VIS spectroscopy ONs (determination of concentration) I–IV 
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Eighteen peptide-oligonucleotide phosphorothioate conjugates were prepared in good yield and
thoroughly characterized with electrospray ionization mass spectra. When applied to the living cells,
conjugates exhibiting membrane translocation and nuclear localization properties displayed efficient
intracellular penetration but failed to show any serious antisense effect. Studies on the intracellular
distribution of the fluorescein-labeled conjugates revealed their trapping in endosomes.
INTRODUCTION
Synthetic peptides having membrane translocation
properties and those possessing additionally nuclear
localization properties have been found to be useful
vectors for efficient internalization of oligonucleotides
into living cells. These peptides and their polylysine
derivatives have been shown to complex with oligonucleo-
tides and hence serve as carriers for cytoplasmic or
nuclear delivery (1, 2). Covalent oligonucleotide-peptide
conjugates have also received considerable attention as
new potential antisense agents exhibiting potentially
enhanced cellular uptake (3-17). The preparation of such
conjugates has been accomplished by various methodolo-
gies, based either on postsynthetic conjugation of oligo-
nucleotides and peptides, both bearing appropriate re-
active groups (3-8, 10, 11, 13, 14, 16, 17) or on solid-
phase assembly (9, 12, 15). Most of these methods concern
the synthesis of conjugates of natural phosphodiester
oligonucleotides, and only few papers describe the prepa-
ration of oligonucleotide phosphorothioates linked to
peptides. Lebleu and co-workers have synthesized a 25-
mer peptide-oligo-dC phosphorothioate conjugate in a
53% coupling yield, assessed from the HPLC trace (8),
However, neither the yield of the isolated product nor
characterization of this conjugate were reported. Heitz
et al. have recently reported on successful use of a carrier
peptide-oligonucleotide phosphorothioate conjugate
(POPC) in transfer of an antisense sequence into living
cells (17). Unfortunately, no experimental details con-
cerning the synthesis, isolation, and characterization of
this interesting compound were given. Since most pep-
tides used as carriers for oligonucleotides possess rela-
tively long hydrophobic sequences, the properties of their
conjugates (e.g. solubility, chromatographic behavior,
etc.) appear to differ considerably from those of oligo-
nucleotide phosphorothioates, which, in turn, possess
some restrictions to the methods that may be applied to
synthesis of POPCs. We believe that appropriate syn-
thetic procedures to obtain well-characterized POPCs are
of considerable importance.
The present paper describes the synthesis of 18 POPCs.
In these, the 3′-terminus of the oligonucleotide phospho-
rothioate is linked by a disulfide bond to the N- or
C-terminus of either a 17-mer membrane permeable
motif (MPM)sthe hydrophobic region of signal peptide
sequence of the Kaposi fibroblast growth factor, known
to interact with lipid bilayers, or a 27-mer peptide (MPM-
NLS), containing in addition to the above-mentioned
MPM motiff a nuclear localization sequence (NLS) of the
transcription nuclear factor kB (18). Furthermore, the
cellular uptake and intracellular localization of fluorescein-
labeled conjugates have been examined and inhibition
of the luciferase gene expression in a cell-free model
transcription-translation system and in living cells has
been attempted.
EXPERIMENTAL PROCEDURES
Peptide Synthesis. Fmoc-L-amino acids for peptide
synthesis were purchased from Bachem and Novabio-
chem. Peptides P1 and P2 were synthesized on Fmoc-
rink amide PEGA resin, peptide P3 on Fmoc-Cys(Trt)-
NovaSynPA500 resin, and peptide P4 on Fmoc-Pro-
NovaSynPA500 (Scheme 2), all from Novabiochem. The
pyridinium salt of 3-tritylthiopropionic acid was obtained
by the standard tritylation procedure and finally crystal-
lized (ether/hexane); mp 175-177 °C. 1H NMR (CDCl3):
δ 7.43-7.19 (m, 15H, arom.), 2.45 (t, 2H, J ) 7.4 Hz,
-CH2-), 2.33 (t, 2H, J ) 7.4 Hz, -CH2-). The synthesis
of all peptides was performed by a solid-phase method
on a Milligen 9050 synthesizer. Standard protocols based
on Fmoc/HBTU/TEA chemistry were used. 3-Tritylthio-
propionic acid was introduced to the N-terminus of two
peptides (P2, P4) directly on a synthesizer (HBTU/TEA
condensation).
Oligonucleotide Synthesis. The oligonucleotide phos-
phorothioates were prepared on a solid support, bearing
a disulfide linker (19). 2′-Deoxyribonucleoside 3′-phos-
phoramidites, fast-sulfurizing reagent, and fluorescein
phosphoramidite were products of Glen Research. The
solid-phase synthesis was performed on a PE Applied
Biosystems 392 DNA synthesizer on a 1 μM scale.
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Cationic Lipid Formulations. Formulations with
Cytofectin GS (Glen Research) were prepared following
the manufacturer’s procedure.
HPLC Techniques. The peptides and their 2-pyridyl-
sulfide derivatives were analyzed and isolated by reversed-
phase chromatography (RP) (column, Genesis C4, 300 Å,
4 μm, 4.0 × 150 mm, Jones Ltd.; buffer A, 0.05 M
triethylammonium acetate; buffer B, 0.05 M triethylam-
monium acetate in 80% MeCN; flow rate, 1.0 mL min-1;
a linear gradient from 40 to 100% B in 30 min was
applied). The oligonucleotides containing disulfide tethers
were analyzed and isolated by ion-exchange chromatog-
raphy (IE) (column, PolyWax LP 300 Å, 4 μm, 4.6 × 100
mm, buffer A, 0.05 M KH2PO4 in 50% aqueous form-
amide, pH 6.7; buffer B, A + 1,5 M NaBr; flow rate, 1.0
mL min-1; a linear gradient from 0 to 70% B in 30 min
was applied) and RP [column, Genesis C18, 300 Å, 4 μm,
4.0 × 150 mm, Jones Ltd.; buffer A, 0.05 M triethylam-
monium acetate (TEAA); buffer B, 0.05 M TEAA in 80%
MeCN; flow rate, 1.0 mL min-1; a linear gradient from 0
to 50% B in 30 min was applied]. The conjugates were
analyzed by IE as described for oligonucleotides. The final
isolation and analysis of the conjugates were performed
by RP HPLC similar to that described for oligonucleotides
(a linear gradient from 0 to 100% B in 30 min was applied
in this case).
Methods to Synthesize Disulfide Cross-Linked
Conjugates. Oligonucleotide O2a. A 5% triethylamine
(TEA) in ethanol (40 μL) was added to a solution of
oligonucleotide O2 (20 OD) in 0.05 M TEAA buffer (1.5
mL). Dithiothreitol (3 mg) was then added, and the
mixture was left for 3 h at rt and finally concentrated to
a volume of 0.5 mL. The oligonucleotide bearing a free
mercapto group was isolated by RP HPLC and used
immediately.
Oligonucleotide O2b. Oligomer O2a (20 OD) in 0.05
M TEAA buffer (1.5 mL) was diluted with an equal
volume of ethanol. 2,2′-Bis(dipyridyl)disulfide (3 mg) was
then added, and the mixture was left to stand for 1 h at
rt. The corresponding 2-pyridyl sulfide derivative O2b
was then concentrated to a volume of 0.5 mL and
separated from the excess of 2,2′-bis(dipyridyl)disulfide
and other byproducts with RP.
Peptide P2a. Peptide (P2, 3 mg) was dissolved in a
mixture of ethanol and formamide (1:1, 1 mL). 2,2′-Bis-
(dipyridyl)disulfide (5 mg) was then added to a solution
and the mixture was left for 1 h at rt. The pyridyl sulfide
derivative was purified by RP HPLC. The appropriate
peak (1.5 mL) was collected and diluted with formamide
to a volume of 30 mL, followed by addition of 5% TEA in
ethanol (300 μL).
Method A. Oligomer O2a (2 OD) in 0.05 M TEAA buffer
(0.15 mL) was added to a solution of peptide P2 (0.3 mg)
in formamide-TEA (100:1, 3.03 mL) immediately after
its separation. The mixture was kept overnight at rt and
applied onto a DEAE-Toyopearl 650M column (10 × 80
mm, Br-), equilibrated with 50% formamide. The column
was washed with 50% formamide (50 mL), and the
conjugate was eluted with 1 M NaBr and 0.05 M
potassium phosphate buffer in 50% formamide (pH 6.5).
Crude conjugate was finally analyzed, purified by RP
HPLC, and desalted.
Method B. Oligomer O2b (2 OD) in 0.05 M TEAA
buffer (0.15 mL) was added to a solution of peptide P2
(0.3 mg) in formamide-TEA (100:1, 3.03 mL). The mixture
was kept overnight at rt and the crude conjugate was
analyzed and purified as in method A.
Method C. Oligomer O2a (2 OD) in 0.05 M TEAA buffer
(0.15 mL) was added to a solution of peptide P2a (0.3
mg) in formamide-TEA (100:1, 3.03 mL). The mixture
was kept overnight at rt and the crude conjugate was
analyzed and purified as in method A.
Peptide-Oligonucleotide Phosphorothioate Con-
jugates. Each conjugate was synthesized according to
method C, starting from 20 OD of initial oligonucleotide.
Scheme 1
Scheme 2
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Electrospray Ionization Mass Spectrometry. Mass
spectra were acquired using an LCQ quadrupole ion trap
mass spectrometer equipped with an electrospray ioniza-
tion source (Finnigan MAT, San Jose, CA). The spray
needle was set to -3 kV. The nitrogen sheath gas flow
rate was set to 70. The stainless steel inlet capillary was
heated to 200 °C, and the capillary voltage was -39 V.
The number of negative charges was maximized by
calibrating the tube lens offset with a 15-mer oligonucle-
otide (data not shown). The value chosen was -10 V. The
spectra were measured using 200 ms for collection of the
ions in the trap, and 5-12 microscans were summed. The
eluent consisted of 80% acetonitrile containing 25 mM
TEA. The eluent flow rate was set to 10 μL/min, and 5
μL samples containing 1-20 pmol of conjugates were
injected to the system. Positive ion mass spectra of the
peptides were acquired by using 50% methanol as the
eluent. The sample concentration was 10 μg/mL, and 5
μL was injected. The spray needle potential was set to 5
kV, capillary voltage 20 V, and tube lens 10 V. Other
conditions were as in negative ion mode. The molecular
weights of the compounds were calculated using com-
puter program Gretas Carbos, created by Hines and
Gibson (UCSF).
32P-Labeling of Phosphorothioate Oligonucle-
otides and Oligonucleotide-Peptide Conjugates
and Their Gel Electrophoresis. Oligonucleotides and
conjugates were 5′-32P-labeled with T4 polynucleotide
kinase (Pharmacia), purified on the OPS cartridge (PE-
Applied Biosystems). A 15% PAGE was employed to
analyze the oligonucleotides and conjugates.
Development of Stable Cell Lines Expressing
Luciferase Activity. CHO-AA8-Luc cells expressing
luciferase activity were purchased from Clontech Inc.
(Palo Alto, CA). Stable cell lines expressing tetracycline-
regulated luciferase mRNA and activity were developed
by the method of Gossen and Bujard (20) according to
the instructions and plasmids from Clontech Inc (Palo
Alto, CA). Briefly, monkey kidney fibroblast CV1-P and
human retinal pigmented epithelium D407 cell lines were
transfected with pTet-Off with calcium phosphate trans-
fection (21), and cells with stably integrated plasmid
DNA were selected in the presence of 0.4 mg/mL G418
(Calbiochem, La Jolla, CA) and tested for the expression
of tetracycline-sensitive regulator by transient transfec-
tion of pTRE-luc and pCMV-beta-galactosidase plasmids,
culturing in the presence or absence of 2 mg/L tetracy-
cline and luciferase assays. Those cell lines displaying
tetracycline-repressible luciferase activity were expanded
and transfected with pTRE-luc plus pTK-hyg plasmids.
Cells with stably integrated luciferase cDNA were se-
lected in the presence of both 0.4 mg/mL G418 and 0.1
mg/mL hygromycin B (Calbiochem) and screened again
for tetracycline-repressible luciferase activity. This pro-
cedure yielded derivatives indistinguishable from their
parent CV1-P and D407 with respect to cell morphology
and growth characteristics. The CV1-P derivatives CV-
11 and CV-19 and D407 derivative 6-2 were used in this
study.
Uptake of 32P-Labeled Oligonucleotides and Con-
jugates. CV1-P cells were plated in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco) with 10% fetal bovine
serum (FBS, Gibco) in 96-well plates, 2 × 105 cells/well,
and grown for 24 h in a humidified cell incubator with
5% CO2 at 37 °C. After washing the cells, medium was
replaced with 180 μL of the serum-free medium contain-
ing a mixture of 5′-labeled (3.5 × 104 - 1.75 × 106 cpm)
and unlabeled oligonucleotide or conjugate (0.1-5 μM).
After 4 h of incubation at 37 °C, cells were washed several
times with medium, phosphate buffer saline (PBS, Gibco),
high salt-low pH buffer solution (0.4 M NaOAc, 1 M NaCl,
pH 3.3), and finally with PBS (22, 23). The cells were
solubilized in 1% sodium dodecyl sulfate (SDS, Sigma)
solution and the radioactivity was measured in the same
plates with Micro Beta counter (Wallac). Aliquots of 20
μL from each well were taken for protein measurement.
Background estimation experiments were conducted in
parallel in separate plates without cells, where the
corresponding amounts of cold and labeled oligonucle-
otides or conjugates were added. Both protein content
data and background estimation experiments were taken
into consideration while presenting the results of cellular
uptake experiments. The stability of the oligonucleotides
and conjugates in the cellular uptake experiments was
controlled by PAGE electrophoresis which did not reveal
any substantial degradation of the compounds.
Antisense Activity of the Oligonucleotides and
Oligonucleotide-Peptide Conjugates. The luciferase-
expressing cells were plated in 24-well plates at a density
of (4-5) × 104 cells/well and grown for 24 h to ap-
proximately 60-80% confluence. CV1-P cells were grown
in DMEM with 10% of FBS, D 407 cells in DMEM with
5% of FBS, and CHO cells in R-modified Eagle’s medium
(R-MEM, Gibco) with 10% of FBS and medium before
transfection was replaced by serum-free medium con-
taining oligonucleotides, conjugates, or their Cytofectin
GC formulation and incubated for 4 h. Cells were then
grown in the normal medium for 12-20 h, washed with
PBS, lysed, and tested for the luciferase activity as
described earlier (24).
Luciferase Expression Assay. The influence of the
compounds on the luciferase expression in vitro in the
cell-free system was studied using TNT Coupled Wheat
Germ Extract Systems kit (Promega) as described earlier
(24).
RNase H Cleavage Experiments. Synthetic RNA
fragment 5′-UACUGUUGGUAAAAUGGAAGACGCCA-
AAAACAUA-3′ (M) was 5′ labeled with 32P using T4
polynucleotide kinase (Pharmacia). One picomole of
labeled matrix was annealed to 1 pmol of oligonucleotides
or conjugates by heating to 70 °C and slowly decreasing
the temperature to 25 °C overt 2 h. Annealed complexes
were incubated with 1 unit of RNase H (USB-Amersham
Pharmacia Biotech) in 20 mM Tris-HCl buffer, pH 7.5;
containing 20 mM KCl, 10 mM MgCl2 , 0.1 mM EDTA,
and 0.1 mM cystamine for 30 min at 37 °C. Products of
the reaction were analyzed by 15% PAGE and subsequent
autoradiography.
Confocal Fluorescence Microscopy. Luciferase-
expressing cells were plated in glass Lab Tek 8-chamber
slides (NUNC Inc.) at a density of (6-10) × 104 cells/
well and cultured for 36 h. The culture medium was
discarded and after washing replaced by the serum-free
medium containing fluorescein-labeled oligonucleotides,
oligonucleotide-peptide conjugates, or their Cytofectin
GC formulation. Cells were incubated for 4 h and washed
twice with the serum-free medium and three times with
PBS. After washing, cells were fixed with 0.1% glutaric
dialdehyde in PBS for 5 min, washed with PBS, and
mounted in 90% glycerol in PBS. Cells were examined
under the confocal laser scanning microscope (Leica).
RESULTS AND DISCUSSION
Comparison of Methods To Synthesize Disulfide
Cross-Linked Peptide-Oligonucleotide Phospho-
rothioate Conjugates. It is obvious that the yield of
any reaction leading to the disulfide cross-linked POPC
strongly depends on the spatial structures of the peptide
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and the oligonucleotide in question. To develop a method
of cross-linking that is as independent as possible of the
structures of the molecules to be linked together, the
composition of the solvent mixture and concentrations
of the reacting components were first optimized. A large
number of preliminary experiments demonstrated that
the best yields were obtained when the resulting conju-
gation mixture contained about 90% of a chaotropic
solvent, formamide, the concentration of peptides being
about 0.09 mg/mL and that of oligonucleotides about 0.6
OD/mL. In principle, there are at least three straight-
forward routes to generate a disulfide bond between an
oligonucleotide phosphorothioate tethered with a linker,
bearing a mercapto group, and a synthetic peptide also
having a mercapto function. This function may reside
either in peptide’s C-terminal cysteine or in a mercap-
topropionic acid residue, attached to the N-terminus. We
have investigated the applicability of these possible
alternative procedures by binding peptides P1-P4 to
oligonucleotide O2: method A, the reaction of a thiol
containing peptide with an oligonucleotide bearing mer-
captoalkyl group [analogous to the approach mentioned
in the literature (17)]; method B, the reaction of a thiol
containing peptide with an oligonucleotide possessing a
pyridyl disulfide function, similar to procedure reported
by Lebleu et al (8); and, finally, method C, the reaction
of a pyridyl disulfide containing peptide with an oligo-
nucleotide having a mercaptoalkyl group (Scheme 1).
The results of these experiments have demonstrated
that the yield of isolated conjugate strongly depends on
the method of coupling and the peptide’s structure.
Method A gave yields ranging from 0.4 to 23%. Testing
of method B has also revealed relatively low yields from
7 to 24%. Method C, however, have demonstrated the
highest yields, ranging from 36 to 88%.
An additional experiment, employing method C, was
carried out in order to demonstrate the absence of
coupling between the peptide, activated by a pyridyl
disulfide function and the phosphorothioate groups of the
oligonucleotide. In this experiment, a control oligonucle-
otide phosphorothioate had the same sequence as O1, but
contained no 3′-mercaptoalkyl function. After 12 h at rt,
IE HPLC has revealed no formation of any conjugated
structure. Oligonucleotide phosphorothioate appeared to
be intact. RP HPLC, in turn, has demonstrated the
formation of only 3% of peptide dimer, with the rest of
the activated peptide remaining stable in the reaction
mixture.
Thus, method C appears to be the procedure of choice
for preparation of the disulfide cross-linked peptide-
oligonucleotide phosphorothioate conjugates.
Synthesis and Characterization of Peptide-Oli-
gonucleotide Phosphorothioate Conjugates. Method
C was employed to synthesize 18 POPCs (Scheme 2). In
all of these conjugates, the oligonucleotide moiety is a
15-mer (O1-O4) or 25-mer (O5) phosphorothioate. The
peptide moiety is either a modified 17-mer hydrophobic
MPM (P1, P2) or a modified 27-mer sequence, containing
the above-mentioned 17-mer sequence and a the basic
10-mer NLS (P3, P4). The disulfide bridge was formed
between the 3′-ends of O1-O5 oligonucleotides and
either the C-termini (P1, P3) or N-termini (P2, P4) of
peptides. The yields of conjugates synthesized were 35-
60%, and purity, as assessed from RP HPLC was higher
than 95%. The 15% denaturing PAGE (data not shown)
revealed good purity for all conjugates synthesized. The
migration rate of the conjugates of peptides P1 and P2
was about 0.73-0.75 times, and that of peptides P3 and
P4 conjugates 0.63-0.65 times that of the parent oligo-
nucleotides. The final characterization of POPCs was
achieved by electrospray ionization mass spectrometry
(ESI-MS), which has proven to be a powerful method for
the characterization of oligonucleotides (25, 26) as well
as their peptide conjugates (27). In our study, the
negative ion ESI mass spectra of the conjugates displayed
a series of deprotonated molecules (M - nH)n- as major
peaks, the charge states ranging from 4 to 9. Figure 1
demonstrates a typical ESI mass spectrum obtained after
injection of 5 μL of conjugate O4-P3. Mass deconvulation
program can be used for reconstruction of the molecular
weight of the conjugate using the m/z values of the
multiply deprotonated molecules (Figure 2). The mea-
sured and theoretically calculated average molecular
weights of compounds reported here were in excellent
agreement. The difference between the calculated and
measured molecular masses was always less than 3.1
mass units (0.05%).
Attempted Inhibition of Luciferase Gene Expres-
sion in Vivo in Living Cells by Peptide-Oligo-
nucleotide Phosphorothioate Conjugates. The pep-
tide moiety of conjugates reported here contains membrane
translocation and nuclear localization motives which are
supposed to assist the oligonucleotide in passing through
the cell membrane and reaching the nucleus. The oligo-
nucleotide moiety is expected to display its antisense
effect in the cytoplasm and nucleus, inhibiting the target
gene expression (28).
We have attempted to influence the luciferase gene
expression in stably transfected CV1-P, CHO-AA8-Luc,
or D-407 luciferase producing cells with our conjugates.
As in O1, the oligonucleotide sequence in the tested
conjugates O1-Pn was complementary to the initiation
codon region of firefly luciferase mRNA and was reported
earlier to work as an effective antisense compound (29).
The rest of the conjugates were used as controls contain-
ing either a reversed (O2-Pn) or a sense (O3-Pn)
stretches. More than 10 identical experiments were
performed in which the influence of these compounds on
the reporter gene expression was compared to the inhibi-
tion of expression by the cationic lipid formulation of O1
or O1-P3 with the Cytofectin GC. These experiments
have demonstrated the inability of the conjugate O1-
P3 alone to display any serious antisense effect. We have
obtained more or less similar results for conjugates O1-
P1, O1-P2, and O1-P4 and conjugates O5-P3 and
O5-P4, which contain a longer antisense oligonucleotide
sequence O5 in comparison to O1. It is noteworthy that
a substantial inhibition of luciferase expression was
observed in all experiments with the Cytofectin formula-
tion of O1 or O1-P3. It appears that unlike the case
where cationic lipid formulation was used, our conjugates
alone fail to display reproducible antisense action.
Nevertheless, it was still interesting to find out which
part of these conjugates (oligonucleotide or peptide) failed
to play the desired role.
Cellular Uptake Studies with 5′-[32P]-Oligonucle-
otide Phosphorothioates and Peptide-5′-[32P]-Oli-
gonucleotide Phosphorothioate Conjugates. Our
unsuccessful attempt to inhibit the luciferase gene
expression in cells raised some points of substance. First,
it was necessary to verify if any of our conjugates were
taken up by these cells. If some conjugates entered living
cells, then it would be interesting to find out whether
they remain intact throughout our experiment. Figure 3
demonstrates a typical result of cellular uptake experi-
ments. One can see a relatively strong association of
conjugate O2-P3 with CV1-P cells in comparison to
conjugates O2-P1 and O2-P2 and oligonucleotide O2.
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It is clear that the presence of the long 27-mer peptide
with both membrane translocation and nuclear localiza-
tion properties (O2-P3) is somehow responsible for this
strong association, while the presence of mere membrane
permeable motif (O2-P1 and O2-P2) for some reason
retards association even as compared to oligonucleotide
O2. This conclusion received additional support from the
stability test. Figure 4 shows the autoradiography of
PAGE of cell lysates after incubation with 32P-labeled
conjugates and careful washingsstandard procedure,
Figure 1. Negative ion ESI mass spectrum of conjugate O4-P3. The major multiply charged ions represent negative charge states
from 5 to 9. Sample: 5 μL of conjugate O4-P3. Eluent: 10 μL/min of 80% acetonitrile with 25 mM triethylamine.
Figure 2. Reconstructed molecular weight spectrum of conjugate O4-P3 (calculated mass 8418.1).
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and O1-P4 was noticably smaller than that of O1. This
fact may be attributed to the reduced binding affinity of
oligonucleotide part of conjugates to the target RNA,
when compared to that of oligonucleotide phosphorothio-
ate O1.
As indicated above, our conjugates contained sequences
complementary to the initiation codon region of the firefly
luciferase mRNA, and therefore, it was reasonable to
probe their antisense properties in a cell-free luciferase
gene expression system which proved to be a rather
useful tool in our previous studies (24). In fact, this type
of experiment would mimic the testing with living cells
better than the enzymatic assay with RNase H, and it
would hence better elucidate the potency of our conju-
gates as antisense agents. Figure 6 shows that conjugates
O1-P3 or O1-P4, as well as oligonucleotide O1, all
containing the antisense sequence, were able to decrease
the luciferase activity by 60-80% at 2 μM concentration,
while the control conjugates O2-P3, O2-P4, and control
oligonucleotide O2, all containing reversed sequence,
showed inhibition of only 10-20% under the same
conditions. Hence, it became obvious that our conjugates
are taken up by the cells and they are in principle capable
of showing the antisense properties. Their failure to
demonstrate these features in the experiments with cells
should be attributed to their “incorrect” intracellular
distribution, i.e., absence from the cytoplasm and/or
nucleus, where they have to be present in order to display
antisense properties.
Cellular Localization of Peptide-Oligonucleotide
Phosphorothioate Conjugate. To gain insight into
localization of our conjugates in cells, we treated CV1-P
cells with 5′-fluorescein-labeled oligonucleotide O4, con-
jugate O4-P3, and finally with O4-P3 as a cationic lipid
formulation with the Cytofectin GC, and examined the
cells with confocal microscopy. Figure 7A demonstrates
that while most of the conjugate O4-P3 associated with
cells is localized in endosomes, there is only faint
fluorescence in cytoplasm and nucleus. Even lower level
of nuclear fluorescence was detected when CV1-P cells
were incubated with oligonucleotide O4 (Figure 7B)
alone. The cytoplasmic fluorescence detected in this case
was much weaker than with conjugate O4-P3, and it
may in all likelihood be attributed to very low level of
oligonucleotide phosphorothioate internalization. In con-
trast to that, when the conjugate O4-P3 was employed
as a cationic lipid formulation, a very strong fluorescence
was found within the nucleus (Figure 7C), indicating a
different type of intracellular distribution as compared
to results with pure conjugate (Figure 7A). Taken to-
gether, the microscopy results clearly show that although
our conjugates as such indeed possess a clear affinity to
cells they are trapped in the endosomes unlike the
liposomal formulation. Therefore, the access of POPCs
to their target in cytoplasm and nucleus is limited.
CONCLUSION
We have optimized the preparation of disulfide cross-
linked POPCs. According to our results, the most efficient
procedure makes use of a disulfide exchange reaction
between an oligonucleotide phosphorothioate tethered
with a mercaptoalkyl group and a peptide bearing a
pyridyl disulfide function in 90% formamide. Eighteen
compounds were prepared in a yield of 35-60% and
thoroughly characterized by electrospray ionization mass
spectroscopy.
The present work demonstrates that our POPCs are
capable of inhibiting the luciferase gene expression in a
cell-free model transcription-translation system. When
applied to the living cells, some of conjugates with MPM-
NLS peptide display the efficient intracellular penetra-
tion properties but fail to show any serious antisense
effect. Studies on the intracellular distribution of the
fluorescein-labeled conjugates have revealed their endo-
somal localization, thus indicating a failure to reach the
cytoplasm and/or nucleus and hence to produce the
antisense effect. On the contrary, when used as a cationic
lipid formulation with the Cytofectin GC, our conjugates
achieved effective and selective antisense inhibition of
the reporter gene expression. All these data taken
together brings over the conclusion that the structure of
the conjugates of oligonucleotide phosphorothioates with
peptides, exhibiting membrane translocation and nuclear
localization properties, yet has to contain some additional
feature to avoid endosomal trapping. It appears that
mere conjugation of antisense oligonucleotides and pep-
tides possessing membrane penetration and nuclear
localization properties does not necessarily result in a
reliable delivery system which works well with a number
of cell types. However, the chemical methodology devel-
Figure 6. Influence of the antisense and control oligonucleotides and/or oligonucleotide-peptide conjugates on the luciferase reporter
gene expression in cell-free system.
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removing the noninternalized conjugates and dead cells,
capable of accumulating labled compounds (22, 23). Very
little if any degradation was detected, demonstrating
sufficient stability of the peptide-oligonucleotide phos-
phorothioate conjugates throughout our experiments with
cells.
RNase H Mediated Cleavage of Synthetic RNA-
Conjugate Complexes and Inhibition of Luciferase
Gene Expression in an in Vitro Transcription-
Translation System. The next question was whether
our conjugates were capable of triggering the RNase H
mediated cleavage of the target RNA. The answer to this
question appears to be of significant importance since this
type of mRNA degradation is believed to be the most
common mechanism of the antisense action (30). To
investigate this subject, we synthesized a 34-mer oligori-
bonucleotide (M), corresponding to the -13 to +21
fragment of the luciferase mRNA. This RNA fragment
was 5′-32P-labeled and subjected to the action of RNase
H in the presence of oligonucleotide O1 and conjugate
O1-P3 or O1-P4, all containing the 15-mer comple-
mentary sequence. Conjugates O3-P3 and O3-P4 con-
taining the sense sequences were used as controls. The
autoradiography of PAGE referring to these experiments
is shown in Figure 5. One can see that while conjugates
O1-P3 or O1-P4, as well as oligonucleotide O1, clearly
triggered the RNase H activity (Figure 5, lines 1, 2, and
5), control conjugates O3-P3 and O3-P4 were unable
to recruit the enzyme for the RNA fragment digestion
(Figure 5, lines 3 and 4). The observed effect of O1-P3
Figure 3. Uptake of the 32P-labeled oligonucleotide and oligonucleotide-peptide conjugates by CV1-P cells. Dependence of cell
associated radioactivity on the concentration of 32P-labeled oligonucleotides and oligonucleotide-peptide conjugates in the incubation
mixture. Cells were incubated with control substances for 4 h, washed and lysed as described in Experimental Procedures.
Figure 4. Stability of the oligonucleotide-peptide conjugates
in the cells. Autoradiogram of 15% PAAG electrophoresis of the
cell lysates and control 32P-labeled conjugates: lines 1-3scells
incubated with mixtures of 5 μM unlabeled and 1.75 × 106 cpm
of 32P-labeled O1-P3, O1-P1, or O2-P3 respectively; lines
4-6s32P-labeled O1-P3, O1-P1, or O2-P3. The migration
position of O1 is indicated with arrow.
Figure 5. RNase H digestion of [32P]M in the presence of
oligonucleotides and conjugates: line 1sin the presence of O1-
P3; line 2sin the presence of O1-P4; line 3sin the presence
of O3-P3; line 4sin the presence of O3-P4; line 5sin the
presence of O1; line 6s[32P]M.
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oped by us allows conjugation of oligonucleotides also to
peptide sequences enhancing endosomal escape and
hence antisense activity.
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Abstract 
The synthesis of disulfide-cross-linked circular oligonucleotides, employing two 
different approaches, was accomplished. Several circular oligomers, which bear a 
C(5)-aminoalkyl-tethered thymidine unit, were labeled with photoluminescent 
europium(III) chelates. All circular structures were thoroughly characterized with 
denaturing PAGE and electrospray ionization mass spectrometry. It was 
demonstrated that the disulfide cross-linking, resulting in circularization, 
considerably increases the enzymatic stability of phosphodiester oligonucleotides in 
biological media. In addition, UV melting experiments, followed, where possible, by 
extraction of thermodynamic parameters, revealed that several circular oligomers 
appear to be more selective towards their complementary targets than their 
corresponding linear precursors. Finally, the mixed-phase hybridization 
experiments have demonstrated that use of circular probes indeed improves the 





















* Adapted from: Tennilä T, Ketomäki K, Penttinen P, Tengvall U, Azhayeva E, 
Auriola S, Lönnberg H, Azhayev A. 2004. Selective circular oligonucleotide probes 
improve detection of point mutations in DNA. Chem Biodivers. 1(4): 609–625. 
Reprinted with kind permission from John Wiley & Sons, Inc. 
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Abstract
Covalent post-synthesis or solid-phase conjugation of peptides to oligonucleotides has been reported as a possible
method of delivering antisense oligonucleotides into cells. While synthesis strategies for preparing these conjugates have
been widely addressed, few detailed reports on their structural characterization have been published. This paper
discusses the negative ion electrospray ionization mass spectrometric (ESI-MS) and liquid chromatography/mass
spectrometric (LC/MS) analysis of various peptide/oligonucleotide conjugates ranging from small T6-nucleopeptides
to large peptide/oligonucleotide phosphorothioate conjugates and ribozyme/peptide hybrids (3/13 kDa). Molecular
weight determination with mass errors of 0.1/3.1 amu were conducted, employing on-line IP-RP-HPLC and high m /z
range mode to facilitate the analysis of large compounds and difficult modifications.
# 2003 Elsevier Science B.V. All rights reserved.
Keywords: Antisense oligonucleotides; Oligonucleotide/peptide conjugates; MS; LC/MS
1. Introduction
Antisense oligonucleotides are new potential
drugs showing promise for the treatment of viral
infections and cancer [1,2]. Their systemic ther-
apeutic use is, however, hindered by their poor
cellular uptake and inability to reach the nucleus.
Oligonucleotides have been found to be taken into
cells by endocytosis, after which they remain
entrapped in endosomal compartments [3]. Several
strategies have been introduced to overcome this
problem, including the attachment of lipophilic or
cell receptor-binding molecules to oligonucleotides
[4]. Peptides possessing various beneficial proper-
ties have been seen as a possible method of
delivery [5]. Several studies have employed hydro-
phobic peptide sequences known to penetrate
cellular membranes [6,7], nuclear localization se-
quences [8], or both of them combined [5,9]. Many
* Corresponding author. Tel.: /358-17-16-2469; fax: /358-
17-16-2456.
E-mail address: seppo.auriola@uku.fi (S. Auriola).
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of the conjugates have indeed exhibited enhanced
cellular delivery and accumulation in the nucleus
[6,9]. In addition, 3?-conjugation seems to stabilize
phosphodiester oligonucleotides against nucleases
[10], and no adverse effect on duplex formation
has been observed [8,11]. The use of noncovalently
complexed peptide/oligonucleotide hybrids has
been reported [6,10], but the main interest has
lately been on covalently attached conjugates.
They can be synthesized either by post-synthetic
coupling of pre-purified peptides and oligonucleo-
tides [9,12] or by stepwise solid phase synthesis
without intermediate purifications [11,13,14], the
latter being more convenient for routine applica-
tions because of its speed and easiness.
Electrospray ionization mass spectrometric
(ESI-MS) analysis of peptides and, increasingly,
of oligonucleotides can be considered a routine
method. A number of peptide/oligonucleotide
conjugates have been characterized by MALDI-
MS [15,16], ion spray MS [11] or ESI-MS
[7,9,13,14,17]. However, very few detailed articles
can be found on the mass spectrometry of
peptide/oligonucleotide conjugates. The success-
ful ESI-MS of peptide/oligothymidylates has been
reported on a triple/quadrupole system, including
attempts to sequence these conjugates by tandem-
MS [18].
In this study, negative ionization ion trap ESI-
MS and LC/MS were used to characterize several
peptide/oligonucleotide conjugates synthesized
either by post-synthetic conjugation (convergent
synthesis) or direct solid-phase assembly (stepwise
synthesis).
2. Experimental
2.1. Reagents and chemicals
DNA synthesis reagents were obtained from
Glen Research, except 2,6-lutidine (99%) and N -
methylimidazole (99/%, redistilled) which were
from Aldrich. The Fmoc-L-amino acids and resins
for peptide synthesis were purchased from Bachem
and Novabiochem. 2,2?-Bis-dipyridyl disulfide
(98%, AldrithiolTM) and threo-1,4-dimercapto-2,3-




SAS1 5?-TGG CGT CTT CCA TTT-3?
LSAS1 5?-TTT TGG CGT CTT CCA TTT TAC CAA C-3?
SC1 5?-TTT ACC TTC TGC GGT-3?
SC2 5?-ACC GCA GAA GGT AAA-3?
Rza 5?-gscsas gsug gcc gaa agg Cga gUg aGG uCu agc uca
B-3?
SAS1 and LSAS1, antisense inhibitors of firefly luciferase
mRNA; SC1, reversed control; SC2, sense control; Rz, ribo-
zyme ‘‘zinzyme’’.
a Lower case, 2?-OMe; C, 2?amino-C; U, c-allyl-U; G, ribo












MPM, membrane permeable motif (hydrophobic region of a signal peptide sequence of the Kaposi fibroblast growth factor); NLS,
nuclear localization sequence of transcription nuclear factor kB ; TAT, truncated HIV-1 Tat protein basic domain; ANT, 43/58
homeodomain of pAntennapedia ; c, thiol group at C-terminus; n, thiol group at N-terminus.
U. Tengvall et al. / J. Pharm. Biomed. Anal. 32 (2003) 581/590582
53 
Aldrich. Acetonitrile (ACN) and other solvents
were HPLC grade.
LC/MS eluents containing triethylammonium
acetate (TEAA) and dimethylhexylammonium
formate (DMHA-F) were prepared by adjusting
the pH of 25 mM triethylamine (TEA; puriss. p.a.,
for HPLC, /99.5%, Fluka) to 7 with acetic acid
or by adjusting the pH of 20 mM N ,N -dimethyl-
hexylamine (DMHA; 98%, Aldrich) to 7 with
formic acid. The pH was adjusted before adding
ACN to any eluents. The eluents containing
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP; puriss.




The oligonucleotides were synthesized on an
Applied Biosystems 392 DNA/RNA synthesizer
using standard methods, as described earlier [20],
introducing a masked mercapto function at the 3?-
Fig. 1. Structures of the conjugates prepared by convergent synthesis: linked via (1) peptide C-terminus and oligonucleotide 3?-
terminus, (2) peptide C-terminus and ribozyme 5?-terminus or (3) peptide N-terminus and oligonucleotide 3?-terminus.
Fig. 2. Structures of the conjugates prepared by stepwise
synthesis: (1) HseGly-linker, (2) APD-linker. X/O (phospho-
diester T6) or S (phosphorothioate SAS1).
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terminus of each oligonucleotide. The sequences
included 15- and 25-mer antisense inhibitors of
firefly luciferase mRNA and 15-mer reversed and
sense control sequences (Table 1). The 15-mer
antisense oligonucleotide was also fluorescent
labeled at the 5?-terminus by using fluorescein
phosphoramidite during synthesis. In addition to
these, a 34-mer ribozyme bearing a C6-thiol linker
at the 5?-terminus, synthesized at RPI (Ribozyme
Pharmaceuticals, Inc.), was used for conjugation.
The peptides were synthesized on a Milligen
9050 peptide synthesizer, using Fmoc/HBTU/TEA
chemistry [9]. The peptide sequences ranged from
10 to 27 amino acids and included a K-FGF
Fig. 3. Full scan (A) and reconstructed (B) negative ion ESI mass spectra of conjugate T6-(APD)-MPM (calculated MW 3412.2).
Direct injection in 25 mM TEA/80% ACN.
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membrane permeable motif, NF-kB nuclear loca-
lization signal, HIV-1 Tat basic domain and
Antennapedia homeodomain (Table 2). 3-Tri-
tylthiopropionic acid was attached to the N-
termini of some of the peptides directly on the
synthesizer.
The peptide/oligonucleotide conjugates were
prepared by activating the free thiol group of the
peptide with bis-2,2?-dipyridyl disulfide and react-
ing it with the free thiol group of the oligonucleo-
tide. The masked thiol function of the
oligonucleotide was first released by reducing it
Fig. 4. Full scan (A) and reconstructed (B) negative ion ESI mass spectra of conjugate SAS1-(APD)-MPM (calculated MW 6414.9).
Direct injection in 25 mM TEA/80% ACN.
U. Tengvall et al. / J. Pharm. Biomed. Anal. 32 (2003) 581/590 585
CHARACTERIZATION OF ANTISENSE OLIGONUCLEOTIDE–PEPTIDE CONJUGATES WITH 
NEGATIVE IONIZATION ELECTROSPRAY MASS SPECTROMETRY* 
56 
with dithiothreitol [9]. The general structures of
the conjugates are shown in Fig. 1.
2.2.2. Stepwise synthesis
In the stepwise solid-phase synthesis, the peptide
MPM (see Table 2) was first assembled with the
synthesizer mentioned above, employing standard
Fmoc/TBTU/TEA chemistry and a solid support
bearing either a homoserine/glycine (HseGly) or
3-aminopropan-1,2-diol (APD) linker [17]. The
oligonucleotide part, which was either phospho-
diester T6 or phosphorothioate SAS1 (see Table 1),
was then synthesized with the synthesizer men-
tioned above, cleaved and deprotected using
standard protocols. The general structures of the
conjugates are shown in Fig. 2.
Fig. 5. Selected ion chromatogram (A) and full scan negative ion ESI mass spectrum (B) of ribozyme conjugate Rz-ANT. Injection of
30 pmol, (A), TEAA (pH 7; 25 mM), (B) TEAA (pH 7; 25 mM) in 75% ACN, gradient: 5/100% B, 5/1 min, 100 ml/min, Luna C18
column (50/2 mm i.d., Phenomenex).
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Fig. 6. Selected ion chromatograms (A) and full scan negative ion ESI mass spectra (B/E) of short conjugates SAS1-NLSc and SAS1-
NLSn, long oligonucleotide LSAS1 and long conjugate LSAS1-MPM-NLSc, respectively. Injection of 20 pmol each, (A) DMHA-F
(pH 7; 20 mM), (B) 90% ACN, gradient: 10/80% B, 20/3 min, 100 ml/min, Genesis C4 column (50/2 mm i.d.).
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2.3. ESI-MS
The conjugates were analyzed on an LCQ
quadrupole ion trap ESI mass spectrometer (Fin-
nigan MAT, San Jose, CA) in the negative ion
mode. The compounds were diluted to 10/30 mM
for direct injection and 1/10 mM for LC/MS
analysis. Some of the measurements were done in
the high mass-to-charge (m /z ) range mode which
facilitates the analysis of large compounds by
enabling the detection of lower charge states up
to m /z 4000.
Most of the conjugates were analyzed using
direct 5 ml injections to the mass spectrometer, the
eluent consisting of 25 mM TEA in 80% ACN.
The eluent flow rate was 5/10 ml/min. The spray
needle was set to /3 kV, the nitrogen sheath gas
flow rate to 70 and the tube lens offset to /10 V
Fig. 6 (Continued)
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(/30 V for high m /z range). The stainless-steel
inlet capillary was heated to 200 8C, and the
capillary voltage was /39 V. The spectra were
measured using 200 ms for collection of the ions in
the trap, and 5/12 microscans were summed.
The LC/MS measurements were done in similar
conditions, using narrowbore LC columns and
flow rates of 100/200 ml/min. Typically, a 50/2
mm C18 column was used with a gradient of 10/
90% ACN or methanol and 15/25 mM TEAA or
DMHA-F as the ion-pair reagent.
The mass spectra were deconvoluted, i.e. the
molecular weights of the compounds were recon-
structed from the spectra, either manually using
the formula z2/(m /z1/1)/(m /z1/m /z2) or with
computer programs (e.g. BIOMASS deconvolu-
tion).
3. Results and discussion
As reported earlier, the behavior of
oligonucleotide/peptide conjugates in ESI-MS is
mainly due to their oligonucleotide portion and
negative ionization is suitable for their analysis,
especially when the oligonucleotide contributes
more to the conjugate mass than does the peptide
[18]. As is the case for oligonucleotides, the mass
spectra obtained here show a series of multiply
deprotonated ions (M/nH)n as major ions [21].
The charge states range from 2 to 12 lost protons,
depending on the size of the molecule, on the MS
conditions during analysis and on the eluent used
[22]. Some sodium adduct ions are also seen after
direct injection ESI-MS of conjugates, although
the samples were desalted and the eluent contained
organic base. As can be seen from the spectra in
Figs. 3 and 4, the degree of cation adduction
increases with the length of the oligonucleotide
and is more extensive with phosphorothioates than
with phosphodiesters [23].
The background noise is, however, significantly
reduced by the use of LC/MS. The high m /z range
further increases the signal-to-noise (S/N) ratio; it
is especially useful when analyzing molecules
larger than 10 kDa which often produce unin-
terpretable spectra below m /z 2000 (Fig. 5). Using
LC/MS, a fair resolution of relatively similar
compounds can be obtained. As can be seen
from Fig. 6(A/C), the almost identical conjugates
SAS1-NLSc and SAS1-NLSn are not completely
resolved*/the chromatogram peaks overlap and
peaks corresponding to both compounds are seen
on the spectra. Nevertheless, the spectra obtained
are more than adequate for simple molecular
weight confirmation. The longer oligonucleotide
and its conjugate are well resolved (Fig. 6(D/E)).
LC/MS eluents used for oligonucleotides contain
organic bases such as TEA, tripropylamine (TPA)
or diisopropylethylamine (DIPEA), while the acid
component of the ion pair reagent is usually acetic
acid, formic acid or carbonic acid [24/26]. Some
Table 3
Measured and calculated molecular weights of conjugates
Conjugate Calculated Measured Error (amu)
SAS1-MPMc 6536.4 6533.3 3.1
SAS1-MPMn 6521.4 6519.7 1.7
SAS1-NLSca,b 6305.1 6304.5 0.6
SAS1-NLSna,b 6290.1 6289.3 0.8
SAS1-MPM-NLSc 7803.0 7800.5 2.5
SAS1-MPM-NLSn 7788.0 7787.3 0.7
SAS1-TAT 6740.2 6739.0 1.2
SAS1-ANTa,b 7268.0 7268.1 0.1
FL-SAS1-MPMc 7151.5 7151.7 0.2
FL-SAS1-MPMn 7138.5 7137.2 1.3
FL-SAS1-MPM-NLSc 8418.1 8418.0 0.1
FL-SAS1-MPM-NLSn 8405.1 8403.2 1.9
LSAS1-MPM-NLSca,b 10 987.7 10 986.5 1.2
LSAS1-MPM-NLSn 10 974.7 10 973.3 1.4
SC1-MPMc 6536.4 6534.5 1.9
SC1-MPMn 6521.4 6518.6 2.8
SC1-MPM-NLSc 7803.0 7801.8 1.2
SC1-MPM-NLSn 7788.0 7787.7 0.3
SC2-MPMc 6630.5 6627.5 3.0
SC2-MPMn 6615.5 6613.9 1.6
SC2-NLSc 6399.2 6398.5 0.7
SC2-NLSn 6384.2 6383.3 0.9
SC2-MPM-NLSc 7897.1 7896.9 0.2
SC2-MPM-NLSn 7881.5 7880.7 0.8
SC2-TAT 6833.4 6834.8 1.4
Rz-ANTa,b 13 929.9 13 933.9 0.4
T6-HseGly-MPM
a,b,c 3497.3 3498.0 0.7
T6-(APD)-MPM
a,b,c 3412.2 3413.8 1.6
SAS1-HseGly-MPMa,b,c 6500.0 6499.5 0.5
SAS1-(APD)-MPMa,b,c 6414.9 6415.9 1.0
a Measured using the high m /z range mode.
b Measured with LC/MS.
c Prepared by stepwise solid-phase synthesis.
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papers report also the advantages of using HFIP
with TEA and a methanol gradient [19,27]. It was
found during this study that at least TEAA and
DMHA-F with ACN gradients seem to work well
for the LC/MS of peptide/oligonucleotide con-
jugates (Figs. 5 and 6).
Altogether, 30 conjugates were successfully
characterized. The measured molecular weights
correlated well with the calculated values, the
error being 3.1 amu or less in all cases (Table 3).
While the ESI-MS of oligonucleotide/peptide
conjugates is generally as straight-forward as that
of oligonucleotides, some difficult modifications
remain that cause problems during analysis. These
include conjugates where the peptide part contains
a large number of arginine and lysine residues
which can bind various salts irreversibly during
HPLC purifications, thus severely complicating
the spectra, and conjugates assembled by stepwise
solid-phase synthesis where no intermediate pur-
ifications are used to remove side products, yield-
ing complex mixtures analyzable by HPLC but
showing no MS peaks corresponding to the right
mass. Hence, some synthesis products were en-
countered during this work which could not be
successfully measured with the current MS meth-
ods (data not shown). Fortunately there were very
few of these compounds, and the methods de-
scribed here can be used as an efficient and rapid
way to characterize novel peptide/oligonucleotide
conjugates in most cases.
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A number of assays based on multiplexed mixed-phase hybridization have been 
reported and used over the last decade. Such assays utilize either oligonucleotide 
arrays on solid supports (Lipshutz et al. 1999) or mixtures of categorized 
oligonucleotide-coated microparticles (Fulton et al. 1997; Hakala et al. 1998b). 
Although both approaches allow for a number of applications, some hurdles have 
yet to be overcome. For example, quantitative measurements with microparticles on 
a solid phase have shown that reliable detection of point mutations and deletions is 
still problematic, as the selectivity of hybridization is markedly changed when going 
from one sequence to another (Hakala et al. 1998a, 1998b). In addition, the distance 
between mismatch and site of immobilization within a probe (Ketomäki et al. 2002, 
2003), the loading of oligonucleotide probes onto the particle, and, to a lesser 
extent, the homogeneity of probes all affect selectivity (Hakala et al. 1997a, 1997b, 
1998a). Accordingly, detection of single-base alterations within certain sequences 
may still be difficult and even when possible, depends on time-consuming 
optimization of the probe length. Earlier, we reported the synthesis and highly 
selective binding of looped oligonucleotides to single-stranded DNA (Azhayeva et al. 
1995a, 1995b) and also the interesting inhibitory properties of double-helix-forming 
circular oligomers (Azhayeva et al. 1997). More recently, we investigated the 
interaction of some double-helix-forming circular oligonucleotide probes with 
various DNA targets, employing thermodynamic analysis. Our preliminary results 
indicated that these circular oligonucleotides were capable of forming stable 
complexes with complementary target, and that the selectivity of circular probes 
appears to be superior to the selectivity of conventional linear probes in a number of 
cases. 
These preliminary data resulted in the conclusion that restriction of the 
conformation of a hybridization probe may be associated with an increase in 
selectivity of target recognition. Circular probes may display additional advantages, 
as they are expected to be more stable towards enzymatic digestion, a common 
problem for oligonucleotides in biological matrices or cell growth media. In this 
report, we describe the synthesis of circular disulfide cross-linked oligonucleotides. 
The circular compounds, bearing both phosphodiester and phosphorothioate 
internucleotide linkages, were characterized by electrospray ionization mass 
spectrometry and liquid chromatography–mass spectrometry, and their enzymatic 
stability in serum and cellular extracts was assessed using solid-phase extraction 
sample pre-treatment coupled to ion-exchange HPLC analysis. The interactions of 
these double-helix-forming circular oligonucleotides with model DNA targets were 
examined by thermodynamic analysis, and the interactions of circular probes 
labeled with a photoluminescent lanthanide chelate with complementary and single-
mismatch-containing DNA sequences were investigated by sandwich-type mixed-
phase hybridization assays and compared with the data obtained from conventional 
linear probes. 
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7.2 Materials and methods 
7.2.1 Oligonucleotide synthesis 
The  oligomers  were  prepared  on  a  solid  support  1 bearing  a  disulfide  bond,  or  on  
commercially available nucleoside-bound solid supports (Glen Research, Sterling, 
VA, USA). Monomer 2, bearing an ester function, was prepared as described by 
Hovinen et al. (1994a). Monomer 3, which has a disulfide bond for its introduction 
on the 5’-termini of oligonucleotides (thiol-modifier C6 S–S; Method B), was also a 
commercial product (Glen Research). Conventional 2’-deoxyribonucleoside 3’-
phosphoramidites and the amino-modifier C6 dT phosphoramidite 4 were also 
obtained from Glen Research. Oligonucleotides were assembled on an Applied 
Biosystems 392 DNA synthesizer on a 1-
M scale. Introduction of the cystamine 
residue into assembled oligonucleotides bearing ester functions was achieved with 1 
M cystamine as the free base (Method A). Generation of free thiol functions on the 
5’- and 3’-termini of the oligomers, and the subsequent cross-linking by the 
disulfide-bond formation via oxidation, to give the corresponding circular 
oligonucleotide (Methods A and B), was performed as described by Azhayeva et 
al. (1995a, 1995b). A phosphorothioate oligonucleotide was also synthesized with 
standard methods, employing the Beaucage reagent for oxidation during DNA 
synthesis, and circularized with the same method (data not shown).  
7.2.2 Labeling of oligonucleotides  
Labeling of the circular oligonucleotides co8co10 and co12co14, and two linear 
reference sequences, o2 (5’-*TCA CCG CCC GGT ACA CC-3’; same sequence as co8) 
and o3 (5’-*TTA TAA CCG AGA AGA GA-3’; same sequence as co12), was achieved 
with the isothiocyanate, Eu-i, and dichlorothiazin, Eu-t, activated terpyridine 
derived  Eu(III)  chelates  (Mukkala  et  al.  1993)  on  the  aliphatic  amino  group  of  a  
C(5)-amino-tethered thymidine unit T. The oligonucleotide (50 
g, ca. 9 nmol) was 
dried in a small Eppendorf tube. Dichlorotriazine or the isothiocyanate-activated 
europium(III) terpyridine chelate (Mukkala et al. 1993) was added in 50 mM aq. 
NaHCO3/Na2CO3,  pH 9.510.0,  in  10-  to  20-fold excess,  estimated on the basis  of  
UV absorption (UVmax 320 nm,  =27 000 M1 cm1) in 1020 
l. The reaction was 
incubated overnight in the dark. The resulting mixture was initially passed through 
a NAP-5 gel filtration column with H2O. The oligonucleotide fraction obtained was 
then purified with RP-HPLC on a ThermoHypersil C-18 column (4.6 mm × 150 mm; 
buffer A: 0.1 M triethylammonium acetate (TEAA), buffer B:  0.1  M  TEAA  +  65%  
MeCN; linear gradient 040 min 040% B; tR ca. 35 min) and desalted.  
The identity of each labeled oligonucleotide was confirmed by ESI-TOF mass 




PAGE was carried out as described by Azhayeva et al. (1995a). Anion exchange by 
HPLC to purify and characterize oligonucleotides was performed on a PolyWAX LP 
(300 Å, 5 
m, 4.6 × 100 mm) column (PolyLC).  
Electrospray ionization mass spectra of the non-labeled oligonucleotides were 
recorded on an LCQ quadrupole ion trap mass spectrometer (Finnigan MAT). The 
voltage at the spray needle was set to 2.5 kV, and the nitrogen sheath gas flow was 
68. The stainless steel capillary was set at a temperature of 200	C and a voltage of 
39 V. The tube lens offset was 10 V. The spectra were measured by collecting ions 
in the trap for 200 ms, summing 5–12 microscans and averaging 3–10 scans for 
each injection. For direct injection analyses, the eluent flow rate was 3 
l/min and 
injection volume 2–5 
l. The samples contained 1–20 pmol of oligonucleotide in 25 
mM triethylamine–80% MeCN. For LC/MS analyses, we used narrowbore reversed-
phase columns with 50 × 2 mm dimensions (e.g. XTerra C-18 and Genesis C-4), flow 
rates of 100–200 
l/min, and 5–20 min MeCN gradients. The ion-pair reagents 
used were triethylammonium acetate (TEAA, pH 7) and N,N-dimethylhexyl-
ammonium formate (DMHA-F, pH 7). The theoretical molecular weights of the 
compounds were calculated manually using average atomic weights. 
7.2.4 Stability of circular oligonucleotides 
Fetal bovine serum (FBS) was diluted in 0.05 M KH2PO4 (pH 7.4). CV-1 and D-407 
cells were washed with phosphate buffered saline (PBS) several times and scraped 
in One-Phor-All Buffer (10 mM Tris-acetate, 10 mM magnesium acetate, 50 mM 
potassium acetate, pH 7.0). The cell suspension was sonicated several times to lyse 
the cells, and centrifuged at 4	C (13,000 rpm, 3 min). The supernatant was 
collected, stored at 70	C, and used undiluted for the incubations. A stock solution 
of each oligonucleotide was mixed with the medium to a final oligonucleotide 
concentration of 2 
M.  
The circular phosphodiester oligonucleotides were incubated at 37	C for 10 h, 
and the phosphorothioates for 24–42 h. Several samples containing 170–300 pmol 
of oligonucleotide were taken during the incubation (linear and circular 
oligonucleotide, 6 samples; linear tethered precursor, 3 samples). Each sample was 
immediately diluted with 1 ml of H2O and solid-phase extracted with a small DNA 
synthesis column (Empty Synthesis TWIST Style Column, Glen Research) packed 
with Toyopearl DEAE-650M anion-exchange resin (TosoHaas). After loading the 
sample, the column was washed with 5 ml of H2O, proteins were removed with 5 ml 
of 75 mM NaCl, and the oligonucleotides were eluted with 5 ml of 0.75 M NaCl. For 
phosphorothioates, the NaCl concentrations were 150 mM and 1.5 M, respectively. 
The sample was then desalted with PolyPAK™ cartridges (Glen Research). The 
cartridge  was  first  equilibrated  with  2  ml  of  MeCN  and  2  ml  of  2  M  TEAA.  The  
sample was then loaded on the cartridge, the salts were washed out with 3 ml of 0.1 
M TEAA, and the oligonucleotides were eluted with 1 ml 0f 50% MeCN. The solution 
was evaporated to 50100 
l, depending on the initial volume of the sample.  
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The samples were then analyzed by ion-exchange HPLC, with a DNAPac PA-100 
column  (4  ×  250  mm;  Dionex  Inc.).  The  column  temperature  was  set  to  30	C for 
both linear and circular oligomers to enhance the resolution, using a MetaTherm™ 
HPLC Column Temperature Control oven (MetaChem Technologies Inc.). Buffer A 
was 0.1 M sodium acetate (pH 8) in 20% MeCN, and buffer B was 0.4 M NaClO4 in 
buffer A. The flow rate was 1 ml/min. Different two-stage gradients were selected for 
each oligonucleotide to ensure good resolution of metabolites and tR values of 2527 
min for intact oligomer. The gradients used were: i) for linear phosphodiester 
oligonucleotides, 5–15%B (10 min) and 15–18%B (20 min); ii) for the circular 
phosphodiester oligonucleotide, 5–16%B (10 min) and 16–19%B (20 min); iii) for 
the linear phosphorothioate, 10–25%B (10 min) and 25–65%B (20 min); and iv) for 
the circular phosphorothioate, 10–30%B (10 min) and 30–70%B (20 min). The 
percentage of intact oligonucleotide left in each sample was calculated, relative to all 
peak areas in the chromatogram. The half-lives of each oligonucleotide in different 
media were estimated by fitting the data to semilogarithmic plots.  
7.2.5 Melting experiments 
UV spectra were recorded and melting experiments were performed on a Varian 
Cary 300 Bio UV/VIS spectrophotometer, equipped with Cary temperature 
controller and multicell Peltier block. The Cary Win UV thermal application 
software was used to increase temperature at a rate of 0.5	C/min, recording the 
melting curves at 260 nm. The oligomer concentrations were in the 
M range in a 
buffer  containing 10 mM Tris-HCl,  pH 6.8;  0.1  M NaCl;  10 mM MgCl2. Extinction 
coefficients of oligonucleotides were calculated by the nearest-neighbor method 
(Petersheim et al. 1983). The thermodynamic parameters for dissociation melting 
curves of complexes were extracted by employing the MeltWin software (a kind gift 
from Prof. Douglas H. Turner, University of Rochester, USA). Uncertainty in the 
G	37	, H	, and S	 values was estimated to be less than ±10% and Tm values less 
than ±0.3	C, based on triple repetition of each measurement. 
7.2.6 Preparation of oligonucleotide-coated microparticles 
The polymer particles  ( =  50 
m) used to immobilize the oligonucleotide probes 
were made of glycidyl methacrylate (40%) and ethylene dimethylacrylate (60%) 
copolymer, then derivatized with diethylenetriamine, yielding a 1-mmol/g density of 
primary amino functions (SINTEF). A desired proportion (828 
mol/g) of the 
amino groups was acylated with [(4,4’-dimethoxytrityl)oxy]acetic acid, and the 
remaining groups were capped by repeated acetylations (Hovinen et al. 1994b). Two 
oligonucleotide probes, 3’-TTT AAG CTG TCG CTG CAC C-5’ and 3’-TTT CGA CAG 
CTT CGC GAG C-5’, were assembled on these supports via a normal phosphor-
amidite strategy, as described in detail by Ketomäki et al. (2003). 
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7.2.7 Hybridization assays 
Hybridization assays were carried out in Tris buffer (50 mM, pH 7.5, containing 0.5 
M NaCl and 0.01% Tween 20). Typically, 50 oligonucleotide-coated particles were 
shaken in 10 
l of buffer containing the target oligonucleotide (T3T47)  and  the  
fluorescent probe (o2/Eu, o3/Eu, co8/Euco10/Eu, co12/Euco14/Eu) at a 
concentration of 17 or 51 nM. The mixtures were shaken in sealed tubes with a 
rotamix  (15  rpm)  at  25	C overnight. The particles were then rapidly washed with 
buffer, and 10 of the particles were subjected to a time-resolved measurement of the 
fluorescence emission directly from the particle, one after another (Ketomäki et al. 
2003).  The  standard  deviation  ranged  from  5  to  20%.  The  emission  signal  was  
converted to the number of fluorescent probes attached to the particle with the aid 
of a calibration line obtained by determining the amount of Eu(III) ions released 
from  the  particle  by  the  DELFIA  protocol  (Hemmilä  et  al.  1984),  as  described  in  
more detail by Hakala et al. (1998a). 
7.3 Results and discussion 
7.3.1 Synthesis and characterization of circular oligonucleotides 
We previously demonstrated the applicability of disulfide linkers for the cyclization 
of oligonucleotides (Azhayeva et al. 1995a, 1995b, 1997). In the present study, 
introduction of the disulfide functions at both the 5’- and 3’-termini of the oligomer 
was achieved as an initial and a final step in oligonucleotide assembly (Method A, 
Scheme 1, and Method B, Scheme 2). These disulfide bonds were subsequently 
cleaved by a reduction reaction, and the resulting oligomer contained two SH 
functional groups, which were allowed to cross-link by disulfide bond formation 
upon oxidation to give a circular oligonucleotide  bearing the conjugated 5’- and 3’-
termini. To synthesize various circular oligomers, solid support 1 and the ‘active 
ester’ monomeric block 2 (Method A, Scheme 1) or ‘disulfide’ monomeric block 3 
(Method B, Scheme 2) were employed. In addition, a C(5)-amino-tethered thymine 
monomer block 4 was used for several sequences (Method B, Scheme 2). This 
modification allowed the straightforward labeling of oligonucleotides for mixed-
phase hybridization experiments described below. Oligonucleotide sequences, 
comprised of linear precursors lo1lo14 and circular probes co1co14 (Schemes 1 
and 2), are presented in Table 1. 
Labeling. Labeling of the circular oligonucleotides co8co10 and co12co14, 
and two linear reference sequences, o2 and o3, was achieved with the 
isothiocyanate, Eu-i, and dichlorothiazin, Eu-t, activated terpyridine derived Eu(III) 
chelates (Mukkala et al. 1993; structures shown in Scheme 3) on the aliphatic 
amino group of a C(5)-amino-tethered thymidine unit T, introduced by monomer 4, 
resulting in the photoluminescent oligomers co8/Euco10/Eu, co12/Euco14/Eu, 
o2/Eu, and o3/Eu. The sequences of the labeled circular oligonucleotides were 
identical to those of the corresponding parent oligonucleotides. 
Electrophoresis. The 15% denaturing PAGE showed reasonable purity for all of 
the synthesized compounds. All circular oligomers migrated differently than their 
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linear precursors or linear oligonucleotides with two terminal SH groups. These 
products were obtained by treating either the precursors lo1lo14 or circular 
oligomers co1co14 with dithiothreitol (DTT) in the presence of Et3N, prior to the 
application on the gel. While circular structures shorter than 29-mer migrated faster 
than their linear counterparts, cyclic oligonucleotides longer than 30-mer always 
migrated slower than their linear precursors. Interestingly, the migration rates of 
the circular and linear 29-mer oligomers were nearly equivalent (data not shown). 
HPLC. Anion-exchange HPLC also appears to be characteristic to the circular 
oligonucleotides, which displayed retention times longer by ca. 2 min than those of 
their linear precursors. RP-HPLC demonstrated that the purity of all circular 
oligonucleotides was >95% (data not shown). 
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Table 1. Sequences comprising linear and circular oligonucleotides. 
Oligomer Sequence1 
lo1, co1 5’-TTT TGG CGT CTT CCA TTT TAC CAA C-3’ 
lo2, co2 5’-CTT TTG GCG TCT TCC ATT TTA CCA ACC-3’ 
lo3, co3 5’-ACT TTT GGC GTC TTC CAT TTT ACC AAC CA-3’ 
lo4, co4 5’-ACT GTT TTG GCG TCT TCC ATT TTA CCA ACC A-3’ 
lo5, co5 5’-ACT GCG TTT TGG CGT CTT CCA TTT TAC CAA CCA-3’ 
lo6, co6 5’-ACT GCG TTT TTT GGC GTC TTC CAT TTT ACC AAC CA-3’ 
lo7, co7 5’-ACT GCG TTG TTT TTG GCG TCT TCC ATT TTA CCA ACC A-3’ 
lo8, co8 5’-TCA CCG CCC GGT ACA CC-3’ 
lo9, co9 5’-TTT CAC CGC CCG GTA CAC CCT T-3’ 
lo10, co10 5’-TTT TTT CAC CGC CCG GTA CAC CCT TTT T-3’ 
lo11, co11 5’-CTA TAA CCG AGA AGA GAT C-3’ 
lo12, co12 5’-TTA TAA CCG AGA AGA GA-3’ 
lo13, co13 5’-TTT TAT AAC CGA GAA GAG ACT T-3’ 
lo14, co13 5’-TTT TTT TAT AAC CGA GAA GAG ACT T-3’ 
1 T = C(5)-amino-tethered thymidine used to attach Eu(III) label. 
 
Scheme 3 Structures of the isothiocyanate (Eu-i) and dichlorothiazin (Eu-t) activated 
terpyridine-derived Eu(III) chelates. 
 
Mass spectrometry. Electrospray ionization mass spectrometry is a sensitive 
method for the analysis of circular oligonucleotides (Azhayeva et al. 1997). The 
measured and theoretically calculated average molecular masses of the circular 
phosphodiester oligonucleotides are shown in Table  2, including those for the 
fluorescently labeled oligonucleotides co8/Euco10/Eu and co12/Euco14/Eu, 
which were measured by our collaborators elsewhere since we failed to succeed in 
measuring them with the ESI–quadrupole ion trap. For all other compounds, good 
quality ESI mass spectra were obtained by direct injection analysis, using 25 mM 
TEA in 80% MeCN as eluent, or, when necessary, by LC/MS using narrowbore RP 
columns and ion-pair reagents. The error between measured and calculated mass 
exceeds 0.03% only in one case, and none of the measurements exceed a mass error 
of 0.05%, which might be considered a threshold for failing results. Eight of the 14 
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compounds measured in our lab display a mass error of 0.01% or less, which is the 
highest accuracy routinely attainable with ESI–quadrupole ion trap MS. 
Figure 1 shows the direct injection and LC/MS spectra of the 37-mer circular 
phosphodiester oligonucleotide co7, illustrating the usefulness of LC/MS in the 
analysis of large modified oligonucleotides. The direct injection ESI spectrum 
displays an extremely high degree of noise and cation adduction, despite using 
organic bases in the eluent. LC/MS of the same compound, in contrast, improves the 
spectral quality remarkably. In addition, similar spectra were measured for a 25-
mer circular phosphorothioate oligonucleotide (Figure 2). While this compound is 
not as large, the phosphorothioate backbone attracts more contaminating species 
and is more difficult to purify than a phosphodiester of corresponding length. While 
the two main peaks are clearly visible even in the direct injection spectrum, LC/MS 
significantly enhances the signal-to-noise ratio.   
Table 2. Measured and theoretically calculated average molecular masses of the 
circular oligonucleotides. 
Oligonucleotide Calculated mass Measured mass Mass error (%) 
co1 7898.2 7897.2 0.01 
co2 8476.6 8475.2 0.02 
co3 9103.0 9101.8 0.01 
co4 9736.4 9735.0 0.01 
co5 10354.8 10352.3 0.02 
co6 10963.2 10960.6 0.02 
co7 11596.6 11600.7 0.04 
co8 5579.8 5577.9 0.03 
co9 7084.9 7085.2 <0.01 
co10 8910.1 8910.0 <0.01 
co11 6333.4 6333.0 <0.01 
co12 5755.0 5753.1 0.03 
co13 7260.0 7259.6 <0.01 
co14 8172.6 8172.4 <0.01 
co8/Eu1 6384.4 6385.3 0.01 
co9/Eu1 7958.9 7959.8 0.01 
co10/Eu1 9784.1 9783.6 <0.01 
co12/Eu1 6629.0 6628.5 <0.01 
co13/Eu1 8134.0 8134.5 <0.01 
co14/Eu1 9046.6 9046.9 <0.01 
1 Measured with ESI-TOF MS. 
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Figure 1 a) Direct injection ESI mass spectrum1, b) ESI–LC/MS spectrum2, and the 
structure of circular phosphodiester oligonucleotide co7 (mol. weight = 11597). 
1Eluent: 25 mM triethylamine in 80% MeCN, flow rate: 10 
l/min; 2Genesis C-4 









Figure 2 a) Direct injection ESI mass spectrum1, b) ESI–LC/MS spectrum2, and the 
structure of 25-mer circular phosphorothioate oligonucleotide Sco1 (mol. weight 
= 8316). 1Eluent: 25 mM triethylamine in 80% MeCN, flow rate: 20 
l/min; 
2XTerra C-18 column, 5 min MeCN gradient + TEAA (pH 7), flow rate: 200 

l/min. [Previously unpublished.] 
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7.3.2 Stability of circular oligonucleotides 
Unmodified oligodeoxyribonucleotides undergo rapid degradation by nuclease 
enzymes in serum and cells, with half-lives of ca. 30 min (Woolf et al. 1990). Since 
the primary degrading activity in biological media is due to 3’-exonucleases, it 
seemed possible to design phosphodiester oligonucleotides where only the 3’-
terminus was protected from degradation. End-capping was achieved by replacing a 
few of the 3’-terminal nucleotides with nuclease-resistant modifications, e.g., 
phosphorothioates, or by designing circular oligonucleotides that have no 5’- or 3’-
termini. In some cases, 3’-capping had indeed conferred significant improvement 
towards the stability of phosphodiester oligonucleotides (Woolf et al. 1990; Crooke 
et al. 1995). The enzymatic stability of oligonucleotides has frequently been 
evaluated by purified nucleases, but more applicable results can be obtained by 
conducting these tests in biological systems that are commonly used in antisense-
activity studies.  
Methods for separating and quantitating the intact oligonucleotide and its 
metabolites include PAGE with autoradiography, CGE, HPLC, and ESI-LC/MS. 
While PAGE is limited by the inconvenience of using radiolabeled compounds 
(Shaw et al. 1991), the other methods often require extensive sample preparation 
such as phenol/CHCl3 extractions, EtOH precipitation and desalting (Bourque and 
Cohen 1993; Gaus et al. 1997). To simplify sample preparation, Leeds et al. (1996) 
introduced a two-step solid-phase extraction (SPE) method by which proteins and 
lipids were first removed with a strong anion-exchange column, followed by 
desalting with a reversed-phase column. Anion-exchange HPLC is compatible with 
these SPE purifications, and good resolution of 25-mer and smaller oligomers has 
been achieved (Bourque and Cohen 1993). 
In the present work, the metabolism of linear and circular oligonucleotides 
bearing either phosphodiester or phosphorothioate backbones was studied in three 
biological systems: 10% fetal bovine serum (FBS), African green monkey kidney 
fibroblast (CV-1) lysate, and human retina epithelial (D-407) cell lysate. Samples 
taken from the incubation mixture were purified by anion-exchange and reversed-
phase SPE before analysis by ion-exchange HPLC. The recovery of oligonucleotides 
from SPE columns varied considerably, and, therefore, the amount of degradation in 
each sample was estimated by calculating the percentage of the peak area 
corresponding to the full-length oligonucleotide, relative to all peaks in the 
chromatogram.  
An illustrative example of the HPLC chromatogram after incubating the linear 
phosphodiester 5’-TTT TGG CGT CTT CCA TTT TAC CAA C-3’ (o1) in D-407 cell 
lysate is shown in Figure 3a–c. A progression of shorter metabolites appears in the 
chromatogram, indicating the usual mechanism of degradation by exonucleases. 
The results for the linear oligonucleotide o1, which has the same sequence as the 3’- 
and 5’-tethered linear precursor lo1 and the circular co1, demonstrate that it was 
rapidly degraded in all media, with less than 10% of the parent compound intact 
after 24 hours of incubation (Figure 4a–c). As the linear precursor lo1 contained 
modified 3’- and 5’-ends, it was expected to be approximately as stable as the 
circular co1. This was true in the case of CV-1 and D-407 cell lysates (Figures 4b 
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and 4c), where ca. 2030% of both parent compounds remained intact after 10 h. 
However, in 10% FBS, lo1 was significantly less stable than co1, with remaining 
amounts at 10 h being 30% and 80%, respectively (Figure 4a). A longer incubation 
of  42 h with co1 in  10% serum (data  not  shown) demonstrated that  the amount  of  
intact co1 was ca. 50%. After fitting the obtained data to semilogarithmic plots, half-
lives of the phosphodiester oligonucleotides were estimated (Table 3).  
Interestingly, the circular compound co1 had  a  much  longer  t1/2 in  10%  serum  
than in cell lysates. This could be due to the higher amounts of endonucleases in 
cells, in agreement with earlier studies (Bourque and Cohen 1993; Fisher et al. 1993; 
Crooke et al. 2000). Endonucleases are capable of degrading end-modified 
oligonucleotides. However, the same is not observed for the precursor lo1, 
suggesting that it may be susceptible to exonucleases despite the terminal 
modifications. The linear phosphorothioate oligonucleotide (So1)  as  well  as  the  
circular phosphorothioate (Sco1) were completely stable in all media for 42 h (data 
not shown). Therefore, concerning enzymatic stability, there is no additional 





Figure 3 Ion-exchange HPLC chromatogram (absorbance at 260 nm vs. time in min) of 
the linear phosphodiester oligonucleotide o1 after a) 0 minutes, b) 30 minutes, 
and c) 2 hours of incubation in human retina epithelial (D-407) cell lysate.      
[A, C: Previously unpublished.] 
A B C
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Figure 4 Amount of intact oligonucleotide (% of initial amount) in a) 10% fetal 
bovine serum, b) CV-1 cell lysate, and c) D-407 cell lysate. 
 
Table 3. Calculated half-lives of the phosphodiester oligonucleotides. 
Oligonucleotide 10% FBS CV-1 lysate D-407 lysate 
o1 1.2 h 1.3 h 0.53 h 
lo1 5.6 h 3.1 h 3.1 h 
































































































7.3.3 Binding of circular oligonucleotides to complementary targets 
Scheme 4 shows the structures of circular and linear oligomer complexes, co1co7 
and lo1lo7, respectively, with a fully complementary DNA sequence T1 and  a  
similar DNA stretch T2, containing a single mismatch in the middle of the sequence. 
To elucidate and compare the affinity and selectivity of circular and linear 
oligonucleotides,  a number of melting experiments were performed. The Tm values 
and thermodynamic parameters for the dissociation were calculated, where 
possible, by applying a two-state model (Petersheim et al. 1983) with the MeltWin 
software, which uses a non-linear least-squares method; i.e., the 
MarquardtLevenberg fitting routine, A vs. T. The melting curves for complexes of 
co1, co2, and co5 with T1 are shown in Figure 5 as an illustrative example. It can be 
seen that the curves referring to circular co1 (X = Z = 0) and co2 (X = 5’–C–, Z = –
C–3’; Scheme 4), incorporating either no mismatching or a very short random 
mismatching sequence, appear to display only one transition, and they strongly 
resemble the melting curve of regular linear DNA fragments. The curve for co5 (X = 
5’–ACTGCG–, Z = –CA–3’; Scheme 4), incorporating eight totally random 
mismatched nucleoside units, shows two distinct transitions. This observation 
indicates a more complex type of association, and does not allow the application of a 
two-state model (Petersheim et al. 1983) and subsequent extraction of 
thermodynamic data from the melting curves. The situation was similar for melting 
curves of complexes co3, co4, co6, and co7 with oligomer T1 (data not shown). 
 
Figure 5 Melting curves for complexes of circular oligonucleotides co1, co2, or co5 with a 
completely matching complementary DNA sequence T1.  
In contrast to circular oligomers (co3co7), the melting curves for the dissociation 
of all linear (lo1lo7)  and  two  circular  (co1 and co2) oligonucleotides resulted in 
only one transition. This allowed for the application of a two-state model in 
thermodynamic analysis. To elucidate the effect of a single mismatch on the 
efficiency of hybridization of circular oligonucleotides, co1 and co2, compared to 
their linear precursors lo1 and lo2, two sets of melting experiments were performed; 
i) the completely matching oligomer T1 with lo1, lo2, co1, or co2 (Scheme 4); and 
ii) the DNA stretch T2, containing a single mismatch in the middle of the sequence 
with lo1, lo2, co1, or co2 (Scheme 4). Figure 6 shows the melting curves for 
complexes of T1 with co1 (A) and co2 (B), and T2 with co1 (C) and co2 (D), and 
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Scheme 4 Structural complexes of linear and circular oligonucleotides with a completely 
matching complementary DNA sequence and a DNA stretch containing a single 
mismatch. (lo1, co1: X and Z = 0; lo2, co2: X = 5’–C–, Z = –C–3’; lo3, co3: X = 
5’–AC–, Z = –CA–3’; lo4, co4: X = 5’–ACTG–, Z = –CA–3’; lo5, co5: X = 5’–
ACTGCG–, Z = –CA–3’; lo6, co6: X = 5’–ACTGCGTT–, Z = –CA–3’; lo7, co7: 
X = 5’–ACTGCGTTGT–, Z = –CA–3’; SS = disulfide linker. Matching 
sequences are given in bold, and mismatching in plain fonts.) 
 
Table 4 summarizes the extracted Tm values and thermodynamic data. It can be 
seen that circular oligonucleotides are capable of forming stable complexes with a 
single-stranded complementary oligomer T1 (Scheme 4 and Table  4). These 
complexes appear to have Tm values lower by ca. 15	C and free energies of 
association (G	37	) 2.55.0 kcal/mol less negative than those of the corresponding 
complexes of T1 and linear oligomers lo1 and lo2. Interestingly, the introduction of a 
single mismatch into the complex leads to a substantial destabilization in the case of 
circular oligonucleotides (Sel37	 = 7.6 kcal/mol for co1 and Sel37	 = 4.6 kcal/mol for 
co2), whereas the complexes of linear oligomers remain more stable (Sel37	 =  2.9  
kcal/mol for lo1 and Sel37	 =  2.6  kcal/mol  for  lo2). These results indicate that the 
cyclization (i.e., restriction of the conformation) of a hybridization probe may be 
associated with a considerable increase in selectivity of target recognition. The 
increased selectivity appears to be of enthalpic origin, although the reliability of the 
breakdown of free energy to enthalpic and entropic contributions on the bases of a 
melting curve’s shape may well be questioned. Unfortunately, no clear-cut 
conclusion may be drawn in most cases, due to the complex nature of the 
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association process for a single-stranded DNA target with five out of the seven 
circular oligonucleotides studied. Clearly, the melting experiments alone are not 
sufficient to answer the main questions; i.e., are the circular oligonucleotide probes 
more selective in target recognition than conventional linear oligonucleotides, and 
can they serve to improve the fidelity of hybridization assays, in dealing with the 
detection of DNA point mutations? 
 
Figure 6 Melting curves for complexes of co1/T1 (A), co2/T1 (B), co1/T2 (C), and co2/T2 
(D). 
Table 4. Melting temperatures (Tm) and thermodynamic parameters for circular and 
linear oligonucleotides with fully complementary (T1) and mismatched (T2) 
DNA sequences. Thermodynamic data were calculated as mean values of 
three melting experiments. 










co1 T1 55.6  194.3 561 20.4  
 T2 46.7 8.9 111.9 320 12.8 7.6 
co2 T1 56.2  155.6 442 18.4  
 T2 49.9 6.3 109.78 310 13.8 4.6 
lo1 T1 70.4  139.2 375 22.9  
 T2 62.7 7.7 138.5 382 20.0 2.9 
lo2 T1 70.6  143.7 388 23.4  
 T2 63.0 7.6 147.9 410 20.8 2.6 
1 Tm = Tm (complex formed by completely matching sequences)  Tm (complex formed by sequences 
containing a single mismatch); 
 2 Sel37	 =  G37	 (complex formed by completely matching sequences)  G37	 (complex formed by 
sequences containing a single mismatch). 
7.3.4 Mixed-phase hybridization experiments 
To find out whether the cyclization of an oligonucleotide probe really can increase 
the selectivity of hybridization, and, hence, the reliability in the screening of a single 
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nucleotide polymorphism suggested by the melting temperature, the effect of 
various single-base mutations on the hybridization efficiency of linear and 
circularized probes was examined by an independent method, i.e., the sandwich-
type mixed-phase hybridization assay described by Hakala et al. (1998a) and 
depicted schematically in Scheme 5. This assay is based on the time-resolved 
quantification of a fluorescent probe (C) directly on the surface of the microscopic 
polymer particle. In the present application, the complementary sequence between 
the particle-bound probe (A) and the sandwiched oligonucleotide (B) was kept 
sufficiently long (16 nucleotides) to ensure quantitative binding. Accordingly, the 
intensity of the fluorescence emission that is measured from a single particle is 
proportional to the amount of the fluorescently tagged probe (C), either circular or 
linear, that is bound to the sandwiched oligonucleotide (B). It should be noted that, 
when a lanthanide chelate is used as a reporter group, no concentration quenching 
occurs  (Hakala  et  al.  1997b,  1998a).  The  length  of  the  complementary  region  
between the fluorescent (C) and sandwiched (B)  probes  varied  from  10  to  17  
nucleotides, according to the design of probe B, and one-base mismatches were 
generated similarly within this region. 
Scheme 5 Principle of the mixed-phase hybridization assays. 
 
 
Two sets of experiments were performed. The first set was a comparative study on 
the hybridization of a linear, o2/Eu, and three circular oligonucleotides 
co8/Euco10/Eu, all incorporating the same sequence, 5’-TCA CCG CCC GGT ACA 
CC-3’. The circular oligomers differed from each other with respect to the ring size. 
The hybridization of these probes with sequences T3, T7, T11, T15, and T19, fully 
complementary with the probes over 17, 13, 12, 11, and 10 nucleotides in length, 
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respectively, was quantified. In addition, the effect of three different one-base 
mismatches (GT,  CG,  CT) on the hybridization efficiency of these fully 
complementary targets was determined (Scheme 6 and Table 5). The second set 
was, in principle, similar, but the linear (o3/Eu)  and  circular  (co12/Euco14/Eu) 
probes incorporated the sequence 5’-TTA TAA CCG AGA AGA GA-3’, and the length 
of the complementary region varied from 10 to 16 nucleotides (Scheme 6 and 
Table 6). In brief, and concerning the oligonucleotides o3/Eu and co13/Eu (Table 
6) in particular, the cyclization of the probe considerably improved selectivity. For 
example, a single-base mismatch close to the 3’-terminus of the probe (o3/Eu – T23 
vs. o3/EuT24T27; Table 6) decreased the affinity of a linear oligonucleotide by 
only 2050% when the concentration was 51 nM, and the complementary region 
consisted of 16 base pairs. By contrast, with a circular probe, the affinity decreased 
by more than 90% (co13/EuT23 vs. co13/EuT24T27, Table 6), hence allowing 
unequivocal detection of the mutation. Moreover, excellent selectivity remained 
when the length of the complementary region varied over a wide range; i.e. from 16 
to  11  base  pairs  (co13/EuT23 vs. co13/EuT24T27, co13/EuT28 vs. 
co13/EuT29T32, co13/EuT33 vs. co13/EuT34T37, and co13/EuT38 vs. 
co13/EuT39T42; Table 6). With a linear probe, similar selectivity was achieved 
only at one particular length of the complementary region (11 base pairs; 
o3/EuT38 vs. o3/EuT39T42, Table  6). With oligonucleotides o2/Eu and 
co9/Eu (Table 5), the superiority of the circular probe was slightly less impressive.  
 
Scheme 6 Structural complexes of linear (o2/Eu, o3/Eu) and circular (co8/Eu–co10/Eu, 
co12/eu–co14/Eu) oligonucleotides with sequences T3 and T23. (co8/Eu: X and Z 
= 0; co9/Eu: X = 5’–TT–, Z = –CTT–3’; co10/Eu: X = 5’–TTTTT–, Z = –CTTTTT–
3’; co12/Eu: X = 5’–T–, Z = 0; co13/Eu: X = 5’–TTT–, Z = –CTT–3’; co14/Eu: X = 
5’–TTTTT–, Z = –CTT–3’; *T = photoluminescent tagged thymidine unit; SS = 
disulfide linker. Matching sequences are given in bold and mismatching plain.) 
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Clearly, no reasonable detection was possible with a linear probe. The affinity of a 
linear probe in complexes o2/EuT3 vs. o2/EuT4T6 (Table 5) decreased by only 
less than 5% when the concentration was 51 nM, and the complementary region 
consisted of 17 base pairs. On the contrary, the circular probe allowed for the 
detection of a single-base mismatch. For example, a single-base mismatch 
(co9/EuT3 vs. co9/EuT4T6, Table 5) decreased the affinity of a circular probe 
by 3595% when the concentration was 51 nM, and the complementary region 
consisted of 17 base pairs. Comparison of the results of circular probes with different 
ring size (co13/Eu with co12/Eu or co14/Eu; Table 5) indicates that a ring size of 
22 nucleotides is optimal. In general, the results obtained with a 17-mer (co8/Eu, 
co12/Eu)  or  2528-mer (co14/Eu, co10/Eu) circular oligonucleotides were parallel 
to those described for the 22-mers. 
Table 5. Hybridization efficiencies of linear oligonucleotide o2/Eu and circular 







% of o2/Eu 
17 nM/51 nM 
Hybridization, 
% of co9/Eu 
17 nM/51 nM 
Hybridization, 
% of co8/Eu 
17 nM/51 nM 
Hybridization, 
% of co10/Eu 
17 nM/51 nM 
T3 17 28/32 29/27 8/15 26/47 
T4  54/28 0/1 0/0 25/13 
T5  35/31 8/18 1/6 14/33 
T6  27/30 11/15 7/14 9/22 
T7 13 26/35 4/6 1/1 7/17 
T8  2/4 0/0 0/0 0/0 
T9  30/32 0/1 0/0 2/8 
T10  29/31 0/1 1/1 2/8 
T11 12 31/33 1/1 0/1 2/7 
T12  1/1 0/0 0/0 0/0 
T13  32/29 0/0 0/0 0/1 
T14  23/29 0/0 0/0 0/1 
T15 11 26/44 1/2 0/0 2/9 
T16  0/0 0/0 0/0 0/0 
T17  0/2 0/0 0/0 0/0 
T18  0/0 0/0 0/0 0/0 
T19 10 1/3 0/0 0/1 0/0 
T20  0/0 0/0 0/0 0/0 
T21  0/0 0/0 0/0 0/0 











Table 6. Hybridization efficiencies of linear oligonucleotide o3/Eu and circular 







% of o3/Eu 
17 nM/51 nM 
Hybridization, 
% of co13/Eu 
17 nM/51 nM 
Hybridization, 
% of co14/Eu 
17 nM/51 nM 
Hybridization, 
% of co12/Eu 
17 nM/51 nM 
T23 16 11/56 2/62 84/100 2/6 
T24  3/37 0/2 2/4 0/0 
T25  3/49 1/6 4/8 1/1 
T26  2/38 1/4 5/8 1/1 
T27  2/30 0/2 3/5 0/1 
T28 13 10/44 1/42 41/89 1/5 
T29  2/10 0/1 2/2 0/0 
T30  3/19 0/1 1/3 0/0 
T31  2/21 0/1 2/3 0/1 
T32  3/14 0/0 0/2 0/0 
T33 12 7/43 1/30 17/40 1/2 
T34  3/5 0/0 0/1 0/0 
T35  4/5 0/0 0/1 0/0 
T36  4/7 0/0 0/0 0/0 
T37  6/6 0/0 0/0 0/0 
T38 11 3/30 0/28 5/34 0/1 
T39  1/0 0/0 0/0 0/0 
T40  2/3 0/0 0/0 0/0 
T41  1/4 0/0 0/0 0/0 
T42  1/1 0/0 0/0 0/0 
T43 10 3/15 0/2 0/4 0/2 
T44  0/0 0/0 0/0 0/0 
T45  0/0 0/0 0/0 0/0 
T46  0/0 0/0 0/0 0/0 
T47  0/0 0/0 0/0 0/0 
 
7.4 Conclusions 
The synthesis of circular oligonucleotides, their labeling with photoluminescent 
europium(III) chelates, and characterization by ESI-MS was achieved. The disulfide 
cross-linking, which resulted in circularization, apparently increased the enzymatic 
stability of phosphodiester oligonucleotides, especially in serum but also in cell 
extracts. This novel feature of circular probes may be very useful in tuning 
hybridization assays performed with biological samples and, in certain cases, may 
even be useful for some antisense experiments. In addition, the use of circular 
probes instead of conventional linear probes may considerably improve the 
detection selectivity of point mutations in DNA. In particular, cyclization of the 
probe may help in screening these frequently encountered point mutations, which, 
for some reason, do not markedly destabilize the duplex formation of linear 
oligonucleotides.  
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Abstract 
Oligonucleotides such as short interfering RNA (siRNA) comprise a promising 
group of therapeutics that suffers from inefficient cellular uptake and enzymatic 
degradation. To overcome these disadvantages, researchers have introduced 
numerous delivery vehicles. These vehicles include gold nanoparticles (GNPs), 
which can be surface-coated with cationic molecules to form a complex with siRNA. 
In addition, various cell-penetrating peptides (CPPs) are known to enhance the 
intracellular delivery of biomacromolecules and nanocarriers. However, few studies 
have examined cell-penetrating peptide-modified gold nanoparticles (CPP–GNPs) 
for siRNA delivery.  
In this study we combined gold nanoparticles with cysteamine and a cationic 
analog of Tat4860, one of the most extensively investigated CPPs. The CPP–GNPs 
were prepared by a one-step procedure, characterized by microscopic and 
spectroscopic methods, and complexed with siRNA. The effect of the CPP–GNPs on 
cellular viability and gene silencing was then analyzed in a human retinal pigment 
epithelial cell line stably producing the reporter enzyme secreted alkaline 
phosphatase (SEAP-ARPE-19). Our results indicate that the CPP-GNPs form stable 
complexes with siRNA and are able to deliver siRNA into cells in an active form, 
causing a dose-dependent gene silencing of 49% or more. The complexes inhibited 
SEAP production in serum-containing growth medium as well, suggesting that the 
gold particles shield their cargo from enzymatic degradation. Although we found the 
peptide itself toxic at high concentrations, we observed no toxicity for the CPP–
GNPs at any of the concentrations tested. Furthermore, the CPP–GNPs increased 
both the SEAP secretion and cell viability of SEAP-ARPE-19 cells above 100%, 












* Adapted from: Tengvall U, Elizarova T, Takashima Y, Pietilä L, Reinisalo M, 
Laurén P, Urtti A, Antopolsky M, Yliperttula M. One-step production of peptide-




Short interfering RNA (siRNA) and other oligonucleotides show great potential 
against many genetic diseases currently lacking effective and non-toxic treatments 
(Bennett and Swayze 2010). However, this promising group of therapeutics is still 
not in clinical use because of its unfavorable pharmacokinetics. Oligonucleotides are 
extensively metabolized by serum nucleases and excreted by the kidneys in vivo 
(Juliano et al. 2009). Moreover, they exhibit poor permeability through cell 
membranes due to their negatively charged nature. Even when oligonucleotides do 
enter cells via endocytosis, they frequently remain trapped in endosomes, and do 
not gain access to their targets in the cytoplasm (Beltinger et al. 1995). A good 
delivery vehicle would thus protect the oligonucleotide against degradation and aid 
its endosomal escape or, alternatively, use non-endocytic pathways for cellular 
internalization. Most of the current methods of choice are lipid-containing 
formulations such as cationic lipids, which destabilize the endosomal membrane, 
thereby releasing the cargo into the cytoplasm (Zelphati and Szoka 1996). RNA 
interference (RNAi) was accomplished in vivo by covalently conjugating the sense 
strand of siRNA to cholesterol (Soutschek et al. 2004) and by complexing siRNA 
with stable nucleic acid lipid particles (SNALPs) (Zimmermann et al. 2006). The 
first successful systemic administration of siRNA in humans involved transferrin-
mediated targeting to solid tumors by cyclodextrin-based nanoparticles (Davis et al. 
2010), a good example of the current multifunctional approach employing a 
biocompatible nanoparticle core with various surface moieties for cellular uptake, 
nuclear targeting or avoiding recognition by phagocytes. 
Another versatile nanocarrier candidate is colloidal gold, which is anticipated to 
be biocompatible due to its chemical inertness and has been widely investigated for 
diagnostic and therapeutic applications (Ghosh et al. 2008). Citrate-stabilized 
(Chithrani et al. 2006) and oligonucleotide-coated (Giljohann et al. 2007) gold 
nanoparticles (GNPs) enter cancer cells efficiently via endocytosis mediated by 
adsorbed serum proteins. GNPs have been used for the delivery of various 
biomacromolecules, including antisense oligonucleotides (Rosi et al. 2006). In vitro 
delivery was demonstrated for covalent siRNA–GNP conjugates prepared either by 
co-loading thiolated siRNA and thiolated poly(ethylene glycol) (PEG) (Oishi et al. 
2006) or by attachment of siRNA to pre-loaded SH–PEG–NH2 via a disulfide linker 
(Lee  et  al.  2009).  RNAi  in vitro was also achieved with non-covalent siRNA/GNP 
complexes, in which the GNPs were rendered positively charged by coating them 
with cations such as cysteamine (Lee et al. 2008), poly(ethylene imine) (PEI) (Song 
et  al.  2010),  or  cationic  lipids  (Kong  et  al.  2012).  The  GNP  core  could  also  be  
functionalized with cell-penetrating peptides (CPPs), short cationic peptides that 
contain membrane translocation and/or nuclear localization sequences (Fonseca et 
al. 2009). CPPs are known to deliver molecules into cells, and several CPPs have 
been employed in siRNA delivery (Simeoni et al. 2003; Muratovska and Eccles 
2004).  One  of  the  most  promising  and  extensively  studied  CPPs  is  the  Tat4860 
peptide, which comprises the basic region of the HIV-1 TAT protein responsible for 
its efficient cellular uptake and nuclear localization (Vivès et al. 1997). Tat4860 has 
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been shown to enter cells via various, predominantly endocytic mechanisms, while 
rapid translocation leading to cytoplasmic distribution has also been seen at high 
concentrations and with smaller cargoes (Tünnemann et al. 2006; Duchardt et al. 
2007). The key factor triggering CPP internalization by any of the mechanisms 
seems to be the ionic interaction with negatively charged glycosaminoglycans at the 
cell  membrane  (Richard  et  al.  2005;  Nakase  et  al.  2007).  A  study  comparing  the  
cellular uptake of several Tat4860 analogs, all bearing the same number of cationic 
amino acids, found no difference between the sequences, indicating that the ionic 
interaction is in fact crucial for the uptake to occur (Subrizi et al.  2012). According 
to that study, in contrast to earlier results, the absence of cell-surface 
glycosaminoglycans enhanced rather than diminished the uptake. The intracellular 
distribution suggested an endocytic cell entry and endosomal entrapment, which 
had also previously been found to preclude the antisense effect of oligonucleotide–
CPP conjugates (Antopolsky et al. 1999). However, some CPPs can facilitate the 
endosomal escape of cargoes (Jääskeläinen et al. 2000). Effective siRNA delivery 
has been achieved by covalent conjugation of Tat to one of the siRNA strands (Chiu 
et al. 2004; Meng et al. 2009) and by complexing siRNA with Tat-derived peptides 
(Arthanari et al. 2010; Uchida et al. 2011). Multifunctional nanoparticles such as 
gold nanoshells (Braun et al. 2009), quantum dots (Jung et al. 2010), and poly(-
caprolactone) block copolymer micelles (Kanazawa et al. 2012) have been linked to 
Tat for siRNA delivery. Gold nanospheres, in contrast, have so far only been 
conjugated with Tat peptide for nuclear targeting studies (de la Fuente and Berry 
2005; Berry et al. 2007) but not for enhancing the cellular uptake of siRNA.  
Here we describe the straightforward, reproducible one-step synthesis of 
positively charged gold nanoparticles (GNPs) surface-coated with cysteamine and a 
cationic CPP modified from the Tat4860 sequence, the characterization of the 
particles with various methods, complex formation with siRNA and subsequent 
transfection of ARPE-19 cells stably producing the reporter protein secreted alkaline 
phosphatase (SEAP). Our purpose was to produce good quality peptide-modified 
GNPs by facile synthesis methods, characterize them thoroughly, and investigate 
their efficacy in the intracellular delivery of anti-SEAP siRNA as well as their effect 
on the growth and viability of SEAP-ARPE-19 cells. 
8.2 Materials and methods 
8.2.1 Peptide synthesis 
Tat-related CPP (H-CGRKKRWWPQRWWRWWRPPQ-OH) (Subrizi et al. 2012) 
was synthesized with ACT-396 peptide synthesizer, using Wang resin, double 
coupling standard Fmoc-chemistry protocols, TBTU/HOBT as coupling reagent, 2% 
DBU/2% piperidine in NMP for Fmoc deprotection, and a mixture of phenol:H2O: 
EDT:thioanisol:TFA (1.5:1:1:1:10) for 2 h at room temperature for final cleavage and 
deprotection. All coupling reagents, amino acid derivatives and resins were 
purchased from GL Biochem Ltd (Shanghai, China). After cleavage and 
deprotection, the crude peptide was precipitated with ice-cold diethyl ether, filtered, 
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dried and analyzed by RP-HPLC (HP 1050 series chromatography, Supelco 
Discovery C18 column, 15 cm × 4.6 mm, 5 m,  = 220 nm, linear gradient from 0 to 
60%  B  in  40  min;  A  =  0.1%  TFA;  B  =  0.1%  TFA  in  80%  MeCN).  Purification  was  
performed by RP-HPLC (Supelco AscenticTM C18 semi-preparative column, 15 cm 
×  10  mm,  5  m).  After  purification  the  peptide  was  freeze-dried,  its  purity  was  
analyzed by RP-HPLC (Supelco Discovery C18 column, 15 cm × 4.6 mm, 5 m,  = 
220 nm, linear gradient from 0 to 50% B in 40 min; A = 0.05 M KH2PO4, pH 3.0; B 
= 0.05 M KH2PO4 in 70% MeCN, pH 3.0), and it was characterized by MALDI-TOF 
mass spectrometry. The peptide was stored frozen at 20°C. 
8.2.2 Oligonucleotide synthesis 
All siRNAs were synthesized with ASM-800 DNA/RNA synthesizer. Each strand 
was synthesized separately following standard RNA synthesis protocols, using TOM-
protected monomers purchased from Glen Research (Sterling, VA, USA), and 
following standard protocols for cleavage and deprotection. The oligonucleotides 
were then purified by ion-exchange HPLC (TOSOH TSKgel DEAE-2SW column, 25 
cm × 4.6 mm,  = 280 nm, linear gradient from 0 to 50% B in 30 min; A = 0.1 M 
sodium acetate in 20% MeCN; B = A + 0.4 M sodium perchlorate), desalted either 
by gel permeation chromatography (Sephadex G-10 column, 10 × 150 mm, elution 
with  RNAse-free  water  at  a  flow  rate  of  0.5  ml/min)  or  by  using  PolyPak  II  
cartridges (Glen Research) following standard protocol, and kept frozen in water 
solution at 70	C. The siRNAs were quantified by measuring the absorbance of each 
strand at 260 nm, assuming the generally accepted amount of single-stranded RNA 
per optical unit (1 OD = 40 μg/ml). The siRNA strands were annealed immediately 
prior to biological experiments following standard procedures in Dharmacon siRNA 
buffer (20 mM KCl, 6 mM HEPES, 0.2 mM MgCl2 × 6H2O, pH 7.5). 
Model double-stranded oligodeoxyribonucleotide was synthesized with the same 
equipment using monomers purchased from Glen Research and following standard 
DNA coupling protocol. It was cleaved/deprotected, purified and characterized in 
the same manner as described above. 
8.2.3 Synthesis of cell-penetrating peptide-modified gold 
nanoparticles 
The cell-penetrating peptide-modified gold nanoparticles (CPP–GNPs) with a 40:1 
ratio (mol/mol) of the surface stabilizing agent (cysteamine) and CPP, were 
prepared with the following method: 5 mg (14 mol) of gold(III)chloride trihydrate 
(ACS  Reagent;  Sigma-Aldrich,  St.  Louis,  MO,  USA)  was  dissolved  in  5  ml  of  
deionized water and, while stirring, 2.4 mg (21.2 mol) of cysteamine (98%, Fluka, 
Sigma-Aldrich) and 1.55 mg (0.53 mol) of peptide co-dissolved in 4 ml of deionized 
water was added. After 5 min of stirring at room temperature, a solution of 0.02 mg 
of NaBH4 (98.5%, Sigma-Aldrich) in 0.5 ml of deionized water was added dropwise 
within 20 min and the reaction mixture was left overnight under vigorous stirring. 
The reaction mixture was transferred into a dialysis tube (MWCO 12–14 kDa; 
Medicell International Ltd., London, UK) and dialyzed against deionized water for 
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48 h. The resulting colloidal solution of CPP–GNPs was kept in a glass flask at room 
temperature. All other CPP–GNPs were synthesized in a similar manner, varying 
only the ratio between CPP and cysteamine as mentioned in Table 1. The 
concentration of CPP–GNPs (mg/ml) was calculated from the amount of gold 
chloride added to the reaction solution, assuming 100% reduction, resulting in a 
CPP–GNP  solution  containing  0.5  mg/ml  gold  (5  mg  of  gold  chloride  in  a  total  
volume of 9.5 ml). After determining the diameter of the particles, the average 
amount of gold atoms per particle and the molar concentration of the solution were 





where N = the average number of gold atoms per particle,  =  density  for  fcc  gold 
(19.3 g/cm3),  D  =  particle  diameter  (cm),  M  =  atomic  weight  of  gold  (197  g/mol),  





where  Ntotal = total number of gold atoms (equivalent to the initial amount of gold 
salt added to the reaction solution) and V = the volume of the reaction solution (in 
liters). The molar concentration calculated for 20-nm CPP-GNPs was 10 nM. 
8.2.4 Preparation of siRNA/gold nanoparticle complexes 
The complexes were prepared 30 minutes prior to use by mixing the corresponding 
amounts of double-stranded siRNA in RNase-free water and CPP–GNP. Different 
siRNA:gold ratios (by mass) were prepared and tested for complex stability by 
electrophoresis, using a double-stranded oligodeoxyribonucleotide as a model for 
siRNA (see next section). 
8.2.5 Characterization of gold nanoparticles and siRNA/gold 
nanoparticle complexes 
Transmission electron microscopy. The CPP–GNPs were visualized with JEOL 
1200-EX II transmission electron microscope on carbon-coated copper grids with 
magnifications from 100 K to 200 K. The particle diameters were measured 
manually  with  Scion  Image  4.0.2  software  (Scion  Corporation,  Frederick,  MD,  
USA). 
UV/VIS spectroscopy. Optical  spectra  from 200 to  800 nm of  the CPP–GNPs 
and siRNA/CPP–GNP complexes were measured with Cary 100 Conc UV/VIS 
spectrophotometer (Varian, Agilent Technologies, Santa Clara, CA, USA).                             
Loading measurements. After the reaction of CPP-modified GNPs had been 
completed, an 1-ml aliquot of the reaction mixture was analyzed for the presence of 
free CPP by RP-HPLC as following. The CPP–GNPs were precipitated by adding 100 
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l of 2 M HCl and centrifuged. The amount of unattached peptide in the supernatant 
was analyzed by RP-HPLC as described for peptide synthesis and compared to a 
calibration curve obtained for peptide concentrations from 0.05 to 1.0 mg/ml.                            
Gel electrophoresis. A double-stranded oligodeoxynucleotide, bearing the 
same sequence as the active siRNA, was synthesized to serve as a model compound 
for siRNA/CPP-GNP complex stability. Different oligonucleotide:peptide mass 
ratios were prepared and tested with 15% PAGE, using GeneRuler™ DNA ladder 
(Ultra low range, 10 bp; Fermentas, Thermo Scientific Life Sciences, Waltham, MA, 
USA) as MW standard, to see if the complexes were stable. Lability of the complexes 
would be seen as presence of free oligonucleotide on the gel. 
8.2.6 Engineering of stable ARPE-19 cell lines expressing secreted 
alkaline phosphatase 
To produce a cell line stably expressing secreted alkaline phosphatase (SEAP), 
human ARPE-19 retinal pigment epithelial cells (CRL-2302™; ATCC, Manassas, 
VA, USA) were seeded on 100 mm culture dishes (1 × 106 cells/dish). After overnight 
culture, the cells were transfected with 7 μg of pCMV-SEAP2/neo reporter plasmid 
(Wikström et al. 2008) complexed with 25 kDa branched poly(ethylene imine) 
(PEI25;  Sigma-Aldrich,  St.  Louis,  MO,  USA)  at  a  charge  ratio  of  +4.  Cells  were  
cultured in the presence of 0.8 mg/ml neomycin analog, G418 (Calbiochem, Merck 
KGaA, Darmstadt, Germany), as a selective agent. Formed cell colonies were 
trypsinized and expanded in 48-well plates with medium containing 0.6 mg/ml 
G418. The SEAP expression levels of the cells were quantified by using a 
chemiluminescent assay (The Great EscAPe SEAP Kit; Clontech, Mountain View, 
CA, USA). Several cell colonies displaying various SEAP expression levels and 
normal growth rate were chosen for future experiments. 
8.2.7 Cell culture and transfection 
SEAP-ARPE-19 cells (colony 12.7, P5–15) were cultured in DMEM/F-12 (Gibco, Life 
Technologies Corporation, Carlsbad, CA, USA) supplemented with 10% fetal bovine 
serum (FBS), 50 IU/ml penicillin, 50 μg/ml streptomycin, 2 mM L-glutamine, and 
0.4 μg/ml G418 (Geneticin®, Gibco). The cells were grown at 37	C under a 7% CO2 
atmosphere and subcultured once a week. For transfection, the cells were seeded on 
96-well plates (Nunc, ThermoFisher Scientific, Waltham, MA, USA) at a density of 
104 cells  per  well  in  100  μl  of  growth  medium.  After  24  h  of  incubation,  the  cells  
were washed with PBS, and 100 μl of transfection mixtures diluted either in Opti-
MEM (Gibco) or DMEM/F-12 (supplemented as mentioned above but without 
G418) were added. The first experiment was conducted by washing the cells with 
PBS and adding 100 μl of fresh DMEM/F-12 growth medium 3 h after transfection, 
followed by SEAP assay at 6, 24 and 48 hours after transfection to see how the 
expression changed over time and if it was affected by the CPP–GNPs. In other 
experiments, the cells were tested for SEAP production and/or cell viability either 
24 h or  48 h after  transfection.  In the latter  case,  fresh medium was added to  the 
cells 24 h post-transfection. In one experiment, the effect of CPP–GNPs on the 
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proliferation of cells was studied by transfecting the cells with CPP–GNPs and 
counting the amount of transfected and non-transfected cells at 24 and 48 h after 
transfection. The cells were counted manually using erythrosine dye and a Bürker 
counting chamber. 
8.2.8 Cell viability assay 
The viability of transfected cells was tested using the MTT assay. First, a 5 mg/ml 
solution of MTT (thiazolyl blue tetrazolium bromide, BioReagent, 97.5%, Sigma-
Aldrich,  St.  Louis,  MO,  USA)  was  prepared  in  PBS  and  filtered  through  a  0.2  μm  
membrane. After transfection and either 24 or 48 hours of incubation, the cells were 
washed  with  PBS,  and  100  μl  of  a  mixture  of  DMEM/F-12  and  the  MTT  solution  
(10:1, v/v) was added to each well, including negative control wells without cells and 
positive control wells with non-transfected cells. The cells were incubated for 2 h at 
37	C  and  7%  CO2.  After  this  the  medium  was  removed  and  100  μl  of  DMSO  
(BioReagent, 99.9%, Sigma-Aldrich) was added to dissolve the formazan crystals 
formed by intact cells. Absorbance at 570 nm was then measured with VarioSkan 
Flash multimode reader (ThermoFisher Scientific, Waltham, MA, USA). Cell 
viability was expressed as percentage of positive control after subtracting the 
negative control from all values. To ensure that the gold did not interfere with the 
absorbance measurement, cells transfected with high concentrations of CPP–GNPs 
were tested using a modified assay where only growth medium was added to the 
cells instead of the medium–MTT mixture. 
8.2.9 SEAP expression assay 
The SEAP production of the cells was analyzed using the Great EscAPe SEAP 
Chemiluminescence Kit 2.0 (Clontech, Mountain View, CA, USA). A typical assay 
was performed in the following way: After transfection and incubation, 60-μl 
samples were taken from the growth medium. The samples were centrifuged at 
12,000 rpm for 1 min, the supernatants were transferred to new tubes, and stored at 
20	C until assaying. The thawed samples were then diluted 20 times in 
conditioned growth medium, 15 μl aliquots were transferred to a 96-well plate 
(white IsoPlate or Optiplate; PerkinElmer Inc., Waltham, MA, USA), and 45 μl of 1x 
Dilution Buffer from the kit was added. The sealed plate was incubated at 65	C for 
30  min,  the  samples  were  cooled  on  ice  for  2–3  min,  and  equilibrated  to  room  
temperature. SEAP substrate solution (60 μl) was then added, the samples were 
incubated at room temperature for 60 min, and the SEAP signal was detected using 
either Microbeta 1450 luminometer/liquid scintillation counter (Wallac, 
PerkinElmer Inc.) or VarioSkan Flash multimode reader (ThermoFisher Scientific, 
Waltham, MA, USA). 
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8.3 Results and discussion 
8.3.1 Synthesis and characterization 
The synthesis of CPP–GNPs is a modified version of the Brust–Schiffrin reaction 
(Brust  et  al.  1994),  using  NaBH4 as reductive agent, and its more recent water-
soluble variant yielding 30-nm cysteamine-coated cationic GNPs (Niidome et al. 
2004). Our reaction introduces the cysteamine and the CPP in one step (Scheme 
1), resulting in a mixed monolayer of cysteamine moieties and two to three CPP 
residues per nanoparticle, as determined by assaying unattached peptide from the 
reaction mixture. The most favorable cysteamine:CPP ratio was found to be 40:1 
(mol/mol), as it produced the most stable nanoparticles (data not shown). TEM 
analysis revealed spherical GNPs with a diameter of 22.1 ± 4.5 nm (mean ± SD; n = 
23) (Figure 1a), while two other batches gave diameters of 20.9 ± 3.5 nm (n = 50) 
and 13.4 ± 2.0 nm (n = 50). The UV/VIS spectrum of CPP–GNPs showed a surface 
plasmon resonance band at about 520 nm (Figure 1b), characteristic for gold 
nanospheres  of  this  size  range  (Link  and  El-Sayed  1999;  Jain  et  al.  2006).  The  
absorbance of siRNA/CPP–GNP complexes was strongly red-shifted and broadened. 
This may reflect some degree of interparticle aggregation into larger clusters due to 
charge neutralization, as was seen previously for siRNA/cysteamine-coated GNP 
complexes (Lee et al. 2008). 
 
Scheme 1 Synthesis of cell-penetrating peptide-modified gold nanoparticles (CPP–GNPs). 
 
 




Figure 1 (a) TEM image of cell-penetrating peptide-modified gold nanoparticles (CPP–
GNPs; magnification 300 K). (b) UV/VIS spectra of CPP–GNPs (straight line) 
and their complexes with anti-SEAP siRNA-1795 (siRNA/CPP–GNPs, 1:40 by 
mass) (dotted line). 
8.3.2 Complex formation with siRNA 
The stability of siRNA/CPP–GNP complexes was studied by gel electrophoresis 
using a model oligonucleotide instead of siRNA (Figure 2). Complexes with a 1:40 
ratio of oligonucleotide to gold (w/w) exhibited higher stability than complexes with 
ratios 1:10 to 1:30, as assessed from the absence of free oligonucleotide on the gel, 
and were therefore used in the biological experiments. A weight excess of gold was 
also desired to maintain the complexes sufficiently cationic for cell adhesion. In 1:40 
(w/w) complexes, the corresponding molar ratio remains in favor to siRNA (about 
100:1  siRNA:gold).  However,  Lee  et  al.  (2008)  found  that  a  single  cysteamine-
coated 15-nm GNP may have over 5000 primary amine groups on its surface, which 
would in our case translate into an N/P ratio of approximately 1.25. Moreover, 
Niidome et al. (2004) successfully transfected HeLa cells with plasmid 
DNA:cysteamine-coated GNP complexes with a weight ratio of 1:17, even though 
plasmid DNA is significantly larger and contains more negative charges than siRNA. 









Figure 2 Gel electrophoresis (15% PAGE) of complexes of model oligonucleotide and 
cell-penetrating peptide-modified gold nanoparticles (CPP–GNPs). Lane 1, 10 
bp DNA ladder; lane 2, free oligonucleotide; lane 3, empty; lane 4, complex 
1:10 (oligonucleotide: gold m/m); lane 5, complex 1:20; lane 6, complex 1:30; 
lane 7, complex 1:40; lane 8, complex 1:80. The absence of free 
oligonucleotide indicates stable complexes that are retained in the wells. 
8.3.3 Cell viability 
Gold nanoparticles with different sizes and surface modifications have been shown 
to be non-toxic in various cell lines (Connor et al. 2005; Shukla et al. 2005; Arnida 
et al. 2010). Since Lee et al. (2008) found no cytotoxicity for their cationic 
cysteamine-coated GNPs similar to our particles, it can be hypothesized that any 
toxicity caused by our particles would probably be due to the peptide. The native Tat 
peptide has been found to be relatively non-toxic in various cell lines at 
concentrations up to 100 
M (Cardozo et al. 2007; Sugita et al. 2008). Our modified 
Tat peptide was previously found non-toxic in ARPE-19 cells at 2 
M, corresponding 
to 0.6 
g in 100 
l (Subrizi et al. 2012). Here the CPP concentration might be even 
lower if the CPP–GNPs contained only GNP-bound peptide; however, it cannot be 
overlooked that the solution may contain free unbound peptide even after dialysis. 
Hence, to obtain full toxicity profile for the CPP, we tested the cell viability over a 
range of concentrations from 2 
M up to 153 
M, which exceeds the theoretical 
maximum concentration estimated from the amount of peptide added to the CPP-
GNP synthesis reaction, 0.16 mg/ml. Table 1 shows the toxicity (as decrease in cell 
viability compared to positive control cells) of different CPP concentrations found by 
MTT assay. First we tested the toxicity 24 hours after transfection in a reduced-
serum medium (Opti-MEM). Pure peptide at the theoretical maximum 
concentrations was compared to the corresponding amounts of CPP–GNPs and 
siRNA/CPP–GNP complexes at siRNA doses of 0.3 to 1.0 
g (Figure 3). The 
peptide was non-toxic up to 15 
M (4 
g) and exhibited 50% toxicity at 30 
M (9 
g) 
and 90% toxicity  at  45 
M (13 
g).  Remarkably,  the  CPP–GNPs and siRNA/CPP–
GNP complexes show a cell viability of more than 100% compared to untreated 
positive control cells. The fact that the gold nanoparticles increased the amount of 
formazan produced in the MTT assay to almost 200% is indicative of increased 
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cellular proliferation and is discussed in more detail in section 7.3.4. These results 
seem to provide additional proof to the well-known fact that CPPs lose their toxicity 
when they are bound to nanoparticles (M. Antopolsky, personal communication). 
However, since the MTT assay only measures the extent of proliferation and does 
not analyze its causes, it is difficult to assess if the GNP-stimulated proliferation is 
covering any toxic effects in our case. 













2 0.6 non-toxic – – 
15 4.4 non-toxic non-toxic 25% 
30 8.8 50% – – 
45 13.2 90% non-toxic non-toxic 
95 28 – 80% 70% 
153 45 – 98% 94% 
 
 
Figure 3 SEAP-ARPE-19 cell viability (mean  SEM; n = 3) 24 h after transfection with 
cell-penetrating peptides (CPP), CPP-modified gold nanoparticles (CPP–
GNPs), and their complexes with anti-SEAP siRNA-1795 (siRNA/CPP–GNPs; 
1:40 by mass) in reduced-serum medium (Opti-MEM). [For siRNA doses of 0.3 

g, 0.7 
g, and 1.0 








Unexpectedly, when we performed the MTT assay 48 hours after transfection, the 
peptide appeared significantly less toxic; it did not show 90% toxicity until at 153 

M (45 
g; data not shown) and was non-toxic up to 41 
M (12 
g) (Figure 4). This 
initial plummet in cell viability at 24 h post-transfection raises a question whether it 
results from an early shock after membrane perturbation by the CPP, followed by 
gradual  recovery  of  cellular  proliferation.  The  study  by  Subrizi  et  al.  (2012),  
however, found no evidence of non-endocytic cell entry for this peptide, although it 






























However, their study used relatively low peptide concentrations (2 
M), while 
Duchardt et al. (2007) had observed concentration-dependence in Tat uptake, rapid 
non-endocytic uptake occurring at concentrations exceeding 10 
M. In any case, it 
might be worthwhile to do additional toxicity testing with methods that measure cell 
membrane integrity such as the LDH (lactate dehydrogenase) release assay; this 
would also provide a more mechanistic insight into the apparent stimulation of 
proliferation caused by CPP–GNPs. Repeated 48-hour MTT assays confirmed that 
significant toxicity, exceeding that of Lipofectamine 2000, starts at 95 
M (28 
g), 
which is beyond the theoretical maximum CPP concentration in the CPP–GNP 
solution (Figure 4). It must be noted that in this experiment the CPP was tested at 
higher concentrations, which are directly comparable to CPP–GNP but do not 
represent the amounts present in the CPP–GNP solution. Expectedly, the gold 
nanoparticles showed no toxicity at any of the concentrations studied. However, 
here we did not observe the increased cellular proliferation which was seen in the 
24-hour assay. A transfection in a medium containing 10% fetal bovine serum 
(DMEM/F-12) gave similar results, except that the cell viability was again increased 
by CPP–GNPs in some cases and Lipofectamine 2000 was less toxic than in serum-
free medium  (Figure 5). Naked siRNA showed no significant toxicity (data not 
shown), and the complexes of siRNA with CPP and CPP–GNPs at a 1:40 (w/w) ratio 
showed no difference to naked CPP and CPP–GNPs, respectively (Figures 3–5). 
 
 
Figure 4 SEAP-ARPE-19 cell viability (mean ± SEM; n=3) 48 h after transfection with 
cell-penetrating peptide-modified gold nanoparticles (CPP–GNP), anti-SEAP 
siRNA-1795 complexes with CPP–GNPs (siRNA/CPP–GNP, 1:40 by mass), 
cell-penetrating peptide (CPP; 12 
g and 28 
g), siRNA-1795 complexes with 
CPP (siRNA/CPP, 1:40 by mass), and siRNA-1795 complexes with 
Lipofectamine 2000 (siRNA/LF; 3.57 
l LF per 





































Figure 5 SEAP-ARPE-19 cell viability (mean ± SEM; n=3) 48 h after transfection with 
cell-penetrating peptide-modified gold nanoparticles (CPP–GNP), anti-SEAP 
siRNA-1795 complexes with CPP–GNPs (siRNA/CPP–GNP, 1:40 by mass), 
cell-penetrating peptide (CPP; 12 
g and 28 
g), siRNA-1795 complexes with 
CPP (siRNA/CPP, 1:40 by mass), and siRNA-1795 complexes with 
Lipofectamine 2000 (siRNA/LF; 3.57 
l LF per 
g siRNA) in serum-containing 
medium (DMEM/F-12). 
8.3.4 Effect of gold nanoparticles on SEAP secretion 
In the first experiment, we aimed to establish an understanding on how the SEAP 
secretion of SEAP-ARPE-19 cells develops over time. We found the SEAP secretion 
to be at its greatest at 24 h after transfection with CPP–GNPs (48 h after seeding on 
96-well plate) in untreated cells (Figure  6). Surprisingly, the CPP–GNPs were 
found to increase the SEAP secretion compared to untreated cells. The increase 
seemed dose-dependent and close to linear at 6 h and 24 h after transfection; 
however, the effect was lost and even slightly reversed at 48 h. In accordance with 
these findings, our studies indicated a corresponding increase in the number of cells 
after incubating with CPP–GNPs (data not shown) as well as a cell viability of more 
than  100%  in  the  MTT  assay  (vide ultra). The reason for this unexpected 
phenomenon is not known but might be related to the fact that 30-nm GNPs have 
been shown to stimulate the proliferation of human prostate cancer cells (Arnida et 
al. 2010). The authors speculated that this stimulation might arise from the 
previously demonstrated ability of GNPs to reduce the amount of reactive oxygen 
species in macrophages (Shukla et al. 2005). Smaller GNPs with a diameter of 5 nm, 
in contrast, have been found to inhibit the proliferation of multiple myeloma cells 
(Bhattacharya et al. 2007). It is noteworthy that the GNP sizes, the surface 
chemistries and the cell types are different in these studies, which may affect the 
GNP-cell interactions significantly. Due to the large extent and the almost linear 
nature of the increase in SEAP signal, we decided to take it into account in the gene 








































Figure 6 SEAP production of SEAP-ARPE-19 cells (mean ± SEM, n = 3) 6 h, 24 
h and 48 h after transfection with cell-penetrating peptide-modified gold 
nanoparticles (CPP–GNPs) in reduced-serum medium (Opti-MEM). 
8.3.5 Gene silencing 
The first transfections were performed using the previously reported (Khvorova et 
al. 2003) anti-SEAP siRNA 2217 (antisense strand: 5’-UGA CAA CGG GCA ACA 
ACU CdTdT-3’), but no effect was seen below a dose of 0.7 
g (data not shown). 
Sequence 1795 (5’-UGA CAA CGG GCA ACA ACU CdTdT-3’) (Khvorova et al. 2003), 
in  turn,  was  found  active  at  a  dose  of  0.5  
g  when  used  as  a  complex  with  CPP–
GNPs (Figure 7) but not as naked siRNA. At a dose of 0.7 
g, it caused a 49% gene 
knockdown compared to untreated cells, measured 24 h after transfection. 
Furthermore, when compared to the elevated SEAP levels caused by the CPP–GNPs 
(vide ultra), termed from this point forward as ‘expected SEAP’, the gene silencing 
effect was as high as 75%. Similar results were obtained in serum-containing 
medium (DMEM/F-12), where the same dose of siRNA/CPP–GNPs caused a gene 
knockdown of 85% compared to untreated cells and 93% compared to expected 
SEAP, although the results were obscured by the fact that even naked siRNA caused 
a 59% knockdown (Figure 8). Transfected in DMEM/F-12 and measured 48 hours 
after transfection, the CPP–GNPs decrease rather than increase the SEAP secretion 
(Figure 9), as was seen in section 7.3.4 (Figure 6). Hence the 92% knockdown 
caused by siRNA/CPP–GNPs is reduced to 84% when compared to expected SEAP 
instead of untreated cells. In this experiment, naked siRNA was not active, but an 
unexplained increase in SEAP secretion by naked siRNA and lower concentration of 
siRNA/CPP–GNPs were seen. These discrepancies warrant further studies to 
confirm a true specific RNA interference mechanism by mRNA expression studies 
and new experiments with additional controls. Nevertheless, these preliminary 
results indicate that the CPP–GNPs are indeed able to carry siRNA into cells in an 
active form. Furthermore, the anti-SEAP siRNA remains active in the presence of 
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Figure 7 SEAP secretion of SEAP-ARPE-19 cells (mean ± SEM; n=2) 24 h after 
transfection with cell-penetrating peptide-modified gold nanoparticles (CPP–
GNPs) (‘expected SEAP’) or their complexes with anti-SEAP siRNA-1795 
(siRNA/CPP–GNPs, 1:40 by mass) in reduced-serum medium (Opti-MEM). 
 
Figure 8 SEAP secretion of SEAP-ARPE-19 cells (mean ± SEM; n=3) 24 h after 
transfection with cell-penetrating peptide-modified gold nanoparticles (CPP–
GNPs) (‘expected SEAP’), naked anti-SEAP siRNA-1795, or siRNA-1795 
complexes with CPP–GNPs (siRNA/CPP–GNPs, 1:40 by mass) in serum-


















































Figure 9 SEAP secretion of SEAP-ARPE-19 cells (mean ± SEM; n=3) 48 h after 
transfection with cell-penetrating peptide-modified gold nanoparticles (CPP–
GNPs) (‘expected SEAP’), naked anti-SEAP siRNA-1795, or siRNA-1795 
complexes with CPP–GNPs (siRNA/CPP–GNPs, 1:40 by mass) in serum-
containing medium (DMEM/F-12). 
8.4 Conclusions 
Herein we developed a straightforward, reproducible one-step method to synthesize 
positively charged gold nanoparticles surface-modified with a mixed monolayer of 
cysteamine and a Tat-derived cell-penetrating peptide sequence. The peptide-
modified gold nanoparticles proved non-toxic at all concentrations studied, while 
the peptide itself was toxic at high concentrations. Anti-SEAP siRNA as complex 
with the gold particles caused a significant and dose-dependent gene silencing 
effect. This effect was not lost in the presence of serum, indicating that siRNA is 
protected from enzymatic degradation. Furthermore, our studies revealed an 
unexpected phenomenon where the gold particles increased both the cell viability 
and SEAP secretion above those of control cells, possibly due to gold nanoparticle-
induced stimulation of cellular proliferation.  
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9 GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES 
Although oligonucleotide (ON) drugs have encountered more problems than 
expected, they are steadily progressing towards the clinic. Most of the advanced 
applications employ topical or ex vivo administration, allowing the accumulation of 
large amounts of ONs at the site of action. After systemic injections, in contrast, 
unmodified ONs are rapidly excreted by the kidneys. Therefore, systemic ON 
therapies frequently employ nanosize carriers which accumulate mainly in the liver 
and in solid tumors due to their size, unless they are actively targeted to specific 
tissues. Since modified ONs exhibit different in vivo pharmacokinetics than 
phosphodiester ONs, e.g. the high plasma protein binding of phosphorothioate ONs 
delaying their excretion, they may also be injected as such or conjugated to smaller 
cellular uptake enhancers such as cell-penetrating peptides (CPPs). Especially the 
non-ionic ON analogs used for splice correction, phosphorodiamidate morpholino 
oligomers (PMOs) and peptide nucleic acids (PNAs), have been found to benefit 
from CPP-mediated delivery. However, CPPs are not the only alternative; numerous 
lipid-based, polymeric, and gold nanoparticles with or without targeting moieties 
have been investigated to improve ON delivery. We aspired to contribute to this 
research area by developing modifications and carriers to enhance ON delivery in 
vitro. During this process we optimized various synthetic and analytical methods. 
Finally, we tested the biological consequences of these modifications and carriers in 
vitro, using cell-free methods and reporter gene-expressing cell lines. 
Optimization of analytical methods (IIII). Electrospray ionization mass 
spectrometry (ESI-MS) is a sensitive and reproducible method, ideal for the 
molecular weight verification of biomacromolecules. In ESI, the analyte ions are 
formed spontaneously in the eluent, and are simply brought to the gas phase via 
evaporation of the eluent upon spraying through a heated high-voltage capillary. 
ESI does not cause fragmentation of the ions, which might complicate the spectra of 
large molecules. Moreover, ONs are generally always negatively charged in solution. 
The ESI spectra of ONs exhibit a series of multiply charged ions, enabling the 
analysis of large molecules on a low mass range equipment. Peptides, in contrast, 
usually exhibit singly charged positive ions in ESI-MS.  
We optimized an ESI–quadrupole ion trap system for ON analysis, tuning 
parameters such as the tube lens offset to affect the charge states of the ONs. 
Volatile organic bases (e.g. triethylamine) are key components in the eluent; they 
affect the charge state and the amount of non-volatile cation adduct ions which can 
complicate the spectra. Direct injection analysis is usually adequate for normal size 
ONs, including phosphorothioates (PS), although PS-ONs attract more sodium 
adducts than phosphodiesters do (Figure 9, p. 37; previously unpublished). For 
low signal-to-noise samples such as large ONs, complicated modifications, or 
analogs synthesized via unconventional methods, liquid chromatography–mass 
spectrometry (LC/MS) using narrowbore RP-HPLC columns with ion-pair reagents 
is a valuable tool to improve the quality of spectra. We characterized 14 circular 
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phosphodiester ONs and a circular PS-ON by ESI-MS with mass errors ranging 
from <0.01 to 0.04%, employing LC/MS when necessary (III). Figures 1 and 2 
(pp. 72–73; previously unpublished) illustrate the significance of LC/MS in 
improving  the  spectral  quality  for  a  37-mer  circular  phosphodiester  ON  and  a  25-
mer circular PS-ON, respectively: the direct injection spectra are complicated by 
high background noise, although they were purified by HPLC after circularization, 
while LC/MS spectra exhibit excellent signal-to-noise ratio. For unknown reasons, 
we failed to obtain decent spectra of europium-labeled ONs, and they were analyzed 
in their original laboratory by ESI-TOF MS.  
In covalent peptideON conjugates (POCs), each part of the molecule displays 
different properties: the hydrophilic, polyanionic ON with a molecular weight 
typically  of  58 kDa and the peptide exhibiting sequence-depedent size, 
lipophilicity, and number of positive charges. We have synthesized POCs employing 
both convergent (I) and stepwise solid-phase synthesis (Antopolsky and Azhayev 
1999; Antopolsky and Azhayev 2000; Antopolsky et al. 2002) strategies. The 
convergent strategy comprises the post-synthetic conjugation of purified ONs, 
bearing a free thiol group, with purified peptides containing a terminal cysteine or 
other thiol, which is activated by 2,2’-bis(dipyridyl)disulfide. Stepwise solid-phase 
synthesis of POCs does not entail intermediate purifications, and the products may 
contain impurities despite the final purification step. A high level of background 
noise could possibly decrease the accuracy of measurement, especially when using 
mass reconstruction software which may mistake adduct peaks for real ones. 
We successfully characterized 30 POCs, four of which were prepared by stepwise 
synthesis and the rest by the convergent method, by ESI-MS or ESI-LC/MS with 
mass errors less than 0.05% (<0.03% in 25 cases) (II). The POCs were measurable 
by negative ion ESI but not on the positive side, in agreement with previous 
observations that the ON part governs the behavior of the conjugates in ESI-MS 
(Jensen et al. 1996). The accuracy of measurement was not significantly affected 
either by the stepwise synthesis method or by large size of the POCs (up to 14 kDa). 
In addition, we analyzed six more POCs prepared by new stepwise strategies, 
introducing a method for arginine-containing peptides (Antopolsky and Azhayev 
2000) and a novel solid support (Antopolsky et al. 2002), with mass errors less than 
0.04% and 0.03%, respectively. 
To study the enzymatic stability of linear and circular ONs in biological fluids, 
we optimized an assay comprising a two-step sample pre-treatment and subsequent 
analysis of metabolites by ion-exchange HPLC (III). Good resolution of 25-mer and 
smaller PS-ONs had earlier been achieved by strong anion-exchange HPLC using 
preanalytical liquid–liquid extractions, elution by halides, and elevated column 
temperatures (Bourque and Cohen 1993). Leeds et al. (1996) developed a two-step 
solid-phase extraction method with ion-exchange and reversed-phase column, 
requiring a second desalting step by dialysis to render the samples compatible with 
capillary gel electrophoresis. We adapted a similar sample pre-treatment method, 
requiring no additional desalting, for ion-exchange HPLC analysis of circular 
phosphodiester ONs from biological matrices. Baseline resolution of the full-length 
ON and its metabolites was achieved using perchlorate elution and elevated column 
 
107 
temperature. However, our method is semiquantitative at best, since we did not use 
an internal standard and, since the recovery from extractions was found to be poorly 
reproducible, we calculated the amount of intact ON as percentage relative to all 
peaks in the chromatogram. The latter calculation may not yield completely accurate 
results, as it was previously found that shorter ONs do not exhibit equal recoveries 
in the extractions (Leeds et al. 1996). Nevertheless, the method confers valuable 
information on the metabolism of ONs and can be further optimized. 
Chemical modification of oligonucleotides via cyclization (III). Circularized 
ONs display many advantages: they can form triple helices with high affinity and 
selectivity, resist nucleolytic degradation, act as templates for rolling circle 
RNA/DNA synthesis (reviewed in Kool 1996a), form double helices (Azhayeva et al. 
1997), and mimick double-stranded nucleic acids (reviewed in Gambari 2004). 
Cyclization can be achieved enzymatically or via activation of a terminal phosphate, 
the latter requiring template-directed alignment of the ON termini in order to 
succeed for larger ONs (reviewed in Kool 1996a). Kool emphasized in his review that 
non-templated approaches had never succeeded in ligating larger than 14-
nucleotide ONs. However, Azhayeva et al. (1995) had indeed circularized a 31-
nucleotide ON by disulfide cross-linking in 65% yield, although the yield had been 
improved to 76% by the use of a template. We circularized 14 phosphodiester ONs of 
17 to 37 nucleotides in length and one 25-mer PS-ON with the same method (III). 
The circular ONs were characterized by gel electrophoresis and ESI-MS. 
 We demonstrated, using the stability assay described above, that the half-life in 
10%  serum  of  a  25-mer  phosphodiester  was  increased  from  ca. 1  h  to  30  h  by  
circularization. This finding is in agreement with earlier studies incubating 34-mer 
circular phosphodiester ONs in 100% human serum (Rumney and Kool 1992, cited 
in Kool 1996a). The stabilization of our circular ON was not as pronounced in CV-1 
and D-407 cell lysates, where the circular ON exhibited half-lives of 4 to 6 h, 
probably because of the endonucleases present in cells (Fisher et al. 1993) but not in 
serum, where the main source of degradation is due to 3’-exonucleases (Shaw et al. 
1991). This is in line with the observation that the linear precursor ON, bearing 
tether groups at the 5’- and 3’-termini, also displayed somewhat prolongated half-
lives of 5 h in serum and 3 h in cellular extracts, compared to linear ON without any 
5’- or 3’-end modifications. However, its half-life in serum was not nearly as long as 
for the circular ON, indicating that it may be susceptible to exonucleolytic 
degradation despite the terminal modifications.   
Melting experiments showed that the melting points of circular ONtarget DNA 
complexes were ca. 15	C lower than those of linear ONs. More importantly, a single 
mismatch in the target DNA sequence significantly destabilized the complex for 
circular ONs, while their linear precursors showed less destabilization. These results 
were confirmed using a sandwich-type mixed-phase hybridization assay (Hakala et 
al. 1998) employing complementary and mismatched target sequences hybridized to 
a microparticle-bound probe. The hybridization of fluorescently labeled circular 
ONs was destabilized much more by single-base mismatches than that of the linear 
counterparts, e.g. 90% vs. 2050%, respectively.  
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Thus, we concluded that circular ONs are significantly more selective towards 
complementary targets than linear ONs, making them very attractive candidates as 
detection probes for e.g. single-nucleotide polymorphisms. In addition, they exhibit 
increased nuclease stability in biological media, allowing their use in diagnostic 
assays and therapeutic strategies such as the antisense, antigene, or decoy approach.  
Surprisingly few articles can be found on circular ONs, especially as therapeutics, 
despite of their versatile properties. We previously showed that cyclization does not 
adversely affect the RNase H-mediated antisense activity of phosphodiester ONs 
(Azhayeva et al. 1997). Circular dumbbell ONs exhibit a stabilized double-stranded 
structure and have been employed in the decoy approach to inhibit DNA-binding 
proteins in vivo (Kim et al. 2010). Recently, Tang et al. (2010) developed ‘caged’ 
antisense ONs circularized via a photolabile linker, exhibiting light-triggered 
antisense inhibition in vitro.  
Covalent conjugation of oligonucleotides to cell-penetrating peptides (I). 
We attempted to deliver 15- and 25-mer antisense PS-ONs with a chimeric CPP 
containing a hydrophobic membrane permeable motif (MPM) derived from Kaposi 
fibroblast growth factor and a cationic nuclear localization sequence (NLS) from 
NF-B (I). Using the synthesis route producing the highest yields, ONs carrying a 
free mercapto group were covalently conjugated with thiol-containing CPPs 
activated with a 2-pyridylsulfide group, either via the N- or C-termini of the 
peptides. The resulting disulfide-linked conjugates exhibited >95% purity and yields 
of 35–60%, and were characterized using HPLC and ESI-MS. However, the 
conjugates failed to show any significant antisense effect in luciferase-expressing 
cell lines, unless delivered with cationic lipids. Cellular uptake studies using 32P-
labeled ONs showed that the conjugates were strongly associated with cells and 
remained intact in the process. Furthermore, the NLS part was necessary for cellular 
association, as the MPM part alone showed even less uptake than the ON. The 
conjugates were found capable of inhibiting luciferase expression and of activating 
RNase H in cell-free systems. Examination of conjugate-treated cells by confocal 
microscopy revealed that the conjugates were entrapped in endosomes after being 
internalized. Thus the conjugates were able to exert pharmacodynamic effect and 
enter cells, but were not able to reach the site of action in the cytoplasm or nucleus. 
Dokka et al.  (1997) showed efficient PS-ON delivery as complex with this MPM 
coupled to the cationic homopolypeptide poly-(L-lysine) by measuring the 
fluorescence of treated  A549 cells. Their results seem reliable since they treated the 
cells with trypsin prior to measurements in order to remove any surface-bound 
compounds. In contrast to our study, they found a nuclear non-punctate 
fluorescence pattern, indicative of a non-endocytic internalization mechanism, 
supported also by temperature-independence, but they did not perform any 
biological activity measurements to confirm delivery to the site of action. The 
ineffectiveness of the MPM without the cationic part was observed previously by 
Arzumanov et al. (2003) in HeLa cells. We aspired to employ a more effective NLS 
part, which indeed proved necessary for cellular association but failed to deliver the 
ONs to the nucleus; perhaps it could be augmented or replaced with an endosomo-
lytic sequence. The hydrophobic MPM had been shown to interact with lipid 
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bilayers (Lin et al. 1995), suggesting capability for membrane fusion; however, 
interaction with lipid models does not always correlate with the extent of cellular 
uptake (Subrizi et al. 2012). Had we chosen a more efficient CPP, the results might 
have been different, as some CPPs seem to display non-endocytic uptake or 
enhanced endosomal release. Also, when dealing with ionic ON analogs, one must 
assess whether it would be more effective and/or straightforward to employ non-
covalent complexes. Meade and Dowdy (2008) argued that the excess of cationic 
CPP in ON/CPP complexes might enhance their cell-surface association and 
subsequent internalization, and provide additional protection from enzymatic 
degradation. In vivo, however, maintaining such excess would only be possible after 
local administration to closed compartments. Moreover, high concentrations of 
positively charged CPPs might give rise to toxic effects via interaction with proteins 
and other biomolecules. 
Delivery of siRNA by cell-penetrating peptide-modified gold nanoparticles 
(IV). In the case of siRNA, the ON backbone cannot be uniformly modified, and 
naked siRNA is useful mainly for local administration or renal diseases. Systemic 
siRNA therapies usually employ delivery vehicles such as stable nucleic acid lipid 
particles (SNALPs) or other nanoparticles, which are frequently PEGylated to 
increase the plasma circulation half-life. In vivo siRNA delivery, accompanied by 
gene silencing effect, has also been achieved by endosomolytic CPPs such as Chol–
MPG-8 (Crombez et al. 2009) and PepFect6 (El Andaloussi et al. 2011). One of the 
most interesting siRNA delivery vehicles are gold nanoparticles (GNPs), which have 
been extensively investigated in vitro both as covalent conjugates and electrostatic 
complexes (reviewed in Lytton-Jean et al. 2011). However, only three papers have 
been published so far on the in vivo siRNA delivery by GNPs, which exhibited 
photothermal targeted delivery (Lu et al. 2010), pH-responsive release (Han et al. 
2012), and multifunctionality (Conde et al. 2012). Even fewer studies have described 
the combination of CPPs with GNPs for siRNA delivery. Tat–lipid-coated 
siRNA/PEG–gold nanoshells were successfully used for laser-activated gene 
silencing in vitro (Braun et al. 2009). In their study comparing different 
functionalities on GNPs, Conde et al. (2012) also examined the effect of Tat on GNP-
mediated siRNA delivery, and found that rather than augmenting gene knockdown, 
Tat actually diminished the effect.  
We investigated the in vitro delivery of siRNA by electrostatically bound cationic 
GNPs (IV). The GNPs were rendered cationic via stabilization with cysteamine, as 
described by Lee et al.  (2008). In contrast to that study, our GNPs did not contain 
PEG, and were further surface-modified with a Tat-derived CPP analog in a one-step 
synthesis. The CPP was expected to enhance cellular translocation because of its 
previously observed interaction with model membranes, even though that had not 
translated into cellular uptake (Subrizi et al. 2012). The siRNA/CPP–GNP 
complexes were found to elicit a reporter gene knockdown of 49% or more, both in 
serum-free and serum-containing media, and did not affect cell viability of SEAP-
ARPE-19 cells. The peptide alone, in contrast, decreased the cell viability at high 
concentrations. In addition, the GNPs seemed to stimulate cellular proliferation. 
These results, while very promising, warrant further investigations confirming the 
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role of the CPP by control experiments using non-peptide-modified GNPs, 
elucidating the toxic effects by membrane integrity assays, and certifying the RNA 
interference mechanism with additional controls and/or mRNA expression tests.  
Future perspectives. ONs have been found to modulate gene expression via 
numerous mechanisms, offering platforms for various therapeutic strategies. One 
systemic antisense ON has been granted marketing authorization for the treatment 
of severe hypercholesterolemia. This represents a major step forward for ON drugs, 
albeit that its use is limited due to toxic effects. Before this, two locally injected ONs 
for ophthalmic diseases had reached the market, and topical formulations are still 
very abundant in clinical trials. Modified, systemically administered ONs are being 
evaluated against severe conditions, e.g. cancers and genetic muscular dystrophies, 
which could be effectively treated by inhibiting oncogenes or by correcting splicing 
defects, respectively. One nuclease-resistant antisense ON is even being studied as 
an oral formulation against myasthenia gravis. The chemical structure of siRNAs, 
on the other hand, cannot be uniformly modified and remains vulnerable to 
nucleases. As unmodified ONs are rapidly excreted via the kidneys, naked siRNAs 
are being investigated against renal diseases such as graft failure. Nanoparticle 
carriers, in contrast, usually accumulate in the liver because of their size which does 
not allow their filtration in the glomeruli. They may also accumulate in solid tumors, 
either by passive targeting due to the enhanced permeability and retention (EPR) 
effect, or by active targeting ligands, known to be overexpressed in tumors, attached 
to the nanoparticle surface. Cancers, and especially hepatic cancer, therefore 
represent an ideal target for nanocarrier-bound siRNAs. In addition to these 
applications, which have already advanced to the clinical level, preclinical studies 
are being conducted for numerous conditions which remain without cure, e.g. 
Huntington’s disease, rabies infections, and cystic fibrosis. 
In summary, an efficient method for in vivo ON delivery must protect the ON 
from enzymatic degradation and facilitate its cellular uptake and/or endosomal 
escape (Figure 10). The main strategies include:  
(1) Chemical modification of the oligonucleotide backbone, e.g. 2’-O-(2-
methoxyethyl)/phosphorothioate (2’-MOE/PS) or phosphorodiamidate morpholino 
(PMO), to confer (i) nuclease resistance and (ii) favorable in vivo pharmacokinetic 
properties, enabling unassisted delivery to the site of action.  
(2) Use of non-toxic multifunctional nanocarriers to afford: (i) spatial protection 
from enzymes; (ii) avoidance of phagocytes by PEGylation, leading to extended 
circulation half-lives; (iii) active targeting to a specific cell type, allowing 
accumulation at the appropriate site; (iv) enhanced endosomal escape mediated by 
e.g. fusogenic peptides; (v) triggered release from the carrier and/or from the 





Figure 10 Delivery strategies for oligonucleotides. Above: An ideal nanocarrier for 
oligonucleotides such as short interfering RNA (siRNA) protects its 
cargo from degradation and may exhibit various functions: targeting to 
specific cell type; avoidance of phagocytes by PEGylation; and release 
of the cargo triggered by external stimuli such as pH change or light. 
Below: Unmodified oligonucleotides are readily degraded by nuclease 
enzymes, whereas chemically modified oligonucleotides [e.g. 2’-O-(2-
methoxyethyl) phosphorothioates (2’-MOE/PS) or phosphorodiamidate 
morpholino oligomers (PMO)] are highly nuclease resistant and may 





Antisense technology has existed for more than three decades, during which time an 
enormous amount of knowledge has accumulated on its principles, defects and 
possibilities. While many methodological breakthroughs have been made in the 
past, new discoveries continue to emerge. The main objective of this study was to 
design chemically modified and nanocarrier-bound oligonucleotides to overcome 
the pharmacokinetic limitations of oligonucleotide therapeutics, i.e. extensive 
enzymatic degradation and poor cellular uptake. The main conclusions of this thesis 
are the following: 
1)  Electrospray ionization mass spectrometry offers an extremely useful 
platform for characterizing oligonucleotides and peptide–oligonucleotide 
conjugates. Liquid chromatography–mass spectrometry, in particular, 
enables the analysis of samples with an inherently low signal-to-noise ratio 
such as large molecules, difficult modifications, or peptide–oligonucleotide 
conjugates prepared by stepwise solid-phase synthesis without inter-
mediate purifications. In addition, a two-step solid-phase extraction pre-
treatment enables the analysis of metabolites of modified oligonucleotide 
analogs in biological samples. 
2)  Circular phosphodiester oligonucleotides exhibit a significantly enhanced 
enzymatic stability, compared to their linear counterparts, in serum and 
cell lysates. In the latter media, the effect is not as pronounced, probably 
due to endonucleases present in cells. Moreover, circular oligonucleotides 
display improved selectivity towards complementary targets, which makes 
them excellent candidates for the detection of single-nucleotide 
polymorphisms. 
3)  Peptide–oligonucleotide conjugates, where phosphorothioate antisense 
oligonucleotides and a chimeric cell-penetrating peptide are connected via 
bioreducible disulfide cross-links, are taken up by cells but remain 
entrapped in endosomes, which explains the lack of antisense effect in cells 
despite their observed anti-luciferase activity in cell-free systems. 
4) Cationic gold nanoparticles surface-modified with cysteamine and a Tat-
peptide analog form stable non-covalent complexes with siRNA, deliver 
siRNA into cells in an active form in serum-free and serum-containing 
media, and do not affect cell viability. Furthermore, the gold nanoparticles 
seem to have a stimulating effect on cellular proliferation. 
In conclusion, we have optimized chemical methods to synthesize and analyze 
various oligonucleotide analogs and carriers. Many of these methods are easily 
applicable to different oligonucleotide chemistries, therapeutic targets, and 
mechanisms of action. We have also tested the effect of these modifications using 
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